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The epithelial-mesenchymal transition (EMT), one of the hallmarks of cancer, is a set of 
biochemical changes that allow epithelial cells to lose their polarization to transform 
into mobile mesenchymal cells. Epithelial splicing regulatory proteins 1 and 2 (ESRP1 
and 2) are RNA-binding proteins that act as splice factors and regulate a large number 
of transcripts that promote epithelial characteristics in the cell. Among the genes 
regulated by ESRPs, fibroblast growth factor receptor 2 (FGFR2) is well-known that has 
two mutually exclusive exons switching in the EMT. ESRPs were identified as key 
regulators of EMT during cancer progress. The aim of my project is to reveal ESRPs’ role 
in prostate cancer. 
To explore ESRPs’ functions in tumours, I constructed stable PC3 cell lines 
overexpressing either ESRP1, or ESRP2, or both ESRP1 and 2.  These cells were injected 
in nude mice subcutaneously to grow xenografts, and tumour sizes were measured by 
calliper. Functional properties of these cells such as cell growth, migration rate, and 
EMT properties were also measured. 
As ESRPs regulate splicing of FGFR2 in EMT, I have used a biochromatic reporter whose 
fluorescent output is dependent on the inclusion/exclusion of FGFR2 exon IIIc. 
Compounds from the LOPAC library were screened using HEK293 cells with the reporter 
to find hits that promote exclusion of exon IIIc in FGFR2 splicing and possibly block EMT. 
Several assays were carried out including cell growth assay, EMT markers staining, cell 
migration and proliferation assays in vitro. While in vivo, xenografts were developed by 
injecting PC3 cells in nude mice subcutaneously, and then treated with one of the hit 
compounds to explore whether it could affect tumour growth. 
Three chemicals were selected that switch splicing of FGFR2, verified as modulators of 
EMT by increasing E-cadherin expression and junctional localization, showed different 
activities in cell functional assays in vitro, and one of them significantly decreased 
tumour growth in vivo in prostate cancer xenografts mouse models. I have also found 
that ESRPs overexpression may suppress tumour growth in vivo in prostate cancer 
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Chapter 1  Introduction  
1.1 Prostate cancer  
Prostate cancer (PCa) is a heterogeneous disease and the most commonly diagnosed 
non-cutaneous malignancy in men (Cozar et al., 2018; Gatta et al., 2013; Shoag & 
Barbieri, 2016). Currently, PCa is the second most common diagnosed cancer among 
men and has the fifth highest death rate (Stewart BW, 2014). PCa has a high widespread 
presence with a relatively low cancer death (Hema, Thambiraj, & Shankaran, 2018; 
Moghadam, Taheri, & Peiravian, 2018).  
Most cases of PCa can be safely followed by active surveillance or observation. The 
current treatment options such as surgery, hormone therapy, chemotherapy, and 
radiation therapy are insufficient due to the heterogeneity of this cancer and this has 
spurred demand for improved technologies (Hema et al., 2018). Androgen-deprivation 
therapy (ADT) is a typical treatment of advanced or metastatic PCa that is related to 
reduction of bone mineral density (BMD) and increasing frequency of osteoporotic 
fractures (Campos et al., 2018).  
1.1.1 Prostate cancer in Western world  
According to statistics from the US Centres for Disease Control, the incidence of PCa in 
African Americans is highest, followed by Europeans. The lowest incidence of PCa is in 
Asian ethnic groups. In the United States, the five-year survival rate for PCa patients is 
approximately 98.2% (Institute, 2018). PCa is the second highest diagnosed frequency 
rate in men and has the fifth highest cancer mortality (BW & CP, 2014). In 2012, about 
1.1 million men suffered from PCa, and 307,000 died from PCa in the world (BW & CP, 
2014). PCa is the most common form of cancer in men in 84 countries (BW & CP, 2014), 
and it is more common in developed countries, but the prevalence in developing 
countries is increasing (Baade, Youlden, & Krnjacki, 2009). Due to the promotion of PSA 
testing, the discovery rate of PCa in the 1980s and 1990s increased significantly (Stewart 




who did not die of PCa had histological evidence of PCa (Welch & Black, 2010; Zlotta et 
al., 2013). 
According to a report by Prostate Cancer UK (https://prostatecanceruk.org), over 
47,000 men are diagnosed with PCa and more than 11,000 men die from PCa every year 
in the UK. PCa is seen predominantly in men over 50 years old and frequency increases 
with age. Men diagnosed with PCa are usually between 65 and 69 years old. 
1.1.2 Signalling pathways in Prostate Cancer 
The occurrence and development of PCa is characterised by a series of complicated 
processes. The abnormality of intracellular signal pathways plays one of the central 
roles of PCa progression. It has been shown in several reports that growth factors 
contribute to the progress of PCa since they either raise the steroidal hormone level 
directly or increase enzyme effectiveness indirectly. Various studies have revealed that 
Hedgehog signalling pathway, Wnt signalling pathway, Notch signalling pathway and 
mitogen-activated protein kinase (MAPK) signalling pathway play a crucial role in the 
occurrence, invasion and metastasis of PCa. (Joshi et al., 2015). It was found by Kypta 
and Waxman that the Wnt/β-catenin pathway played a special role on tumour cells 
invasion by affecting cell growth, cell variation and the EMT in prostate cancer (Kypta & 
Waxman, 2012). Nguyen et al. presented some evidence concerning the role of the NF-
κB pathway in PCa and discussed therapeutic challenges to target the NF-κB pathways. 
They also indicated that it is essential to further analyse inflammatory pathways in PCa 
in order to develop applicable preventive methods and design novel therapeutic 
approaches (Nguyen, Li, Yadav, & Tewari, 2014). It was revealed that for a normal 
prostate, the Notch signalling pathway was essential, while its dysfunction could 
promote PCa progression (Villaronga, Bevan, & Belandia, 2008). 
1.1.3 Genetic events underlying prostate cancer  
Prostate cancer has a high degree of heterogeneity. Driver mutations contributing to 
cancer development can have high frequency, low frequency, or be rare. Driver 
mutations are mostly identified by their frequencies. Thus, high-frequency drivers are 




low-frequency mutations that were not identified yet, researchers have collected 
whole-genome exon sequencing data reported in recent years and identified 97 
significant mutations. Of the 97 potential prostate cancer oncogenes, 70 are new genes 
with no reports to have been previously linked to cancer development and progression 
in prostate cancer. By comparing the genomes of castration-resistant prostate cancer 
and primary cancer, they confirmed that most of the oncogenic mutations are 
concentrated in signal pathways such as AR, WNT / β-catenin, PI3K, RAS-MAPK, and 
DNA repair (Armenia et al., 2018). Consistently, molecular biology studies of prostate 
cancer have shown that a variety of oncogenes and tumour suppressor genes are 
involved in the occurrence and development of prostate cancer, and their related genes 
(such as p53, BCL-2, PTEN, etc.) and the mechanism of prostate cancer initiation and 
the evaluation of prognosis is closely related (G. C. Wang, Zhao, Spring, & DePinho, 
2018). In addition, some apoptosis-related genes and DNA repair genes are also new 
targets for molecular genetics and gene therapy.  
One of the causes of malignant tumours is the disruption of the dynamic balance of 
apoptosis. Among the regulators of apoptosis, BCL-2 is one of the most important 
suppressors. BCL-2 overexpression occurs in patients with highly malignant prostate 
cancer and is related to androgen resistance and resistance to anticancer drugs (Catz & 
Johnson, 2003; Lin, Fukuchi, Hiipakka, Kokontis, & Xiang, 2007). The research by 
Bubendorf et al. showed that the prognosis of BCL-2 negative prostate cancer is much 
better than that of BCL-2 positive, and the expression of BCL-2 protein in prostate 
cancer tissues is positively correlated with pathological grade (Bubendorf et al., 1996). 
Other studies have shown that the expression of BCL-2 reduces the chances of patients 
becoming resistant to multiple anticancer drugs during chemotherapy, making tumour 
cells sensitive to cytotoxic drugs. BCL-XL can inhibit the apoptosis effect of cytotoxic 
drugs (Chaudhary, Abel, & Lalani, 1999). 
Mutations of the tumour suppressor gene p53 (also called TP53) are common in 
prostate cancer, and the expression of the p53 protein is related to high Gleason grade, 
pathological stage, and localized prostate cancer hyperplasia.  p53 gene responds to 
diverse cellular stresses to regulate expression of genes involved in cell cycle arrest, 




protein expression can be used as an independent prognostic indicator of prostate 
cancer and as a guide to treatment. It has been observed in studies of advanced 
prostate cancer that as the tumour progresses, the P53 expression level increases and 
reaches the highest level in tissues from patients with androgen tolerance (Barbieri et 
al., 2012; Beltran et al., 2016; G. C. Wang et al., 2018). 
In 1997, Li et al. and Steck et al. reported a tumor suppressor gene on chromosome 
10q23.3, called PTEN, independently of each other (J. Li et al., 1997; Steck et al., 1997). 
PTEN is the first tumour suppressor gene with phosphatase activity discovered to date. 
It does not only participate in cell cycle regulation, but also suppresses the PI3K-AKT-
mTOR pathway to regulate cell survival, proliferation and energy metabolism (Barbieri 
et al., 2012; Grasso et al., 2012). PTEN is the most widely mutated tumour suppressor 
gene in prostate cancer. The loss of heterozygosity at this site occurs in 40% of prostate 
cancers, and it rises to 60% in prostate cancer cell lines (Taylor et al., 2010; G. C. Wang 
et al., 2018). Mutations and reductions in PTEN may contribute to the distant metastatic 
potential of cancer cells, and often occur in lethal prostate cancer. Currently, the ability 
of PTEN to regulate the apoptosis of prostate cancer cells is an active area of research. 
Genetic mutations in DNA repair genes are also quite common in metastatic prostate 
cancer, such as mutations in BRCA2, ATM, CHEK2, BRCA1, RAD51D, and PALB2. Studies 
show that more than 10% of men with aggressive prostate cancer carry genetic 
mutations in the DNA repair gene. This ratio is more than four times that of ordinary 
people and more than twice that of patients with localized prostate cancer. It is worth 
noting that patients with advanced prostate cancer are 18 times more likely to carry 
BRCA2 mutations than other men. Anticancer drugs have been approved to treat 
prostate cancers carrying such mutations, such as PARP inhibitors or platinum drugs 
(Pritchard et al., 2016). Furthermore, Amplification, mutation and splicing variants of 
androgen receptor (AR) play an important role in the progression of prostate cancer 
and the resistance to ADT by allowing constitutive activation of the AR pathway 
(Heinlein & Chang, 2004; Okegawa et al., 2018). 
The study of genetic events in prostate cancer is not only a useful supplement to 
molecular pathology research, but also provides a reliable basis for the prognosis of 




therapy of prostate cancer, especially for androgen-independent prostate cancer. Due 
to the complexity of the pathogenesis and molecular biology of prostate cancer, genetic 
events related to prostate cancer still need to be explored. 
1.1.4 Diagnosis and treatment of PCa  
For PCa diagnosing, all the tests have their advantages and disadvantages. There are 
three main generally applied tests for PCa:  blood tests, physical prostate check (known 
as a digital rectal examination or DRE) and biopsy. The blood test, also called a prostate-
specific antigen (PSA) test, detecting the PSA level in blood is a useful tool for diagnosing 
early-stage PCa.  It was shown that prostate-specific antigen had a correlation with 
raised tumour occurrences, while there was no evidence of a connection between it 
and death rate (Djulbegovic et al., 2010). PSA tests are not regular tests offered to 
screen for PCa due to the untrustworthiness of the results. In addition to PCa, the PSA 
level may also raise because of benign prostatic hyperplasia (BPH), an infection of the 
urinary tract or prostate inflammation, which is not related to carcinoma. Also, the 
levels of PSA do not correlate with the stage of PCa. As a consequence, an increased 
level of PSA may result in over-examination and therapy 
(https://prostatecanceruk.org/prostate-information/prostate-tests/psa-test). 
Since most diagnosed PCas are asymptomatic, the US Preventive Medicine Task Force 
(USPSTF) does not recommend the use of PSA testing in order to prevent overdiagnosis 
and overtreatment. The USPSTF believes that the benefits of detection do not exceed 
the possible drawbacks (Fleshner, Carlsson, & Roobol, 2017; Moyer & Force, 2012).  
The most commonly examination routines in hospital for PCa are DRE, serum PSA, 
transrectal ultrasound, and pelvic MRI. As it is quite frequent that a patient with PCa 
develops a bone metastasis, radionuclide bone scans are options available prior to the 
scheduled therapy. Confirmed PCa requires pathological examination by prostate 
biopsy. 
5α-reductase inhibitors may reduce the risk of lower-grade PCa but have no correlation 
with  high-risk PCa and are therefore not a good choice for the inhibition of PCa (Stewart 
BW, 2014). Supplements with minerals or vitamins have no effect on PCa risk (Stewart 




Radical treatment can be used for patients with early PCa. Radioactive particle 
implantation, radical prostatectomy, and radical external radiation therapy can be used 
to cure early PCa. Comprehensive treatment methods should be used for patients with 
intermediate PCa, such as surgery combined with radiotherapy, or endocrine therapy 
plus radiotherapy and so on. 
PCa is a clinically heterogeneous disease (Cozar et al., 2018). Although some of the inert 
male diseases could be observed safely, be treated by local treatments, a major 
subgroup of these diseases will reappear and finally develop an aggressive, castration 
resistant PCa. The castration-resistant metastasis is the main reason for most cases of 
mortal PCa. (Caram, Estes, Griggs, Lin, & Mukherjee, 2018; Moghadam et al., 2018; 
Whang et al., 2013) 
Endocrine therapy is the mainstay of hormone sensitive advanced PCa. Methods of 
endocrine therapy include castration (surgical castration or drug castration) and anti-
androgen therapy (bicalutamide or flutamide) or castration + anti-androgen treatment 
(Moghadam et al., 2018; Okegawa et al., 2018; Wong, Ferraldeschi, Attard, & de Bono, 
2014). The efficacy of surgical castration or drug castration is basically the same. 
However, almost all patients eventually develop hormone-independent PCa or 
hormone-resistant PCa. For patients with castration-resistant PCa, second-line 
endocrine therapy or new endocrine therapy (abiraterone, enzalutamide, etc.) can be 
used. (Armstrong et al., 2011; Caram et al., 2018; Lorch, 2017; Moghadam et al., 2018). 
Patients with hormone-refractory PCa should continue to maintain castration while 
using chemotherapy based on docetaxel and mitoxantrone (Campos et al., 2018; Lorch, 
2017; Okegawa et al., 2018; Shoag & Barbieri, 2016). Patients with PCa with bone 
metastases should be treated with bone protectants (primarily bisphosphonates) to 
prevent and reduce bone-related events, relieve bone pain, improve quality of life, and 
improve survival. External radiation therapy or radionuclides can also improve local 
bone pain. 
In the last few years there have been quite a few efforts to try to correlate PCa clinical 
appearances with genomic information (Cozar et al., 2018; Shoag & Barbieri, 2016). 
Based on this it is possible to find patterns of gene expression that correlate with various 




(Shoag & Barbieri, 2016). Over the last few years, it has also assisted us to gain more 
information about disease pathogenesis, treatment efficiency, and disease 
development.  
Furthermore, the mechanism regulating the metabolism and growth of tumour cells is 
also an important means to controlling the proliferation and metastasis of prostate 
cancer cells. Recently, Andrea Alimonti's group from the Institute of Oncology Research, 
University of Italian-speaking Switzerland found a new mechanism regulating the 
metabolism and growth of tumour cells, suggesting that tumour cells can be "slimmed 
down" to achieve the effect of inhibiting tumour growth (J. J. Chen et al., 2018; M. Chen 
et al., 2018). The glucose uptake and metabolism of prostate cancer cells—Glycolysis 
activity—are increased relative to normal cells, but prostate cancer cells cannot 
maintain cell proliferation if they cannot synthesize enough lipids themselves. They 
detected a nearly 10-fold increase in pyruvate dehydrogenase complex (PDC) activity in 
prostate cancer cells relative to normal proliferating cells. The increase in PDC activity 
is an important reason for the synthesis and accumulation of lipids in prostate cancer 
cells. 
A recent issue of Nature Genetics also published a study by Professor Pier Paolo Pandolfi 
of Harvard University on mouse PCa models (M. Chen et al., 2018). The results showed 
that high-fat foods may relate to PCa metastasis. In the mouse PCa model, a series of 
changes such as tumour suppressor gene mutation and enhanced lipid synthesis activity 
was observed before tumour metastasis. The drugs that Andrea Alimonti studies to 
block lipid synthesis in tumour cells also offer the possibility of preventing PCa 
metastasis. 
Every type of PCa therapy method may result in serious side effects, like erectile 
dysfunction and the loss of bladder control. The latest therapies, for example, high-
intensity focused ultrasound (HIFU) or cryotherapy, have been developed to avoid them. 
Finally, in recent years, a new therapy has emerged - immunotherapy. Tumour 
immunotherapy is a treatment method to control and clear tumours by restarting and 
maintaining the immune system's recognition and killing of tumour cells and restoring 




treatment, immunotherapy acts not directly on cancer cells and tumours, but through 
the patient’s immune system. This kind of therapy not only works well, but also avoids 
damage to the body, so it has received much attention in recent years. 
Immunomodulators are one of the most effective new classes of drugs in PCa 
immunotherapy (Alberti, 2016; Maia & Hansen, 2017).  
Tasquinimod is an immunomodulatory drug that is crucial in modulation of myeloid cell 
function (Brower, 2016; Gupta, Al Ustwani, Shen, & Pili, 2014; Maia & Hansen, 2017; 
Silvestri et al., 2016). It has been revealed that Tasquinimod has a tumour suppression 
function in animal experiments of PCa and has been shown to be useful in clinical trials 
as well (Gupta et al., 2014). As a result of  regulation of immune cells, 
immunosuppression and vessel growth in the tumour microenvironment was reduced 
and metastasis and spread was decreased (Shen et al., 2015). Indoximod, as a well-
known methylated tryptophan blocker for the enzymatic indoleamine 2,3-dioxygenase 
(IDO) pathway - by tryptophan consumption, induces T cell dysfunction and increases 
immunosuppressive effects (Alberti, 2016). In contrast, in a certain number of Tregs, 
Indoximod can enhance the immune response to the Sipuleucel-T vaccine (a kind of 
cancer treatment vaccine (Kantoff et al., 2010)) in metastatic castration-resistant 
prostate cancer (mCRPC) patients (Jha et al., 2017; Kolawole, Hixon, Dameron, 
Chrisman, & Smirnov, 2015). Lenalidomide has been developed as the derivative of 
thalidomide that has fewer side effects. In addition to its anti-inflammatory and anti-
angiogenic features, Lenalidomide also acts to enhance the immune response, which is 
why it is already used alone or in combination with chemotherapy drugs (especially 
docetaxel and paclitaxel), in trial mCRPC patients’ therapy. Unfortunately, although it 
has moderate anti-tumour results, serious adverse reactions have also been revealed. 









1.2 Epithelial-mesenchymal transition 
The epithelial-mesenchymal transition (EMT) was primarily observed and identified as 
a property of embryogenesis by Elizabeth Hay in the early 1980s (Hay, 1995). EMT 
involves in a biological process where epithelial cells transform into mesenchymal cells 
by a specific functional transition. EMT, and its reversal procedure, mesenchymal-
epithelial transition (MET) are vital in organ development, chronic inflammation, tissue 
regeneration, cancer metastasis and various fibrotic diseases (T. Chen, You, Jiang, & 
Wang, 2017; Kalluri & Weinberg, 2009). Epithelial and mesenchymal cells have different 
features and functions, as well as several of the same properties (Lamouille, Xu, & 
Derynck, 2014).  
The key scientific issues in research of the EMT mechanism in tumour metastasis are to 
illuminate the modulation of EMT in tumour cells, to reveal the pathology in the 
initiation, progression and metastasis of tumours, and to develop diagnostic techniques 
and therapeutic approaches targeting EMT key molecules. (Shapiro et al., 2011) 
1.2.1 Definition and mechanisms 
EMT, as a hallmark of cancer, is a set of phenotypical changes that occur when epithelial 
cells convert into mesenchymal stem cells (Ling & Oltean, 2017). Epithelial cells sit on a 
basement membrane (BM) and are linked with each other through junctions. There is a 
polarized distribution of cytoskeleton proteins, like actin, from apex to the base. In 
contrast, mesenchymal cells are low in polarity, shaped like a spindle and linked with 
each other only by the focal point (Kalluri & Weinberg, 2009) (Figure 1-1).  By EMT, the 
epithelial cells lose the epithelial phenotype, through loss of cell polarization 
connectivity with the BM, and gain new properties to migrate and invade, escape from 







Figure 1-1 EMT process and the intermediate phenotypes as cell transition.  
Some common epithelial and mesenchymal cell makers are listed: E-cadherin, Cytokeratin, ZO-1 and miR200 family for Epithelial cells and Vimentin, Fibronectin, 






At the 2007 International EMT Conference in Portland and the 2008 Cold Spring Harbor 
Laboratory Meeting, EMT was categorized into 3 types on the basis of a specific 
biological environment in which EMT occurred: embryogenesis and organ development 
(Type I), organ fibrosis and tissue regeneration (Type II), and tumour progression (Type 
III) (Kalluri, 2009) (Figure 1-2). EMT associated with embryo implantation, development 
and organ formation is called “type I EMT”. Its main biological function is the generation 
of secondary epithelial cells through mesenchymal cell metaplasia (MET), which enables 
the diversification of cell types during embryogenesis. EMT occurring during injury 
repair, tissue regeneration and organ fibrosis is defined as “type II EMT”. Its main 
biological role is through the production of fibroblasts to repair tissue damage caused 
by traumatic and inflammatory reactions. Physiologically, the conversion stops 
spontaneously when the inflammatory response is relieved; however, as the 
inflammatory response continues to be activated, the EMT process will persist and 
eventually lead to organ fibrosis (Kalluri & Neilson, 2003). “Type III EMT” refers to 
phenotypic transformation associated with epithelial malignancies. Primary epithelial 
tumour cells form migratory mesenchymal cells via type III EMT, migrate to different 
sites with blood flow, and then form epithelial tumour metastases by the reverse MET 
process. Unlike mesenchymal cells that completely lose epithelial phenotypes formed 
by EMT type I and type II, metastatic tumour cells formed by type III EMT acquire 
mesenchymal phenotype while maintaining certain epithelial cell characteristics (T. 





Figure 1-2 Classification of EMT into three different subtypes. 
 (A) Type 1 EMT is related embryogenesis which is generally shut during adult life. (B) Type 2 EMT appears in wound healing and fibrosis (C) Finally, type 3 
EMT is associated with the initiation of tumour progression, invasion and metastasis.  Adapted from (Kalluri & Weinberg, 2009).  
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EMT is controlled at several levels – post-translational level, transcriptional and post-
transcriptional, differential splicing regulation and non-coding RNA level (De Craene & 
Berx, 2013) (Figure 1-3). Many transcription factors have been described as contributing 
to the regulation of EMT, including basic helix-loop-helix (bHLH, including TWIST1/2), 
snail family transcriptional repressor 2 (SLUG, also called SNAI2), snail family 
transcriptional repressor 1 (SNAI1, also called SNAIL), and Zinc finger E-box binding 
homeobox (ZEB). These transcription factors work together to regulate the initiation 
and process of EMT through different signalling pathways and interactions between 
pathways. Members of the Snail family encode transcription factors with a zinc finger 
structure, including SNAI1 (SNAIL), SNAI2 (SLUG), and SNAI3 (SMUC), where SNAI1 and 
SNAI2 are important in embryonic development (mesoderm, gastrulation, neural crest 
development), tissue fibrosis and the EMT process in tumours. Snail binds to the E-box 
DNA sequence and promotes EMT phenotypic changes by inhibiting epithelial gene 
expression (Brzozowa et al., 2015). It also disrupts intercellular interactions by inhibiting 
the expression of claudin and occludin which results in promoting the EMT process. In 
addition, receptor tyrosine kinases (RTKs), or glycogen synthase kinase-3β (GSK3β) can 
also affect the EMT process by regulating the expression of Snail in EMT-related 






Figure 1-3 Regulatory interactions regulating EMT. 
Some transcription factors inducing EMT, e.g.  ZEB, TWIST1 and SNAI1, are essential in the 
regulation and collaboration with post-translational control. AS is demonstrated by specific 
splicing factors, like ESRPs and RBFOXs switch splicing towards a certain direction. However, 
non-coding RNAs also control EMT. EMT is instigated by the instability of the networking. 
Adapted from (De Craene & Berx, 2013) 
 
ZEB mainly includes ZEB1 and ZEB2, which are important intranuclear transcription 
factors. The transcriptional repression function of ZEB is mainly accomplished with the 
assistance of C-terminal binding protein (CTBP). In addition, the expression of ZEB is 
usually accompanied by the activation of Snail. SNAI1 alone or in combination with 
TWIST1 can induce the expression of ZEB1 and promote the EMT process.(J. Xu, 
Lamouille, & Derynck, 2009) 
In addition to the several transcription factors that are well-defined in the mechanisms 
mentioned above, other transcription factors also play a central role in regulating EMT. 
For example, forkhead box (FOX) with a winged helix and GATA transcription factor 
(described by their capability to bind to the DNA sequence "GATA") with a zinc finger 
structure can alter the polarity and connectivity of epithelial cells. The SOX (SRY box, 
Sex determining region Y boxes) can synergize with SNAI1 or SNAI2 to promote cell 
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metastasis and invasion (Guo et al., 2012). These transcription factors have been shown 
to have an influence on the EMT process, but the mechanism is not fully revealed. 
Epigenetic modifications suppressing epithelial properties then improve the function of 
these TFs. Though the TFs expression level is crucial for EMT, there are several TFs 
controlled by post-translational regulation which is acting through their distribution and 
degradation in cells (Thiery, Acloque, Huang, & Nieto, 2009).  
Adding to the direct effects of EMT-related transcription factors on gene expression, 
RNA splicing, and miRNA regulation can also have important effects on the structure 
and function of EMT-related proteins. Alternative splicing is a co-transcriptional process 
through which different mature RNAs may result and therefore different proteins. 
Several recently identified splicing regulatory proteins, such as ESRP1 and ESRP2, which 
define specific epithelial or mesenchymal splice variants are involved, adding a new 
level to the regulation network of EMT. Non-coding RNA regulation is also a master level 
that influences the cell type by repressing the genes modulating the epithelial and 
mesenchymal phenotype. 
In embryogenesis, as well as in natural and converted cell lines, EMT is induced by 
numerous signalling pathways (Figure 1-4). Among these signalling pathways, some are 
activated by various proteins of the transforming growth factor-β (TGF-β) family:  Notch, 
Wnts, epidermal growth factor (EGF), fibroblast growth factor (FGF), Hypoxia-Inducible 
Factor(HIF), Hepatocyte Growth Factor (HGF), and many others are included as well 
(Thiery et al., 2009). 
TGF-β is an important cytokine that regulates EMT progression. The TGF-β superfamily 
consists of 33 members, including three TGF-β subtypes, two types of activins, and bone 
morphogenetic proteins (BMPs). It plays an important role in embryonic development, 
wound healing, tissue fibrosis and malignant tumour development. 
TGF-β regulates EMT via the Smad pathway (Smad proteins: homologues of the 
Drosophila protein, mothers against decapentaplegic (Mad) and the Caenorhabditis 
elegans protein Sma). The TGF-β family member binds to the serine/threonine kinase 
receptor and phosphorylates the TGF-β type II receptor (TβRII, also known as TGFR2), 
which in turn activates the TGF-β type I receptor (TβRI, also known as TGFR1). 
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Afterwards TβRI phosphorylates downstream R-Smads (receptor-regulated Smads, 
Smad2 and Smad3); R-Smads binds to Smad4 to form a trimer complex. In BMP 
signalling, Smad1 and Smad5 act synergistically with Smad4 to activate or inhibit 
transcription of related genes by interacting with transcriptional coactivators or 
transcriptional co-inhibitors (Bosukonda & Carlson, 2017). In addition, Smads can 
directly activate the expression of some mesenchymal cell-related genes such as VIM, 
FN and COL1A1, regulating EMT progression (Heldin & Moustakas, 2012; Shin et al., 
2011). 
TGF-β can also regulate EMT through the non-Smad pathway. In the non-Smad pathway, 
TGF-β regulates EMT progression primarily through the Rho family, PI3K/Akt, and MAPK 
pathways in small G proteins. Activation of Rho, Rac (Ras-related C3 Botulinum Toxin 
Substrate) and other GTPases can induce actin recombination and formation of 
lamellipodia and filopodia (Zago, Biondini, Camonis, & Parrini, 2017; Zhou, Shi, Tian, 
Zhou, & Gao, 2016). Inhibition of Akt can inhibit the expression of SNAI1 and increase 
the expression of E-cadherin, thereby regulating the EMT process (X. L. Wang et al., 
2016). In addition, TGF-β can also activate the extracellular regulated kinase (ERK), P38, 
and c-Jun N-terminal kinases (JNK)/MAPK pathways. For example, transforming growth 
factor beta-activated kinase 1 (TAK1) is an upstream kinase of the P38 MAPK and JNK 
pathways. When stimulated by TGF-β, it activates TAK1, thereby activating the p38 
MAPK and JNK pathways (I. T. Chen, Hsu, Hsu, Chen, & Tseng, 2015). c-Jun is a 
component of the activator protein 1 (AP1) complex, which activates c-Jun and 
synergizes with Smad3-Smad4 to regulate TGF-β-induced transcription (Yi, Park, Jung, 
Jang, & Kim, 2015). 
In addition to the TGF-β family, other growth factors are also significant in the EMT 
process. They mainly include FGF, HGF, insulin-like growth factor 1 (IGF1), EGF, platelet-
derived growth factor (PDGF), vascular endothelial growth factor (VEGF), etc., which 




Figure 1-4 EMT Signalling Pathways.  
Various signalling and proteins prompt EMT in cells in embryogenesis, organ genesis, and also 
in human diseases. The above indicates the affected tissues and biological changes after the 
consequent reactions that promote EMT. Adapted from (Thiery et al., 2009) 
 
Recent studies have indicated that microRNAs can also regulate EMT by controlling EMT 
inducers (Korpal, Lee, Hu, & Kang, 2008). 
The miRNA-200 family, including miR-200a, miR-200b, miR-200c, miR-141 and miR-429 
and miR-205 regulate the E-cadherin repressor ZEB1, (closely related to EMT and 
tumour metastasis), inhibit E-cadherin expression and induce EMT. In contrast, 
overexpression of these miRNAs reverses EMT and induces mesenchymal transition 
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(MET). ZEB1 binds to the promoters of miR-200c and miR-141 to inhibit their expression, 
thereby helping ZEB1 to maintain the phenotype of the stromal cells. 
1.2.2 EMT in disease 
EMT plays an important role in epithelial injury, resulting in organ fibrosis and failure, 
and has been proven in kidney, respiratory, and hepatic fibrotic process models (Zavadil, 
Haley, Kalluri, Muthuswamy, & Thompson, 2008). 
Fibrosis is due to the pathological activation of fibroblasts. Fibroblasts accumulate and 
secrete too much collagen. The collagen fibers are stored, and they form a fibrosis 
collagen network, thus disrupting organ function and causing organ degeneration 
(Kendall & Feghali-Bostwick, 2014). Research shows that most of these fibroblasts are 
formed by EMT (Kalluri, 2009; Zeisberg & Duffield, 2010). 
EMT is currently considered a major factor in renal fibrosis, which leads to the 
proliferation of renal interstitial fibroblasts, eventually leading to tubular fibrosis. 
During renal fibrosis, BMP-7 and TGF-β are two major regulators, and high levels of TGF-
β are found in the patient's fibrotic tissue. (Figure 1-5) 
Despite the fact that EMT is essential for embryogenesis, organ generation and 
subsequent for wound healing and organ regeneration, the irregular induction of EMT 
can be harmful during adult life (Kalluri & Weinberg, 2009). The protein inducing EMT 
is locked in adult organs, however it can be restarted when the epithelial status of cells 
is changed, for example, in fibrogenesis (Iwano et al., 2002). SNAI1, one of the EMT 
promotors, is triggered probably following the TGF-β secretion in kidney fibrosis mouse 
models (Sato, Muragaki, Saika, Roberts, & Ooshima, 2003). Remarkably, Snail activation 
disrupts tissue homeostasis and is abundant in prompting EMT, fibrosis, and kidney 
failure in adult transgenic mice and is greatly actuated in renal fibrosis caused by  




Figure 1-5 TGF-β signalling regulates several pathways  
TGF-β signalling controls numerous pathways including promoting SNAI1 stimulation, that 
initiates EMT and helps epithelial cells transform into myofibroblasts which produce and secret 
collagen I. BMP-7 or vitamin D analogue may suppress TGF-β signalling which potentially 
decreases fibrosis in the kidneys. The bold characters represent pathways triggered by TGF-β 
signalling.(Thiery et al., 2009) 
1.2.3 EMT in tumour progression 
A number of studies have confirmed that EMT is vital in tumour invasion and metastasis, 
and the invasiveness of tumour cells is significantly enhanced after EMT (Figure 1-6). 
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Recent studies have confirmed that EMT is present in a number of tumours, like colon, 
breast, prostate cancer, liver cancer, lung cancer and cervical cancer (Brabletz, Kalluri, 
Nieto, & Weinberg, 2018; Tania, Khan, & Fu, 2014).  
EMT enables the invasion required in the initiation of tumour metastasis. Cell-cell 
adhesion mediated by repression of E-cadherin of cancer cells in the primary tumour is 
lost, while adhesion of basement membrane is lost via its basal surface increasing 
invasion and consequently joining the circulation. After that, cells leave the circulation 
to undertake the reverse mesenchymal-epithelial transitions (MET) to settle down at 
the metastatic location. Therefore, the invasion and then metastasis is induced and 
accomplished by EMT and MET (Chaffer & Weinberg, 2011). Furthermore, EMT gives 
cells mesenchymal features, as well as enables them to gain several other properties 






Figure 1-6 EMT plays a role in tumour progress. 
There are some phases undergoing the initiation of tumour progression, invasion and metastasis. Normal epithelial cells lose their polarization and adhesion 
to become invasive. Then the invasive and metastatic cells leave the tumour site to go into the blood vessel. EMTs also involve the next step: tumour cells leave 
the circulation at a distance to form metastases, which potentially undergo METs and therefore reverse to epithelial cells.   (Kalluri & Weinberg, 2009) 
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1.2.4 EMT as a cancer therapeutic target 
There is growing evidence that EMT and MET transitions play a crucial role in the 
regulation of cellular plasticity. At the same time, they may also become important 
targets for the treatment of tumours, metastasis and tumour tolerance. The variety of 
clinical results brought by EMT has shown that EMT is significant; therefore, inhibition 
of EMT has become a very promising treatment. However, the complexity of the signal 
pathways that regulate the EMT process, combined with the existence of a MET 
conversion mechanism that reverses the results of an EMT, makes the situation even 
more complicated. In addition, it is not known which tumour cells should be treated 
and at which stage of the tumour development. Recent studies have shown that tumour 
cells are already starting systemic dissemination at an early stage of tumour 
development. It is too late to give EMT suppression treatment after the tumour is 
clinically diagnosed. However, if tumour metastasis is a continuum (i.e., one metastasis 
spreads to the next), the use of EMT suppression therapy should prevent subsequent 
tumour metastases. 
The TGF-β signal is one of the EMT-inducing signals and is now the most clearly studied. 
Interestingly, while TGF-β inhibits the growth and proliferation of normal epithelial cells, 
it promotes tumour invasion and metastasis, tumour neovascularization, and 
suppresses anti-tumour immune responses in the tumour microenvironment at the late 
stage of cancer. Interestingly, TGF-β signalling can be pro-tumorigenic or tumour 
suppressive. Recently, David et al. published an article on TGF-β promoting pancreatic 
cancer cells entering lethal EMT transformation to suppress tumours. In TGF-β-sensitive 
pancreatic ductal adenocarcinoma (PDA) cells (EMT could be induced by TGF-β in PDA 
cells), the switch of TGF-β-induced Sox4 from a tumorigenesis enhancer into a cell death 
inducer makes EMT fatal. The mechanism is supposed to be relating with remodelling 
of the TF signalling with EMT, involving the suppression of the Klf5 which collaborates 
with Sox4 in tumorigenesis and inhibits cell death stimulated by Sox4 (David et al., 2016).  
Despite the current advances in EMT understanding, we have yet to develop a complete 
EMT-targeted cancer drug. Inhibition of the epidermal growth factor receptor (EGFR) is 
a significant treatment for non-small cell lung cancer (NSCLC) patients. In both 
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prognosing NSCLC and valuing treatment efficiency, EMT monitoring has been 
developed as a probe as expression of mesenchymal markers correlates with a bad 
prognosis and a poorer response to EGFR-TKIs. The EMT process is also linked to EGFR-
TKI resistance in NSCLC. (Jakobsen, Demuth, Sorensen, & Nielsen, 2016) There are lots 
of signalling pathways and proteins that induce and modulate EMT, including NFκB 
pathway, Wnt and Notch proteins, TGF-β, and RTKs and activating GFs such as IGF1, 
GAS6, HGF, FGF and EGF. In the occurrence of EMT triggered by Notch, EGFR-TKI 
treatment is the inducer as EGFR signalling generally suppresses the Notch pathway, 
which results in EMT initiation (Arasada, Amann, Rahman, Huppert, & Carbone, 2014). 
New drugs that target tyrosine kinase activity directed against different receptors in the 
EMT process, including vascular endothelial growth factor receptor EGFR, insulin-like 
growth factor 1 receptor IGF1R, PDGFR, FGFR, etc. are still in phase I clinical trials or in 
preclinical testing. The main problem in this type of study is the lack of a specific 
atraumatic marker of tumour metastasis during treatment that causes minimal tissue 
injury. We believe that the research on EMT and tumour metastasis will open up new 
horizons for the treatment of malignant tumours. 
It is unclear which signalling pathways to suppress during the EMT process to achieve 
the best possible outcome while minimizing side effects. The similarity between the 
EMT program and the normal stem cell program makes the toxic side effects of EMT 
inhibition therapy a major stumbling block. At the same time, the reversible nature of 
the EMT program and the MET program casts doubt on the efficacy of EMT suppression 
therapy. Another key issue is that tumour metastasis often evolves over years, or even 
decades, such as breast cancer - so how can we determine whether EMT suppression is 
effective before the tumour metastasis?  
The problems above indicate that although we have gone through a great deal of effort, 
discovered some of the molecular mechanisms underlying EMT and MET and their 
importance for clinical oncology patients, and developed effective anti-cancer therapy 
based on EMT and MET mechanisms, there are still some important basic issues to be 
solved. However, we believe that with the unrelenting efforts of the researchers, these 
problems will surely be resolved one by one in the near future. 
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Also, as one of the important phenomena in the process of tumorigeneses, EMT is an 
important mechanism in tumour cells invasion and migration and secondary metastasis. 
At present, the research on EMT is gradually deepening, and its role in cancer is being 
continuously uncovered, and the molecular mechanism of EMT continuously revealed. 
With the deepening of research, some new fields such as the interaction of EMT and 
the tumour matrix, the relationship between EMT and tumour angiogenesis, between 
the key events blocking EMT and the suppression of tumour invasion and metastasis 
will also be revealed. This will also provide new ideas and methods for cancer therapy.  
 
1.3 Alternative Splicing 
Alternative splicing is a very important gene regulation mechanism. It refers to the 
process of producing different mRNA splicing isoforms from one mRNA precursor by 
differential splicing (selecting different splice site combinations), then producing 
different proteins with different or mutually antagonistic functions and structural 
features, or different phenotypes due to differences in expression levels in the same 
cells (Chow, Gelinas, Broker, & Roberts, 1977; Y.-J. Kim & Kim, 2012; Konarska, 
Grabowski, Padgett, & Sharp, 1985; Pajares et al., 2007) (Figure 1-7). It is essential in 
differentiation, development, normal physiology, abnormal pathologies even involving 






Figure 1-7 An outline example of alternative splicing. 
Alternative splicing involves the process of producing several mRNA transcripts from one certain 
gene. Adapted from (Chow, Gelinas, et al., 1977) 
 
During splicing, a large protein-RNA complex forms in the cell that becomes a 
spliceosome. Spliceosomes recognize exons and remove introns. Spliceosomes consist 
of more than 120 proteins and 5 small nuclear RNAs. 
Spliceosome splicing involves two steps of biochemical reactions, both of them require 
trans-esterification reactions between the RNAs (Shi, 2017). Spliceosome and self-
splicing esterification reactions occur in a specific order. First, at branchpoint A of an 
intron, the nucleotide will undergo transesterification with the first nucleotide of this 
intron to form two RNA molecules, one being an intron lariat, and the other being the 
exon before intron. Then, the last nucleotide of the first exon will undergo 
transesterification with the first nucleotide of the second exon, ligating the exon and 







Figure 1-8 Two transesterification reactions are involved in spliceosome splicing: branching and 
exon ligation.  
First, the 3ʹ-OH of 3’-intron and the 5ʹ-end phosphate of the 5’-intron were connected to free the 
5ʹ-exon and a lariat was produced intermediately. Second, the two exons are ligated by a 
combination of 3ʹ-OH of the 5ʹ-end phosphate of the two exons and then the intron lariat was 





1.3.1 Pre-mRNA Splicing  
In 1958, the "sequence hypothesis" was first proposed by Crick. In this hypothesis, the 
codon encoding the amino acid sequence of the protein is offered by the nucleotide of 
the genetic material, which is the foundation of the "central rule of molecular biology" 
- the double-stranded DNA is transcribed into a single-stranded RNA molecule, which is 
then translated into a protein (Crick, 1958). Scientists first thought that mRNA 
molecules were translated by ribosomes through copying DNA sequences exactly. 
Roberts and Sharp then proposed the "split gene" hypothesis through their study of 
viral genes (Chow, Roberts, Lewis, & Broker, 1977). They found that in viruses, some 
mRNAs are shorter than the DNA they transcribe, and have large interference gaps, 
called introns. Soon most eukaryotic genes were also found to have this molecular 
structure, and the coding sequence (exons) was interrupted by non-coding sequences 
(introns). During transcription, the introns of Pre-mRNA are removed, and the exons are 
relegated by the splicing process to produce mature mRNA transcripts (Figure 1-9). 
It is now commonly believed that the theory that one gene holds the message for 
creating one amino acid polypeptide chain (Beadle & Tatum, 1941) has proven to be 
over-simplified. In fact, there are much fewer genes in the human genome than 







Figure 1-9: snRNPs in Pre-mRNA splicing.  
Pre-mRNA is transcribed from a gene, introns removed, and exons re-joined by the process of 
splicing to create mature mRNA transcripts under the function of small nuclear 
ribonucleoproteins (snRNPs). Base pairing of U1 to 5’ss and recognition of BP by U2 (formation 
of complex A) are followed by the integration of preformed U4/U6-U5 tri-snRNP to form complex 
B. Prp4, Prp31, and Brr2, Prp8, Prp6 are components of U4/U6 snRNP and U5 snRNP, separately. 
Then Complex B is activated by the phosphorylation of Prp6 and Prp31 (complex BAct). U1, U4, 
Prp4, Prp6, and Prp31 are released from the activated spliceosome that catalyzes the two 





1.3.2 Alternative splicing: a mechanism to increase proteome diversity 
It is predicted that there may be about 19,000 genes in the human genome, about 
14,000 in fruit flies and about 19,000 in C. elegans (Ezkurdia et al., 2014). There seems 
to be a significant difference between the biological complexity and the number of 
genomic genes. The reason is in the proteome. Mechanisms such as gene 
rearrangement, RNA editing, and alternative splicing can produce numerous proteins 
from a single gene, allowing the number of proteins in the proteome to exceed the 
number of genes in the genome. Among them, variable splicing is the most important 
mechanism for expanding protein diversity regarding the number of genes affected and 
the range of biological species (Adams et al., 2000; Consortium, 1998; Ewing & Green, 
2000; Pennisi, 2000).  
There are several important questions about alternative splicing - firstly, the frequency 
of alternative splicing. In 1977 Walter Gilbert put forward the concept of alternative 
splicing (Maxam & Gilbert, 1977). In 1980, Baltimore discovered the first alternative 
splicing in mouse IgM gene to generate membrane-type and secretory IgM (Alt et al., 
1980). By 2001, using classical molecular biology experiments, a total of only a few 
hundred genes with AS were discovered and it was speculated that around 5% of genes 
in higher eukaryotic organisms have alternative splicing (Graveley, 2001; Modrek & Lee, 
2002). 
High-throughput genomic sequencing and expressed sequence tags (EST) sequencing 
make it possible for bioinformatics methods to study alternative splicing. ESTs are 
derived from fully processed mRNAs, which provide a broad range of mRNA diversity 
samples. This diversity can be analysed by computer. In the last few years, several 
research groups have analysed data from human genome sequencing project and found 
consistently that about 35% -60% of human genes have alternative splicing patterns. 
Moreover, for most genes, only a few ESTs or even no ESTs are reported for each gene; 
ESTs are not full-length mRNAs, but mostly at the 5 'and 3' ends of the mRNA; ESTs are 
derived from limited tissue at a limited development stage; it is highly likely that more 
alternative splice variants are not shown in the current EST library. Therefore, the actual 
frequency of alternative splicing may be higher than predicted.  
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More and more human genes have been revealed to undertake alternative splicing 
(Modrek & Lee, 2002; Pan, Shai, Lee, Frey, & Blencowe, 2008; E. T. Wang et al., 2008). 
New data using RNA sequencing has shown that about 95% of human multi-exon genes 
have an alternative splicing process (Pan et al., 2008), and according to the latest human 
genome annotation information (GENCODE Human Annotation, the data provided by 
Version 28, http://www.gencodegenes.org), 58381 genes (including 19,901 protein-
coding genes) in the human genome produce a total of 203,835 transcripts (including 
82335 protein coding transcripts). The number of transcripts encoded on average by 
one gene reached 4.14, which indicates the great contribution of alternative splicing to 
protein diversity. 
Secondly, another issue is the diversity of single gene alternative splicing (Graveley, 
2001). A single gene can produce multiple transcripts in several ways, such as different 
transcription initiation sites, alternative splicing, selection of different tailed signal sites, 
and RNA editing. There are seven modes of alternative splicing: exon skipping; 
alternative 3ʹ-SS; alternative 5ʹ-SS; mutually exclusive exons; intron retention; usage of 
alternative promoters and alternative polyadenylation. The effect of alternative splicing 
on the structure of proteins is also diverse, such as the increase or decrease of one to 
several hundred amino acids in the polypeptide chain; the presence or absence of a 
domain; ineffective translation if alternative splicing changes the reading frame, mRNA 
degraded by the monitoring system - the nonsense-mediated mRNA decay (NMD). 
The production of 10-12 isoforms from a single gene through alternative splicing is quite 
common. Some genes even produce thousands of splicing isoforms. The most 
prominent example is the Dscam gene of Drosophila melanogaster, which produces 
over 38,000 mRNA isoforms through alternative splicing. The Dscam gene encodes a 
neuronal axon-targeting receptor, which has an extracellular domain consisting of 10 
immunoglobulin repeats. Fortynine different splicing isoforms were found by random 
sequencing of 50 cDNA clones of the Dscam gene, indicating that there are at least a 
thousand species of splicing isoforms even if they are not theoretically possible. Genes 
such as Neurexins, N-Cadherins and calcium-activated potassium channels in humans 
also have similar highly diverse splicing isoforms (Schreiner, Simicevic, Ahrne, Schmidt, 
& Scheiffele, 2015; L. J. Tian et al., 2001). 
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1.3.3 Modes of alternative splicing 
Seven basic modes of alternative splicing are recognized (Figure 1-10) (Di et al., 2019): 
1) Exon exclusion: a whole exon is skipped or cassette; 
2) Mutually exclusive exons: one of the two exons is included and the other is 
excluded in splicing; 
3) Intron retention: an intron sequence is retained by mis-splicing; 
4) 5' Alternative donor site: a 5' alternative splice site competes with the natural 
ones to the loss of part of an exon or to include part of an intron in the mRNA; 
5) 5' Alternative donor site: a 3' alternative splice site competes with the natural 
ones to the loss of part of an exon or to include part of an intron in the mRNA; 
6) usage of alternative promoters: use of alternative promoter results in exon 
skipping; 





Figure 1-10 Different patterns of alternative splicing  
Common types of alternative splicing are shown as above: A: exon exclusion – skipping introns 
and entire exon 2; B: alternative splice sites – exon 3 has a 5' alternative splice site. C: alternative 
splice sites – exon 2 has a 3' alternative splice site. The two sites compete with the entire ones 
which result in a part exon or intron inclusion D: mutually exclusive exons – exon 2 or exon A is 
excluded, only one is included; E: intron retention – including intron 2; F: usage of alternative 
promoters – in use of P2 exon 1 is excluded G: alternative polyadenylation – exon 3 is excluded 




1.3.4 Regulation of alternative splicing 
In alternative splicing regulation, splice factors, splicing related proteins and RNA, as 




Figure 1-11 Several regulatory proteins and sequences modulating alternative splicing. 
There are four categories of sequences involved in regulating alternative splicing: 
intronic splicing enhancers (ISEs), intronic splicing silencers (ISSs), exonic splicing 
enhancers (ESEs) and exonic splicing silencers (ESSs). Adapted from (McManus & 
Graveley, 2011). 
 
Splicing enhancers and silencers include intronic splicing enhancers (ISEs), intronic 
splicing silencers (ISSs), exonic splicing enhancers (ESEs) and exonic splicing silencers 
(ESSs). (McManus & Graveley, 2011) The enhancers are identified by activating proteins 
that often come from the SR protein family. Silencers combine with suppressors that 
are most often from the hnRNP protein family. Activators generally help spliceosomal 
components combine to the regulated splice site while suppressors likely prevent the 
spliceosomal components from combining or functioning, which is due to the binding 
sites. In splicing, the combination of ESE/ISE and serine/arginine-rich (SR) protein could 
help with binding U1 small nuclear ribonucleic particles (snRNP) and U2 snRNP to the 
splice site to facilitate the splicing and exon inclusion. However, the binding of exon 
splicing silencer ESS/ ISS and heterogeneous nuclear ribonucleoprotein (hnRNP) 
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prevents U1 snRNP and U2 snRNP binding to the splice site, impedes the splicing and 
thus excludes exons from mature mRNA (exon exclusion). 
Splice factors play an auxiliary role in splicing by binding to ESE/ESS. The fact that most 
ESEs are located adjacent to the splice site they regulate helps to recruit splicing factors 
to the splicing site; changing their location will alter splicing activity or even cause them 
to become trans-acting factors. 
During splicing, some proteins are required to recognize enhancers or silencers in exons 
and introns that, when combined with enhancers or silencers, can recruit U1 snRNP, U2 
snRNP, or serine/arginine-rich splicing factor 1 (SRSF1) to constitute a spliceosome. 
Classically ESE binds to the SR protein, whereas the ESS binds to the hnRNPs. Generally, 
SR protein can promote exon inclusion, while hnRNPs prevent exon inclusion; though, 
in some genes it works differently, such as an exon of GTPase Rac1 being blocked by 
the SRSF1, whereas an abnormal splicing of ceramide blocks exon inclusion via the SR 
protein (Goncalves, Matos, & Jordan, 2009; Sumanasekera et al., 2012). 
Polypyrimidine tract binding protein (PTB) is a well-studied hnRNP. PTB competes with 
SRp30c for regulatory elements of the hnRNPA1 gene (Paradis et al., 2007). In addition, 
there is competition between SR proteins such as SRp20 and SRSF1 in the Rac1b gene 
(Goncalves et al., 2009). Splicing regulatory proteins not only act as antagonists to each 
other but also as collaborators with each other, for example FOX-3 interacts with PSF 
and promotes splicing in neurons (K. K. Kim, Kim, Adelstein, & Kawamoto, 2011). Splice 
factor expression is one of the important level regulating splicing, and splice factors 
usually also have the ability to self-regulate. Expression levels of splice factors by self-
regulating are also generated by splicing isoforms, such as FOX, SRSF1 (Damianov & 
Black, 2010; Sun, Zhang, Sinha, Karni, & Krainer, 2010). 
AS in the non-coding areas of the mRNA may disturb the translation and mRNA stability 
by nonsense-mediated mRNA decay (NMD) depending on the translation machinery 
(Maquat & Carmichael, 2001). 
1.3.5 Splicing in disease 
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Over the last few years, the correlation between alternative splicing and human 
diseases has been gradually revealed. Changes in the ratio of splicing isoforms of some 
key proteins play a role in the development and progression of pathogenic processes. 
It is revealed that the genetic disorders were caused by splicing mutations; however, 
the mutations might be considered less frequent  than in reality (Anna & Monika, 2018). 
Research demonstrated that 15% of human genetic diseases were caused by splicing 
mutations, ranging from neurological to myogenic and metabolic disorders (Faustino & 
Cooper, 2003; Krawczak, Reiss, & Cooper, 1992; Sterne-Weiler & Sanford, 2014). 
Synchronous mutations in disease do not cause changes in the encoded protein 
sequence but may alter ESE and ESS on exons or introns, thereby affecting the splicing 
process. Similarly, since some mutations cause RNA terminators to appear prematurely, 
not only does this RNA have no function in the encoded protein, but it may directly 
affect the splicing process of other normal RNAs and cause disease. 
The classic examples of mutations in cis-acting elements that trigger splicing defects are 
the Tau protein disorders represented by frontotemporal dementia and Parkinsonism 
(FTDP), muscular dystrophy (MD), and spinal muscular atrophy (SMA) (Licatalosi & 
Darnell, 2006; Spillantini, 2003). 
Mutations that occur in the trans-acting element genes regulate the proteins that 
control the splicing process and cause disease. SF3B1 and U2AF1 are the genes 
respectively encoding U2 snRNP and U2AF1 (both are protein complexes involved in 
splicing), and the mutations in these two genes are tumour-associated (Papaemmanuil 
et al., 2011). 
1.3.6 Cancer and alternative splicing 
The biological origin, progression, and metastasis of cancer are related to the diversity 
of mRNA. Cancer-specific alternative splicing is a ubiquitous phenomenon and a major 
post-transcriptional regulatory mechanism involving many cancer types. Every 
'hallmark of cancer' is connected to a splicing change, promoting the tumour to be more 
aggressive (S. Oltean & Bates, 2014). In tumourigenesis and metastasis, genomic 
steadiness is disturbed by oncogenic and cancer suppressing proteins encoded by AS, 
e.g. LEF1, TP63, HNF4A, RASSF1 and BCL2L1 (Carstens, Eaton, Krigman, Walther, & 
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Garcia-Blanco, 1997; Davuluri, Suzuki, Sugano, Plass, & Huang, 2008; E. Kim, Goren, & 
Ast, 2008; Pajares et al., 2007; Rajan, Elliott, Robson, & Leung, 2009; Venables, 2006). 
(Figure 1-12) 
 
Figure 1-12 Alternative splicing functions in tumour progression 
The formation of the tumour is induced by the abnormal proteins in tumour cells. The different 
isoforms of oncogenic and tumour suppressor genes in tumours compared to normal tissues 
might be prospective markers to distinguish normal and tumour cells. Adapted from (Y.-J. Kim & 
Kim, 2012).  
 
While it is still not fully revealed how AS functions in tumours, several of the vital stages 
of the typical splicing pattern are  perceived in tumours (Miura, Fujibuchi, & Sasaki, 
2011).  
Alternative splicing is an essential regulatory step in all of the cancer hallmarks, e.g. 
apoptosis and proliferation. RNA Binding Motif Protein 4 (RBM4) is a splicing factor 
capable of binding to intron splicing facilitating elements to regulate splicing. RBM4 
switches splicing of Bcl-x to control the balance between pro- and anti-apoptotic 
pathways and, thus, promoting tumour cell death and inhibiting cancer progression. 
More importantly, through high-throughput sequencing it was found that RBM4 can 
also regulate the expression of another very important splicing factor, SRSF1, which is 
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known to encourage cell proliferation and decrease apoptosis, and further affect the 
activation of the downstream mTOR signalling pathway which can promote tumour 
development through proliferation. (Y. Wang et al., 2014)  
Angiogenesis, the forming of new blood vessels, is key to tumour development and 
regulated by AS. Vascular endothelial growth factor A (VEGF, also referred to as VEGF-
A) which is controlled by several splicing factors, is a key inducer of vascular formation 
in cancer (Biselli-Chicote, Oliveira, Pavarino, & Goloni-Bertollo, 2012). VEGF has 
multiple alternative splice sites, which increases the diversity of VEGF-A isoforms. AS of 
exon 8 of VEGF-A is the vital factor converting pro-angiogenic VEGF-Axxx isoform to 
anti-angiogenic VEGF-Axxxb isoform (Harper & Bates, 2008). For example, VEGF-A165 
excites immigration and cell growth, promotes vasodilatation, improves permeability in 
endothelial cell in vitro, constantly boosting formation, growth and permeability of 
blood vessels, and pathological retinal neovascularization in vivo, while VEGF-A165b has 
the opposite functions, and reduces some responses in tumours induced by VEGF-A165 
(Bates et al., 2002; Bates & Curry, 1996; Bevan et al., 2008; Ferrara, Houck, Jakeman, 
Winer, & Leung, 1991; Harper & Bates, 2008; Ku, Zaleski, Liu, & Brock, 1993; Mitchell et 
al., 2006).  
For another hallmark of cancer – invasion and metastasis, alternative splicing also plays 
a vital regulation role. During cancer progression, epithelial-mesenchymal transition 
(EMT) is an essential step helping tumour cells to gain more invasive and aggressive 
phenotypes. The EMT process involves a set of biological changes in transcription, post 
- transcriptional modifications and alternative splicing. One of the well-known genes 
alternatively spliced in EMT is fibroblast growth factor receptor II (FGFR2). FGFR2 has 
two mutually exclusive alternative exons - exon IIIb and IIIc. Exon IIIb is selected in 
epithelial cells while in EMT, exon IIIc is selected to produce a mesenchymal phenotype. 
Besides the switch between the two exons, there are a series of functional changes 
inside the cells. Researchers found that the RNA binding proteins hnRNPA1 and PTB, 
which had high expressing level in tumours, played a role in exon IIIc exclusion 
(Yasumoto, Matsubara, Mutaguchi, Usui, & McKeehan, 2004). Two splicing regulatory 
proteins, epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2), were 
recognized by exploring genes that were involved in helping IIIb inclusion. ESRPs are 
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expressed specifically in epithelial cells while lost in EMT. Exon IIIc exclusion of FGFR2 
in mesenchymal cells could be induced by overexpressing ESRPs.  
In addition, AS contributes to protecting tumours from the drug treatment – drug 
resistance. Taking BRAF (a human gene that encodes a protein called B-Raf), an 
oncogene, as an example, it has been found that cancer cell lines with Vemurafenib (a 
kind of targeted cancer drug prohibiting cells expressing BRAF protein from stimulating 
some tumour cells) resistance produce a truncated BRAF variant protein, directly 
affecting cell growth and avoiding the drug effect. Generating of this variant is due to 
abnormal AS – an absence of a part of exon. (Pratilas, Xing, & Solit, 2012) 
BRCA1 splicing and poly ADP ribose polymerase (PARP) inhibitor in breast cancer 
therapy is another example of resistance to therapy. PARP1 is critical for repairing 
damaged DNA and is a vital protein which PARP inhibitors take effect on. PARP 
inhibitors are particularly useful in patients deficient in DNA repair due to mutations in 
the BRCA1 gene. But unfortunately, like many other treatments, cancer cells eventually 
develop resistance. The researchers found that specific PARP1 mutations inhibit the 
combination of proteins and DNA, leading to PARP inhibitors being unable to monitor 
DNA damage in cancer cells. The mutated BRCA1 gene can protect tumour cells from 
dysfunctions of DNA repair of PARP1 and therefore PARP inhibitors. (Pettitt et al., 2018; 
Siegfried & Karni, 2018) 
1.4 Epithelial splicing regulatory proteins 
Warzecha and his lab indicate that Epithelial splicing regulatory proteins 1 and 2 (ESRP1 
and ESRP2) are main regulators that switch splicing during EMT and are specific to 
epithelial phenotype (Warzecha et al., 2010). ESRPs control a large number of genes 
splicing to the epithelial phenotype during EMT. In EMT, ESRPs are usually lost, 
therefore their target genes splice differently which result in a different phenotype - 
mesenchymal phenotype. AS involved in EMT was observed in primary breast cancer 
biopsy, and the change of ESRP1 expression is an important reason for switching mobile 
cells to gain epithelial properties (Shapiro et al., 2011; Warzecha, Sato, Nabet, 
Hogenesch, & Carstens, 2009; Warzecha, Shen, Xing, & Carstens, 2009). Meanwhile, 
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other research demonstrated that depletion of ESRPs resulted in EMT (Horiguchi et al., 
2012). 
It is suggested that the ESRPs are one of the most crucial epithelial-specific genes. 
Mesenchymal transcription factors, e.g. TWIST, SNAI1/2, or ZEB1/2 are main 
suppressors of ESRPs, either acting direct or subtly to accomplish a whole phenotype 
switch in EMT (Warzecha et al., 2010). ESRPs expression is also indirectly down-
regulated by TGF-β. Comprehensive patterns of alternative splicing were found induced 
by TGF-β through downregulating ESRPs, which was the result of TGF-β-mediated 
increasing delta-EF1 family,  delta-EF1 and SIP1 transcription factors (Horiguchi et al., 
2012).  
1.4.1 ESRPs as RNA binding proteins 
RNA binding proteins (RBPs) play a key role in gene regulation. At present, only a few 
RNAs can function alone as ribozymes. Most RNAs bind to proteins to form RNA-protein 
complexes. The regulation of life activities such as synthesis, alternative splicing, 
modification, transport and translation play a key role, so studying the interaction 
between RNA and protein is the key to exploring RNA function.(Lunde, Moore, & Varani, 
2007) 
There are many types of RBPs, accounting for about 6% to 8% of all proteins encoded 
by the cell. So far, only a few studies on the function of RBP are clear, indicating 
Argonaute (AGO), human antigen R (HuR, also known as ELVAL1), ARE/poly(U)-
binding/degradation factor 1 (AUF1), Tristetraprolin (TTP also known as zinc finger 
protein 36 homolog [ZFP36]), and CUG triplet repeat, RNA binding protein 2 (CUGBP2). 
Many of them are interacting with non-coding RNA (ncRNA) to control the intracellular 
localization of ncRNA, methylation modification, formation of miRNA silencing complex, 
and alternative splicing. In the current research on ncRNA such as lncRNA, the function 
of RBP is considered extremely important.  
ESRPs were first known as RBM35a and RBM35b, two well-known RBP proteins. In 2009, 
Carstens Laboratory reported the characterization of epithelial-specific splicing factors 
following a cDNA screen, which identified splicing factors that switch splicing of FGFR2 
to the epithelial isoform - FGFR2 IIIb (Warzecha, Sato, et al., 2009). The two paralogous 
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genes (RBM35A and RBM35B), encoding RNA- binding proteins, are the master 
regulators of exon IIIb retention. Interestingly, they are not only essential to switch 
FGFR2 to the epithelial phenotype, but also to CD44, ENAH, and CTNND1 splicing 
towards epithelial. This suggested that RBM35A and RBM35B are controllers of an 
epithelial cell-type-specific splicing program, which was definitely confirmed in 
consequent research (Warzecha, Shen, et al., 2009). Due to the huge raised expression 
in epithelial cells, the RBM35A and RBM35B genes and their encoding protein products 
were given the names ESRP1 and ESRP2 (Warzecha, Sato, et al., 2009).  
1.4.2 The role of ESRPs in tumour progression 
ESRPs are thought to be tumour suppressors by acting as master regulators of the 
splicing decisions that define the epithelial phenotype (Newman et al., 2006; Warzecha, 
Shen, et al., 2009). 
It has been shown that ESRPs bind to the cis-element in the intron 8 of FGFR; therefore 
they inhibit the exon IIIc inclusion and trigger the exon IIIb inclusion, which result in 
expression of epithelial type proteins (Hovhannisyan, Warzecha, & Carstens, 2006). 
Researchers proposed that ESRPs are important regulators of EMT and essential in 
keeping epithelial properties and therefore inhibiting tumour transformation and 
conversion to cells with mesenchymal properties (Dittmar et al., 2012). Previous work 
on this field also recognised ESRPs as controllers of a complicated alternative splicing 
regulating system that supplements a significant post-transcriptional level to the 
modifications in gene expression. This progress results in complicated alterations in cell 
morphology, polarization, and behaviour that enable transitions between epithelial and 
mesenchymal cell status and involve EMT during cancer development and fibrosis 
(Warzecha & Carstens, 2012; Warzecha et al., 2010).  
The latest reports have also addressed how ESRPs not only down-regulated but also 
sometimes up-regulated in tumour progression. ESRPs proteins are low expressed in 
normal epithelial cells but increased in primary and advanced tumours. Remarkably, 
they decrease before the invasion area. The elastic change of ESRP level indicates their 
conflicting properties in tumour development. Constantly, it has been revealed that 
ESRPs inhibit mobility and proliferation of tumour cells while rescuing cells by improving 
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tolerance to reactive oxygen species (Hayakawa, Saitoh, & Miyazawa, 2017; Ishii et al., 
2014).  
1.4.3 ESRPs splicing targets 
ESRPs switch splicing towards epithelial phenotype of about 200 genes, including FGFR2, 
NUMB, EXOC1, MAPK14, SCRIB and GSK3G (Dittmar et al., 2012; Warzecha & Carstens, 
2012). In EMT, ESRPs are lost, their target genes splice differently which result in a 
different phenotype – the mesenchymal phenotype.  
ESRP1 and 2 are master regulators of many AS events in epithelial cells where 
polarization is maintained by tight and adherent junctions. The cytoskeletons were 
destroyed by essential signalling pathways with actin cytoskeleton alteration in EMT. 
Meanwhile, the switches in cells promote focal adhesion and other structures that 
mediate cell motility forming. Some key proteins of these complexes and pathways 
were highlighted in Figure 1-13. mRNAs that change splicing during EMT or pathways 
that give epithelial and mesenchymal properties are shown in Figure 1-13. Therefore, 
this epithelial splicing regulatory network (SRN) switches the protein to epithelial 
isoforms to keep epithelial cell shape, activities and properties. 
When EMT is activated, splicing is switched among hundreds of genes by inhibiting ESRP 
expression, resulting in proteomes that confer mesenchymal-like characteristics to cells. 
Three independent studies that aimed at fully identifying the splicing changes that 
occurred during EMT resulted in a great number of overlapping data sets (Shapiro et al., 
2011; Warzecha et al., 2010; Y. Q. Yang et al., 2016). This is an important discovery and 
proposes that many gene pools share epithelial and mesenchymal cells, and yield 
different functions through AS. Therefore, this explanation has given many laboratories 
a motivation to consider and study the probability that these distinctly different 
functions of the same gene or protein might be the reflection of the result of the AS 






Figure 1-13 mRNAs that change splicing under control of ESRPs. 
The left of the figure is an example of an epithelial cell while the right is a mesenchymal cell after 
EMT. Junction proteins that are important for polarization are shown. Other proteins important 
in signalling and interactions are shown. Other signalling and protein-protein interactions 
associated with EMT are also indicated.  Adapted from (Warzecha & Carstens, 2012) 
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1.5 Fibroblast growth factor receptor 2 (FGFR2) 
FGFR2 is well-known as a gene controlled by tissue-specific AS (Eswarakumar, Lax, & 
Schlessinger, 2005; Hovhannisyan et al., 2006; Y. Katoh & Katoh, 2009; Matsuda, Ueda, 
& Ishiwata, 2012; Muh, Hovhannisyan, & Carstens, 2002; Newman et al., 2006; Ranieri 
et al., 2016; Warzecha, Sato, et al., 2009). Recently, it has been acknowledged that 
ESRP1 and 2 were master modulators of FGFR2 AS, switching FGFR2 splicing to the 
epithelial phenotype. 
FGFR2 gene abnormalities have been found in lung squamous cell carcinomas, breast 
cancers, endometrial cancers, and renal cancers, which are related to tumour 
development. About 10% of gastric cancer patients and 1% of breast cancer patients 
have FGFR2 gene amplification. 3% of lung squamous cell carcinoma and 2% of 
endometrial cancer patients carry FGFR2 gene mutations. It was indicated that 
increased FGFR2 gene expression leads to a higher risk of breast cancer. Furthermore, 
the single nucleotide polymorphism of the gene is also correlated with breast cancer 
risk. FGFR inhibitors (for example, AZD4547, TKI258, etc.) show good anti-cancer effects 
on tumour cells carrying FGFR2 gene amplification and gene mutations and can inhibit 
cell proliferation and promote apoptosis. FGFR2 gene abnormality - amplification 
and/or mutation can be used as one of the reference factors for predicting the 
anticancer effect of FGFR inhibitors.  
1.5.1 The properties and function of FGFR2 
FGFR2 plays a significant role in embryogenesis and organ regeneration, particularly 
bone and vascular. The FGFR family functions through the bond of ligation and 
dimerization (pairing of receptors), triggering the tyrosine kinase domains to instigate 
a set of consequent signalling pathways (M. Katoh, 2016). Cell division, growth and 
differentiation are induced by these signalling pathways (Helsten, Schwaederle, & 
Kurzrock, 2015; M. Katoh, 2009; C. M. Lu et al., 2015; Tarkkonen et al., 2012). An 
increase in FGFR2 IIIc inclusion and FGFR2 IIIb exclusion has been indicated in the 




1.5.2 FGFR2 isoforms and EMT 
The D3 region of FGFR2 is encoded by three exons. Alternative splicing of the D3 region 
results in the C-terminus being highly variable, resulting in a high-affinity FGFR2 IIIb or 
FGFR2 IIIc subtype with a transmembrane structure (Eswarakumar et al., 2005). The two 
isoforms are mutually exclusive and highly tissue-specific (Figure 1-14) (Eswarakumar 
et al., 2005). Researchers observed a shift between FGFR2 IIIb and FGFR2 IIIc in EMT 
(Thiery & Sleeman, 2006). FGFR2 IIIb is principally observed in epithelial cells while 
FGFR2 IIIc is mainly located in mesenchymal cells (Orrurtreger et al., 1993). FGF7 and 
FGF10 expressed by interstitial cells can specifically activate FGFR2 IIIb, while FGF2, 
FGF4, FGF6, FGF8 and FGF9 specifically activate FGFR2 IIIc (Ornitz et al., 1996; X. Q. 
Zhang et al., 2006).  
In epithelial cells, FGFR2 IIIb functions in suppressing tumours, however FGFR2 IIIc 
performs an oncogenic function. Based on research that the switching of FGFR2 IIIb/ IIIc 
stimulates EMT, the consequence of the abnormal appearance of FGFR2 IIIc in human 
epidermal cell that produces keratin indicated that, by morphological analysis, in 
reverse of FGFR2 IIIb overexpression, the enforced expression and induction of FGFR2 
IIIc induce the epithelial cells to obtain a mesenchymal morphology and actin 
reformation. Furthermore, an increase of invasion and proliferation in FGFR2 IIIc 
transfected keratinocytes was constant of its potential oncogenic function. All above 
biological changes illustrate that FGFR2 splicing was complemented by regulation of 
EMT markers. Ultimately, the investigation of the distinguishing markers expression 
revealed that initiation of FGFR2 IIIc prompts a procession related to the activation of  
the EMT associated with tumours, other than the EMT occurring during FGFR2 IIIb-






Figure 1-14 Splicing event of FGFR2.  
Cells of epithelial phenotype skip exon 9/IIIc while in mesenchymal phenotype exon 9/IIIc is 
included. 
 
1.5.3 Regulation of FGFR2 alternative splicing 
FGFR2 has two mutually exclusive exons, exon8 /IIIb and exon 9/IIIc. The inclusion of 
exon IIIb in FGFR2 IIIb or exon IIIc in FGFR2 IIIc modifies the C-terminal half of the D3 
loop of FGFR2, and is also responsible for the different ligand-binding specificities of the 
two isoforms (Eswarakumar et al., 2005). In recent years, a number of cis- and trans-
acting elements have been identified that regulate the alternative splicing event. Exon 
IIIb suppression is mediated by the presence of weak splice sites flanking the exon, an 
ESS within the IIIb exon and both upstream and downstream ISS (Carstens, Wagner, & 
Garcia-Blanco, 2000; Delgatto & Breathnach, 1995; DelGatto, Gesnel, & Breathnach, 
1996; Wagner et al., 2005; Wagner & Garcia-Blanco, 2001). Binding of hnRNPA1, PTB1, 
SR family proteins and other factors to these elements suppresses the exon IIIb and 
stimulates FGFR2 IIIc expression in mesenchymal cells (Carstens et al., 2000; Del Gatto-
Konczak, Olive, Gesnel, & Breathnach, 1999; Wagner et al., 2005; Wagner & Garcia-
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Blanco, 2001, 2002). In epithelial cells, employment of epithelial specific factors 
switches the splicing events to the inclusion of exon 8.  
ESRP1 and ESRP2 are cell type-specific regulators of FGFR2 splicing binding to an ISE/ISS-
3 region within intron 8 to promote FGFR2 IIIb - specific splicing (Warzecha, Sato, et al., 
2009). In the FGFR2 gene, there are some intronic and exonic cis-elements in and nearby 
exons IIIb and IIIc, in which some elements in intron 8 improve exon IIIb inclusion. 
ISE/ISS-3 is an ESRP binding site and could be disabled through dysfunction by mutants. 
ESRPs increase inclusion of exon IIIb and skip the exon IIIc by binding to ISE/ISS-3 (Figure 
1-15 B). It is indicated that a partial switch from FGFR2 IIIb to FGFR2 IIIc that overlap 
with EMT properties, including reduction of epithelial markers like E-cadherin and 
Keratin 15, and rise of mesenchymal markers like TWIST, N-Cadherin and Vimentin 
correlated with the decrease of ESRPs expressing. This finding is shown by the 
investigation of FGFR2 splicing in EMT stimulated by TWIST. (Warzecha, Sato, et al., 
2009)  
It has been investigated whether Fox-2 is also an inhibitor of exon IIIb and promotor of 
exon IIIc splicing. As Fox binding site and ISE/ISS-3 is nearby, the interaction between 
them might be required by both roles. However, there are numerous other proteins, 
such as hnRNP F, hnRNP H, and hnRNP M, that only inhibit exon IIIc without direct 
effects on exon IIIb inclusion (Hovhannisyan & Carstens, 2007; Mauger, Lin, & Garcia-
Blanco, 2008). A complex of RBFOX2, hnRNPH1 and hnRNPF also contribute to 
epithelial-specific splicing by competing for binding to a site that is occupied by the SR 
proteins SRSF1 in mesenchymal cells (Baraniak, Chen, & Garcia-Blanco, 2006; Mauger 
et al., 2008). Other proteins and sequences have also been identified that contribute to 
the regulated expression of FGFR2 IIIb and FGFR2 IIIc, but the full details of the 
alternative splicing regulation remain to be worked out (Del Gato-Konczak et al., 2000; 




Figure 1-15 Schematic diagram for the regulation of FGFR2 Splicing in epithelial and mesenchymal cells 
A Mesenchymal cell: Splice factors like PTB bind to cis-elements in the introns surrounding exon IIIb to inhibit the inclusion of exon IIIb. Some other unknown 
splice factors (X) bind to cis elements near exon IIIc to activate it. 
B Epithelial cell: splice factors like Fox and Tia collaborate with ESRPs to inhibit the inclusion of exon IIIc and promote the inclusion of exon IIIb. Tia1 or TiaR; 
M, hnRNP M; F/H, hnRNP F or H. Adapted from (Warzecha, Sato, et al., 2009)
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1.6 Using small molecules to modulate alternative splicing 
Pre-mRNA splicing plays a crucial role in gene expression, while AS is an important 
procedure for the abundance of protein variations. AS is also vital to many diseases, 
especially cancer. One of the practical treatment options is to interfere with pre-mRNA 
splicing as some tumours are dependent on specific RNA splicing isoforms. Over the last 
few years, researchers have illustrated numerous RNA splicing regulators, and several 
of them have shown potential in disease treatment. However, the majority of splicing 
regulators target RNA splicing, which can lead to undesired side effects, so the options 
of single splicing selection have been detected (Newman et al., 2006; Warzecha, Sato, 
et al., 2009). Knowing the high incidence of abnormal splicing in tumours, small 
molecule regulators of RNA splicing signify capable new therapeutic strategies in the 
treatment of cancer (Salton & Misteli, 2016). 
1.7 High-throughput screening and drug discovery 
In order to find more effective drugs, pharmaceutical scientists and technologists have 
created a large number of new ways to discover new drugs. Especially with the constant 
progress of science and technology, the technical means are also continuously 
improved, new methods and new technologies are constantly reported (Michelini, 
Cevenini, Mezzanotte, Coppa, & Roda, 2010). 
High-throughput drug screening uses screening models at the cellular and molecular 
levels. The results of these models are to be analysed on a case-by-case basis and need 
to be validated using additional tests. (Michelini et al., 2010) 
Although the high-throughput screening model can reveal the pharmacological activity 
of the sieved substance at varying degrees, and even explain the mechanism of action 
and potency of the compound, it could not accurately explain the potential 
pharmacological or therapeutic effect due to the limitation of the target. For example, 
screening could show that a compound has a higher affinity for a particular receptor, 
but it cannot reveal the specific effect of the compound, neither can it distinguish 
whether it is an agonist or antagonist. In particular, for some targets that are not 
illustrated yet, although the interaction between the compound and the target can be 
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found, further research is needed for the evaluation of pharmacological action of the 
compound. 
In summary, high-throughput screening as a means of discovery of new drugs with a 
wide range of options, lower screening costs, high sensitivity of assay (single molecule 
detection), high speed of assay, and reliable results, is an important means of new drug 
research. Through high-throughput drug screening methods, we can find innovative 
drugs with good effect, high clinical value and independent intellectual property rights. 
1.7.1 Bioassays for use in high-throughput screens 
Bioassays refer to the experimental method used to test the effect of drugs. Since high-
throughput screening requires a small total reaction volume, and the response is highly 
specific and sensitive, higher sensitive screening models are also required. Commonly 
used screening models are established at the molecular level and cellular level to 
observe the interaction of drugs and molecular targets, which can directly understand 
the basic mechanism of action of drugs (Michelini et al., 2010). These models focus on 
receptors, enzymes, channels, and various cellular responses (Michelini et al., 2010; Seo 
et al., 2018). The drug screening model at the genetic level makes the drug screen range 
broader. 
In recent years, there have also been drug screening models developed at the genetic 
level, making the drug screening model more extensive. In particular, various new 
screening models have emerged along with new achievements in basic research of life 
science such as telomerase inhibition, death induction, cell cycle inhibition, 
angiogenesis inhibition and other indicators of activity as a screening model of active 
ingredients of microorganisms. With the continuous elucidation of pathophysiological 
mechanisms, people pay more attention to screening mechanisms based on the 
mechanism of action. Especially with the progress of research on the human genome 
project, it is also very much concerned with the establishment of a screening model and 
a screening method for finding a certain gene as a target.  
In addition, the use of cellular models or molecular-level models for the study and 
screening of compound toxicology and pharmacokinetics is also an important element 
in HTS. Screening of toxicology and pharmacokinetics through molecular cellular level 
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models is a very important step in the early assessment of drug in vivo processes and 
can reduce the upfront investment in the development of a large number of animal 
experimental drugs, in the evaluation of pharmacological effects and development of 
future significance. 
Cell-based screening methods have many significant advantages over in vitro screening 
methods. Firstly, there is no need to purify the target protein, so there is no need to 
invest in a biologically active target. This advantage becomes more apparent as the 
number of drug targets available for treatment increases. It is difficult to establish a 
biochemical method for the identification of thousands of these new proteins in the 
absence of natural substrates. Secondly, the conformation, activity and biological 
function of the target protein in the cell are closer to their natural state. Thirdly, cell-
based screening methods can quickly identify antagonistic compounds that are 
generally cytotoxic or compounds that do not reach the target within the cell across the 
cell membrane. Therefore, hits and lead compounds that have been screened have 
higher reliability. This method saves time and money in the drug development process. 
1.7.2 Examples of High-Throughput Screening derived therapeutics 
In recent years, researchers have identified more than a thousand potential protein 
biomarker molecules due to proteomics and genomics research and the tremendous 
progress made in the modelling of biological processes using computers. The list of 
biomarker candidates has also become longer and longer. However, most protein 
biomarker molecules proposed and documented in the literature are not used in clinical 
applications. The main reason that no progress has been made in the clinical 
development of new biomarker molecules has been the lack of a way to validate most 
biomarker candidates. 
Based on a paper published in the journal Science Translational Medicine on July 11, 
2012, lead author Ruth Hüttenhain and Martin Soste developed a strategy to measure 
potential biomarker molecules on a large scale and quickly validate them for clinical use 
(Huttenhain et al., 2012). This method is based on a high-throughput mass 
spectrometry-targeted technology that enables the determination of proteins present 
in a biological sample at a specific point in time in a reliable and reproducible manner. 
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In their study, the researchers used the developed method to detect 1,157 potential 
biomarkers: detecting their abundance changes in different human cancers and which 
ones are associated with mutations that promote cancer. Researchers eventually tested 
their assays in blood and urine samples from cancer patients and healthy individuals. 
They are capable of detecting more than 180 different biomarker molecules in serum, 
with a detection limit of one billionth of a gram of serum per ml. In urine samples, 
researchers found over 400 different protein biomarker molecules. With this approach, 
the list of potential biomarker molecules can be shortened quickly and effectively. 
Although these tests cannot be used directly in cancer diagnosis, they can shorten the 
gap between basic and clinical applications. 
In the study of the identification of ovarian cancer, researchers confirmed their 
approach was valid: it was able to validate the potential biomarker molecules present 
in the serum. To do this, researchers can not only measure biomarker candidates 
described in the literature, but also measure new biomarker molecules predicted from 
computational models based on genomic data. Therefore, these findings underline the 
great potential of this mass spectrometric method to validate new protein biomarker 
molecules. The study also described the link between cancer, genetic data, and 
proteomic measurements that determine the patient's acute state. In summary, this 
new approach can be used to validate potential biomarker candidates in all patient 
samples and thus strategies for developing highly specific verification methods for 
disease-associated proteins can also be applied to other diseases. 
Recently, researchers from Novartis Institute for Biomedical Research (H. Gao et al., 
2015) established a large number of animal models of Patient-Derived Xenograft (PDX) 
for screening small-molecule anti-cancer compounds. This study shows that the PDX 
model is more effective in drugs of preclinical assessment and prediction of clinical 
outcomes has a very good application prospect. 
In preclinical studies, there is still a lack of an ideal cancer model that can be used to 
characterize the effects of candidate therapies and methods in predicting the efficiency 
of clinical treatment. This shortage also exists in identifying the factors that cause 
heterogeneous responses to individualized treatment.  
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The PDX model is an in vivo model that transplants the patient's fresh tumour cells or 
tissues into immunodeficient mice and relies on the environmental growth provided by 
the mouse to preserve the primary tumour microenvironment and basic characteristics. 
Relying on this model can help with in-depth studies of tumourigenesis and the 
discovery of potential therapeutic targets, but also can help predict the patient's 
possible response to the drug, including efficacy, side effects, absorption and so on. In 
this study, Gao et al created about 1,000 PDX models that carry different cancer-driven 
genes and used these PDX models to perform small molecule compounds in vivo 
screening, evaluating the population response of 62 treatment strategies to 6 indicators 
happening. 
By observing the association between phenotypes, drug response and drug resistance 
mechanisms, the researchers demonstrated that this method has good reproducibility 
and the ability to be transformed clinically. In addition, the study also showed that using 
the PDX model to assess the potential of clinical applications of some treatments is 
more accurate than cell line models. Taken together, this study shows that the PDX 
model has potential applications in preclinical assessment of cancer therapies and 
methods, and in predicting the outcome of clinical trials. 
1.8 Hypothesis and aims 
EMT and alternative splicing are the two processes focused on in this thesis. EMT is one 
of the hallmarks of cancer, so anti-EMT therapy is a potential treatment method for a 
variety of cancers. ESRPs is one of the most important splicing regulatory proteins 
associated with EMT and is an interesting protein with regards to driving alternative 
splicing to epithelial isoforms. Many studies have shown that ESRPs suppress cancer cell 
growth. Some of the pathways involved in regulating this splicing event have been 
elucidated. 
This project aimed to find molecules able to reverse EMT and to explore whether they 
work through modifying ESRP activities. FGFR2 is a well-known gene regulated by ESRPs 
and sensor of EMT. Splicing-sensitive fluorescent reporters based on FGFR2 are 
sensitive tools to screen molecules for EMT activity. Splicing reporters provide a way to 
investigate an alternative splicing event by following the expression of fluorescent 
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proteins. A bichromatic FGFR2 splicing reporter (pRGIIIc) was designed using the 






Figure 1-16 FGFR2 splicing-sensitive bichromatic fluorescent reporters on EMT and MET.  
Upper: Design of the bichromatic reporter. A fusion EGFP protein is produced if exon IIIc of FGFR2 
is selected and dsRED protein is expressed when exon IIIc is skipped. 
Lower: AT3-RGIIIc and DT-RGIIIc cells imaged under immunofluorescence and phase contrast. 






The following aims were considered: 
I. Explore whether ESRPs suppress tumour progression 
II. Use of FGFR2-based splicing--sensitive fluorescent reporters as a molecular 
screening tool: screening for small molecules that can alter FGFR2 exon splicing, 
promoting epithelial IIIb isoform production. 
III. Test molecules which change FGFR2 splicing for EMT activity in vitro and in vivo. 
IV. Further investigate the activity of the small molecules to understand their 
mechanism of action in terms of EMT activity. 
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Chapter 2  Materials and methods 
The methods and protocols described in this section have previously been described in 
my MSc thesis submitted to University of Bristol in 2013 entitled: Interplay of 
alternative splicing and epigenetic modifications in cancer cells. 
2.1 Cell culture 
2.1.1 Cell lines 
HEK293 (Human embryonic kidney 293) is a cell line derived from human embryonic 
kidney cells grown in tissue culture, have been widely used in cell biology research for 
many years, because of their reliable growth and propensity for transfection. HEK293 
cells are typical adherent mesenchymal phenotype cells that expressing completely 
FGFR2 IIIc isoform. HEK293 cells were obtained from Microvascular Research 
Laboratories, University of Bristol, purchased from ATCC (ATCC® CRL-1573™). 
PC3 is a human prostate cancer cell line which was established in 1979 from bone 
metastasis of grade IV of prostate cancer in a 62-year-old Caucasian male. PC3 cells have 
high metastatic potential compared to DU145 cells and LNCaP cells. PC3 cells are 
adherent cells which are more of mesenchymal phenotype and are often used in 
xenograft mouse model to study PCa. PC3 cells were obtained from Microvascular 
Research Laboratories, University of Bristol, purchased from ATCC (ATCC® CRL-1435™). 
LNCaP clone FGC is a human prostate cancer cells that have low metastatic potential, 
that was isolated in 1977 derived from metastatic lymph node lesion of a 50-year-old 
Caucasian male with confirmed diagnosis of metastatic prostate carcinoma. LNCaP is a 
typical adherent epithelial cell line expressing high level of E-cadherin.  LNCaP cells were 
purchased from ATCC (ATCC® CRL-1740™). 
2.1.2 Thawing cells  
Frozen cells were taken out from liquid nitrogen and shaken in a 37 °C water bath until 
thawed. The cell suspension was moved into a 15ml falcon tube and spun down at 
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1500rpm for 5 mins. The supernatant was aspirated, and the pellet was re-suspended 
with 5ml of pre-warmed medium and transferred to T25 flasks. Cells were cultured in a 
37 °C incubator with 5% CO2, the medium was refreshed every 3-4 days until the cells 
grew to 80-90% confluence.  
2.1.3 Sub-culture 
HEK293 cells were cultured in RPMI medium 1640 (1X) (Sigma, R8758) supplemented 
with 10% Fetal Bovine Serum (FBS, Sigma F2442) and 1% Penicillin streptomycin (5000 
U/ml Penicillin, 5000µg/ml Streptomycin, Sigma, P4458). 
PC3 human prostate cancer cells and LNCaP clone FGC human prostate cancer cells 
were cultured in RPMI medium 1640 (1X) supplemented with 10% FBS and 1% Penicillin 
streptomycin (see above concentration). All cell types detailed were incubated (unless 
specified otherwise) at 37 °C and 5% CO2. 
Cells were split when they reached 80-90% confluence. The medium was aspirated and 
1x Phosphate Buffered Saline (PBS, diluted 1 in 10 from 10xPBS, Fisher, BP399-500) was 
added to the wash, then 0.25% Trypsin-EDTA (Gibco, 25200-056) (1ml /T75; 0.5ml/T25) 
was added. The flask was gently swirled and incubated at 37 °C for 3-5 minutes. Then 
the pre-warmed complete medium was added to stop the reaction. Cells at proper ratio 
were transferred to a new flask (e.g. 1:8). 
2.1.4 Freezing cells  
Following trypsinization protocol, freezing medium was prepared (2ml DMSO+8ml FBS) 
and mixed well. The suspension was aliquoted in two Falcon tubes and centrifuged at 
1500rpm for 3 minutes (cell pellet should be observed after). The media was aspirated 
carefully without touching the pellet. 3ml of freezing media was added to each Falcon 
tube and mixed well. Suspensions aliquoted of 1.5ml/vial were stored in a freezing 






2.2 Transfection of cell lines 
2.2.1 Transient plasmid transfection 
ESRP1 and ESRP2 plasmids were used in transfection. ESRP1 plasmid (pIBX-C-FF-B-
Esrp1-2A, obtained from Microvascular Research Laboratories, University of Bristol, see 
figure 2-1) was derived from the core vector pIBX-C-FF-B  by sub-cloning cDNA of ESRP1 
using the upstream StuI site and downstream NotI site (Warzecha, Sato, et al., 2009). 
ESRP1 plasmid has a C-terminal flag and blasticidin resistant. ESRP2 plasmid (pBIGi-
hESRP2, obtained from Dr Keith Brown, University of Bristol, see figure 2-1) was derived 
from the core vector pBIG2r by sub-cloning cDNA of ESRP2 and a flag tag using the 
upstream BamHI site and downstream EcoRV site. ESRP2 plasmid has a TET-on system 
and hygromycin resistant, with length of 725 amino acids and molecular weight of 
78.36KDa. 
PC3 cells were transfected using FuGene® HD Transfection Reagent (Promega E2311). 
PC3 cells were seeded in a 6-well plate at 200,000 cells per well. The following day, 2µg 
of the ESRP1 plasmid (or empty vector was diluted in 100µl Opti-MEM I Reduced Serum 
Medium (Gibco 31985-062). 6µl of the FuGene® HD Transfection Reagent was pipetted 
directly into the medium containing diluted plasmid to form the transfection complex, 
and then the complex was mixed and incubated at room temperature for 15 min. The 
transfection complex was added to cells and the wells swirled to ensure distribution. 
The cells were incubated for 48 hours before splitting to T25 flasks.  
PC3 cells were transfected using FuGene® HD Transfection Reagent. PC3 cells were 
seeded in a 6-well plate at 200,000 cells per well. On the following day, 200ng of the 
ESRP2 TET-on inducible plasmid was diluted in 100µl Opti-MEM I Reduced Serum 
Medium. 6µl of the FuGene® HD Transfection Reagent was pipetted directly into the 
medium containing diluted plasmid to form the transfection complex, and then the 
complex was mixed and incubated at room temperature for 15 min. The transfection 
complex was added to cells and the wells swirled to ensure distribution. The cells were 
incubated for 48 hours before splitting to T25 flasks.  
Stable PC3 ESRP1 overexpressing cells were transfected with inducible ESRP2 plasmids 
as above to construct PC3 ESRP1/2 overexpressing cell lines. 
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Figure 2-1 Plasmids maps 
Left panel: pBIX-C-FF-B-ESRP1-2A plasmid constructed by cloning cDNA of ESRP1 into pIBX-C-FF-
B vector, between StuI and NotI. Right panel: pBIGi-hESRP2 plasmid constructed by cloning 
cDNA of ESRP2 and a flag tag sequence into pBIG2r vector, between BamHI and EcoRV. 
 
2.2.2 Creating stably transfected cell lines 
48 hours after transfection with ESRP1 plasmid or ESRP2 inducible plasmid, the PC3 cells 
were split at several different ratios (e.g., 1:5, 1:10, 1:20) in complete medium 
containing the 10µg/ml Blasticidin (for ESRP1 plasmid) or 150µg/ml Hygromycin-B (for 
ESRP2 plasmid). For the next two weeks, replace the drug-containing medium twice a 
week. During the second week, some “islands” of the surviving cells were formed, and 
then large, healthy colonies was isolated using sterile pipette tips and split into new 
flasks and maintaining with selective medium for up to 5 weeks.  The survived cells after 
selection were drug-resistant cells with transfected plasmids. 
2.3 RNA assays 
2.3.1 RNA extraction 
Cells were lysed directly in the culture plate. 1ml of the TRIzol Reagent (Ambion, 
18132201) was used per well for a six well plate. After the addition of the reagent, the 
cell lysate was passed 10 times through a pipette to form a homogenous lysate. 
Samples were left standing at room temperature for 5 minutes to dissociate 
nucleoprotein complexes completely. After that, 0.2ml of chloroform was added per ml 
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of TRI REAGENT used, and samples were covered tightly and shaken strongly for 15 
seconds. Samples were left to stand at room temperature for 15 minutes and then 
centrifuged at 12,000 rpm for 15 minutes at 4 °C. The mixture was separated into 3 
phases: a red lower phase (containing protein), an interphase (containing DNA), and a 
colourless upper phase (containing RNA). The upper phase was moved to a clean 
Eppendorf tube, and then 0.5 ml of isopropanol was added per ml of TRIzol Reagent 
used in the first step and mixed. 
The sample was left to stand for 10 minutes at room temperature, and then centrifuged 
at 12,000 rpm for 10 minutes at 4 °C. The RNA forms a pellet on the side and bottom of 
the tube. The supernatant was removed while the RNA pellet was washed by adding 1 
ml (minimum) of 75% ethanol (v/v) per 1ml of TRIzol Reagent used. 
Then the sample was vortexed and centrifuged at 10,000 rpm for 5 minutes at 4 °C. The 
RNA pellet was dried for 10 minutes by air-drying. The RNA pellet should not be dried 
completely as this would greatly reduce the solubility. 20μl of DEPC H2O was added to 
resuspend the RNA pellet. Final extracted RNA was without DNA and proteins if the 
measured 260/280 ratio was ≥ 1.7. 
2.3.2 Treatment with DNase and cDNA synthesis  
2μg of RNA was used to make up to a final volume of 8μl by adding DEPC H2O. 1μl of 
RQ1 Rnase-Free DNase 10x Reaction Buffer and 1μl of RQ1 Rnase-Free DNase (1 U/μl, 
final conc. 1U/1μg RNA) (Promega M6101) was added to each reaction and incubated 
at 37°C for 1 hour to degrade any genomic DNA contaminants. 1μl of RQ1 DNase Stop 
Solution was added and incubated at 65°C for 10minutes to terminate the reaction and 
inactivate the DNase. 
The next step was to anneal DNA primers to the RNA template. 500ng of both oligo(dT)15 
(Promega, C1101) and random hexamer primers (Promega, C1181) were used. Primers 
were incubated with template at 95°C for 10 minutes and samples were then cooled on 
ice for 5 minutes.  
After primer annealing, the second filament of cDNA was synthesised. 0.4mM dNTP 
mixture, 5μl M-MLV 5x reaction buffer and 200 units M-MLV reverse transcriptase 
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(M1701, Promega) were added to each reaction (in NO-RT control no M-MLV RT was 
added) and the total volume was made up to 25ul with DEPC water. cDNA production 
was completed via 90 minutes incubation at 37°C. 
2.4 DNA assays 
2.4.1 DNA clean up 
DNA clean-up was done using QIAquick PCR Purification Kit (Qiagen 28104). The pH 
indicator I indicates a pH of ≤7.5 and was added to Buffer PB (1:250 volume). Buffer PB 
with pH indicator I was mixed with the PCR reaction at a 1:5 ratio. If the colour of the 
mixture is orange or violet, 10μl 3M sodium acetate (pH 5.0) was added and the mixture 
was mixed until the colour turned yellow. To bind DNA, the sample was applied to the 
QIAquick column which hung in a 2 ml collection tube and the tube with column was 
centrifuged for 30-60 seconds. The waste at the bottom of the collection tube was 
discarded and the QIAquick column was put back. After that, 750μl Buffer PE (100% 
ethanol was added up to the bottle volume label before use) was added to the QIAquick 
column and the column was centrifuged for 30-60 seconds to the wash. The waste at 
the bottom of the collection tube was discarded and the QIAquick column was put back. 
The QIAquick column was then centrifuged in the 2 ml collection tube for 1 minute to 
remove the remaining wash buffer. Each QIAquick column was put into a clean 1.5 ml 
Eppendorf tube. 50μl Buffer EB (10 mM Tris·Cl, pH 8.5) was added to the centre of the 
QIAquick membrane to elute DNA and the column was left to stand for 1minute and 
then centrifuged for 1 minute.  
2.4.2 Polymerase Chain Reaction 
Polymerase chain reaction was used to amplify and demonstrate splicing pattern of 
FGFR2 (Figure 2-2). Specific primers were designed to amplify both FGFR2 IIIb and 
FGFR2 IIIc transcripts. b-actin primers were used as a quantification control. The 
expected size of PCR products were 240 and 243 base pairs for IIIb and IIIc isoforms 
respectively, and 218 base pairs for b-actin. 25 μl of reaction mixture was made using 
12.5 μl of 2xPCR MasterMix (Promega, M7502), 0.8 μlM of forward and reverse primer 
mixture and DEPC water to bring the reaction to a volume of 23μl. 2μl of cDNA was 
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added to each reaction and amplified using a thermal cycler. A water control with no 
template was needed. The primer sequences used were described in table 1. b-actin 
and FGFR2 share the same PCR cycle condition described in table 2. 
FGFR2 Forward 5’-AGAACGGCAGTAAATACGGG-3’ 
FGFR2 Reverse 5’-GGTAGTCTGGGGAAGCTGTA-3’ 
b-actin Forward 5’-CATCCGCAAAGACCTGTACG-3’ 
b-actin Reverse 5’-CCTGCTTGCTGATCCACATC-3’ 
 Table 1: The primer sequences used for PCR 
 
Step Temperature (℃) Time (min:sec) Go to step Cycle 
1  95 5:00   
2 95 0:30   
3 55 0:30   
4 72 1:00 2 36 
5 65 10:00   
6 4 Forever   




2.4.3 Digestion restriction enzyme treatment 
The two restriction digestion enzymes AvaI (NEB, R0152S) and HincII (NEB, R0103S) 
were used for digesting the two isoforms of FGFR2 PCR products. AvaI only cuts FGFR2 
IIIb and HincII only cuts FGFR2 IIIc. (Figure 2-2) 1µl of AvaI plus 1µl 1x CutSmart buffer 
(NEB, B7204S), and 1µl of HincII plus 1µl Ix NEBuffer™ 3.1 (NEB, B7203S) were added 
into 8µl FGFR2 PCR products separately and incubated at 37 °C for 3 hours. 
 
Figure 2-2 The maps of the RT-PCR products of FGFR2.  
FGFR2 has two mutually exclusive isoforms FGFR2 IIIb and FGFR2 IIIc. As exon IIIb and IIIc have 
similar sizes, restriction digestion analysis is needed. I chose two digestion enzymes- AvaI and 
HincII: AvaI only cut FGFR2 IIIb and HincII only cut FGFR2 IIIc. PCR products have 243bp for FGFR2 
IIIb which was cut into 57bp and for AvaI 186bp, and 240bp for FGFR2 IIIc cut into three pieces 
of 63bp, 119bp and 58bp. Adapted from (Carstens et al., 1997).  
 
2.4.4 Gel electrophoresis 
6 x loading buffer (Thermofisher, R1161) was added to each sample. PCR products were 
run on agarose gel at 90V for about 90 min. For making 2% agarose gel (w/v), 2g of 
agarose was mixed in 100ml 1xTAE (40mM Tris, 20mM Acetate and 1mM EDTA and 





2.5 Protein assays 
2.5.1 Protein extraction 
• Protein extraction from cells 
1x PBS and lysis buffer is prepared ice-cold and all work should be on ice. Cells were 
incubated on ice for 15 min to limit endocytosis (24-well plates in an ice bucket). Then 
the media was aspirated off. Cells were washed 2 times with 1ml/well of ice-cold 1xPBS. 
In the last wash all the PBS left was removed with a pipette. 80μl/well ice-cold lysis 
buffer was added (79.2μl of RIPA+ 0.8μl of protease inhibitor; 1X RIPA Buffer: 20 mM 
Tris-HCl (pH 7.5) 150 mM NaCl, 1 mM Na2EDTA 1 mM EGTA 1% NP-40 1% sodium 
deoxycholate 2.5 mM sodium pyrophosphate 1 mM β-glycerophosphate 1 mM Na3VO4 
1 µg/ml leupeptin) for each well. Cells were incubated on ice for 5 min (the plates were 
swirled occasionally for uniform spreading). Cells were scraped and gathered to one 
side by using a scraper while keeping the plates inclined to one side. The solution was 
mixed up and down several times by using a 200μl pipette for cell lysing. The lysate was 
transferred into a cold Eppendorf tube and incubated on ice for 20 minutes. Then the 
lysate was vortexed at maximum speed for 10sec every 5 minutes a total of four times. 
Samples were centrifuged at 10000rpm for 10 min at 4 °C. Then the supernatant was 
collected and transferred to a fresh cold Eppendorf tube, aliquoted and stored at -20 or 
-80 °C. 
• Protein extraction from tissues 
Fresh tissue was frozen in liquid. Pre-cold lysis buffer (RIPA buffer with protease 
inhibitors) was added to the frozen tissues and mixed. The mixture was transferred in a 
homogenization tube and homogenized up and down slowly on ice until no solid was 
observed (add around 500µl every time and end up at around 10 µg/µl, between 
samples wash the tubes with water and then pre-cold PBS). The mixture was transferred 
into a cold Eppendorf tube. The homogenization tube was kept on ice all the time. The 
homogenized lysis was incubated on ice for 20 mins to maximize protein solubilisation 
and vortexed 10 seconds every 5 mins during the 20 mins. Then the sample was clarified 
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by centrifugation at 10000 RPM for 10 minutes at 4°C and the supernatant was moved 
to a fresh pre-iced tube. 
2.5.2 Total protein quantification 
0.1g of BSA (Bovine Serum Albumin, 4 °C) was weighted and dissolved in 10ml 1x PBS 
to get a stock solution in a concentration of 10mg/ml. The stock solution was diluted 
1:10 (100µl in 900 µl of 1xPBS) to 1mg/ml. 
Standards were made up for a 96 well plate: 
-Eppendorf 1à 700 µl (1mg/ml BSA) 
-Eppendorf 2-7à350µl of 1x PBS+ 350µl of serial dilution 
-Eppendorf 8à 350µl of 1x PBS 
Standard range was set as: 1000, 500, 250, 125, 62.5, 31.25, 15.625 and 0µg/ml of BSA. 
10 µl of each standard was added per well into a 96-well plate in triplicate. The dilutions 
of the samples were made up at 1:50à 1µl of sample+ 49µl of 1xPBS. 
All the samples were kept on ice to prevent digestion from any proteinases. 10µl of each 
sample was added per well into a 96-well plate in triplicate. Bio-Rad Dye was diluted 1: 
5 with 1xPBS (4ml of dye in 16ml of 1xPBS). 200µl of diluted dye was added to each well 
with a multichannel pipette. Then the prepared samples were left in incubation for 5 
min. Analysis was run by Opsys MR Plate reader at 595nm (and 490nm) with 1 second 
shaking.  
2.5.3 Western blotting 
• Wet transfer 
The samples were thawed on ice and protein concentration quantified; 30-50 µg was 
used per lane. Then 5x Protein Loading Buffer (Bioline, BIO-37045) was added in the 
samples and the mixtures were boiled for 5-10 min at 90 °C to break protein bonds. Pre-
cast stain-free gels were loaded into the SDS-PAGE cassette with plates facing inwards; 
1x SDS Running Buffer was added in the central reservoir, the combs were removed, 
and the lanes were rinsed with running buffer to remove debris. 5µl of Precision Plus 
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Protein™ Unstained Standards (Bio-Rad 1610363) and the samples were loaded. The 
gels were run at 150V until the blue dye of the samples was close to the bottom of the 
gel (1h). The running buffer level and whether the gels run properly need to be checked. 
After electrophoresis, the glass plate was lifted off and the stacking gel and the excess 
gel cut off. The gel was activated by Bio-Rad Image Lab and the proteins loaded were 
quantified to check whether they were equally loaded. 
The gels were moved carefully to 1x Transfer buffer (Mix 100 ml of 10x transfer buffer, 
200 ml of methanol, and 700 ml of ddH2O, 10x transfer buffer recipe see table 3). Two 
pieces of sponge and 4 pieces of thick filter paper per gel were soaked in 1x Transfer 
buffer. The Immun-BlotTM polyvinylidene fluoride (PVDF) membrane (Bio-Rad, 1620177) 
was cut and activated by soaking in methanol for 5-10 seconds. Then the membrane 
was washed in distilled water and transferred to 1x Transfer buffer. The wet transfer 
was set up by placing the sponge, filter paper, PVDF membrane and gel into the clamp 
as below (Figure 2-3). Bubbles from each layer were removed gently by using the roller, 
and the clamps were placed into the reservoir and the buffer tank was filled with 1x 
Transfer buffer. (The black sides were put near the black side of the device.) The blot 
was run at 90V for 90 minutes, and then the gels were discarded. The total protein 
transferred to the membrane was relatively quantified by measuring lane and band 
relative quantities on the membrane with Image Lab™ Software (Bio-Rad). 
The membrane was washed in TBS/Tween 0.3% (v/v) [3ml of Tween (Fisher, BP337-500) 
in 1000ml of 1x TBS], placed in a container on the rocking platform and covered with 5% 
BSA (w/v) in 0.3% TBS/Tween [2.5g of BSA in 50 ml of TBS/Tween] and left on the rocker 
for 1h at room temperature. 
The primary antibody was made up of Mouse anti-E-Cadherin and Mouse anti-Vimentin 
both at 1:1000 in approx. 8ml of 5% BSA (w/v) in 0.3% TBS/T (v/v). The membrane was 
placed in a box with the primary antibody and left in incubation on a rocker in the DNA 
lab overnight at 4 °C. The membrane was moved into a new box the next morning and 
washed with TBS/Tween 0.3% (v/v) for 5 min five times.  
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The membrane was placed in a black box with the secondary antibody anti-mouse at 
1:15000 for 1h at room temperature. The membrane was washed several times with 
TBS/Tween 0.3% (v/v) before running on the machine.  
1ml detection reagent 1: Peroxide solution and 1ml detection 2: Luminol Enhancer 
solution (Pierce™ ECL western blotting substrate) was added to the membrane and 
mixed. After incubating for 5 mins the membrane was imaged by UVP ChemiDoc-It 
Imaging System. 
 
10x Running Buffer: 10x Transfer Buffer: 10x TBS Buffer: 
Tris Base (250mM): 30.4g Tris Base (250mM): 30.4g Tris Base (250mM): 24.2g 
Glycine (1.92mM):144.2g  Glycine (1.92mM): 144.2g  NaCl: 80g 
SDS: 10.0g   
Add ddH2O to 1L Add ddH2O to 1L Add ddH2O to 1L and adjust PH=7.6 with HCl 
Table 3: Recipes of Buffers used in Western Blot  
 
Antibody Catalogue number 
Mouse anti-E-cadherin primary antibody BD Biosciences, 612131 
Mouse anti-Vimentin primary antibody BD Biosciences, 550513 
Rabbit anti-ESRP1 primary antibody Sigma, HPA023719 
Rabbit anti-ESRP2 primary antibody Abcam, ab113486 
Goat anti-Mouse IgG secondary antibody Abcam, ab205719 
Goat anti-Rabbit IgG secondary antibody Abcam, ab205718 
Alexa Fluro 488 Goat anti-Mouse IgG (H+L)  Invitrogen, A11001 




• Semi-dry transfer for ESRP1 detection 
Gel electrophoresis was done as described above, except that the gel was run at 100V 
until the blue dye of the samples was close to the bottom of the gel (90mins). The 
running buffer level and whether the gels ran properly were checked. After 
electrophoresis, the plate was lifted off and the stacking gel and the excess gel were cut 
off. The gel was activated by Bio-Rad Image Lab and the proteins loaded were quantified 
to check whether they were equally loaded. 
The gels were moved carefully to 1x Transfer buffer. Two pieces of sponge and two 
pieces of thick filter paper per gel were soaked in 1x Transfer buffer. The Immuno-BlotTM 
PVDF membrane was cut and activated by soaking in methanol for 5-10 seconds, then 
washed in distilled water and transferred to 1x Transfer buffer. The semi-dry transfer 
blotter was set up by placing the sponges, filter papers, PVDF membrane and gel into 
the clamp to construct a gel “sandwich” (Figure 2-4). The membrane was put on the 
anode (bottom) side relative to the gel. The semi-dry transfer kit was closed, and the 
power supply connected to transfer at constant AMPs (0.8mA/cm2), not volts, for 75 
min. 
The membrane was washed in TBS/Tween 0.1% (v/v)  [1ml of Tween in 1000ml of 
1XTBS], placed in a container on the rocking platform and covered with 5% BSA (w/v)  
in 0.1% TBS/Tween (v/v)  [2.5g of BSA in 50 ml of TBS/Tween] and left on the Rocker for 
1~2 hours at room temperature. 
The primary antibody was made up of rabbit anti-ESRP1 (see table 4) at 1:1000 in 10ml 
of 5% BSA (w/v) in 0.3% TBS/T (v/v). The membrane was placed in a box with the 
primary antibody and left for incubation on a rocker in the cold room over 24 hours at 
4 °C. The membrane was moved to a new box the next morning and washed with 
TBS/Tween 0.3% (v/v) five times and for 5 minutes each time.  
The membrane was incubated with the secondary antibody anti-rabbit IgG (see table 4) 
at 1:10000 for 1~2 hours at room temperature. The membrane was washed several 




Figure 2-3 Diagram of a classical wet transfer blotter.  
Between two plates (positive and negative), the following are placed: the sponge, filter papers, PVDF membrane and gel, and another layer of filter paper. 
The sandwich was inserted into the transfer tank with transfer buffer and the positive plate is on the anode side while the negative plate is on the cathode 





Figure 2-4 General set-up of a semi-dry transfer.  
Between two plates (anode and cathode) connected to a power source, the following are placed: 





2.6 Bacterial transformation 
Agar and LB broth (Agar: Agar packet + 500ml dH2O; LB Broth: 10g LB broth + 500ml 
dH2O) were prepared and autoclaved at 121 °C for 15 minutes. Once the agar had 
cooled down, 100 µg/ml ampicillin was added and mixed. The mixture was poured into 
plates (10-15ml/plate) with lids on and left to set. Bunsen burner flame was kept on 
while pouring and setting plates. 
Plates kept at 4 °C were warmed in an incubator while DH5a bacteria were thawed on 
ice. 1µl plasmid was added to 30µl bacteria then mixed by stirring. The mixture was put 
on ice for 30 minutes and heat-shocked at 42 °C for 30 seconds. After that the mixture 
was iced for 2 minutes. 300µl of SOC media was added to bacteria and the mixture was 
shaken for 45 minutes at 37 °C. 
Warm plates were moved out of the incubator. Pasteur pipette was sterilized using 
ethanol and the Bunsen burner. 50µl of bacteria was pipetted onto a plate and spread 
with the Pasteur pipette. Plates were incubated at 37 °C overnight. 
5ml of LB broth was put in a Falcon tube with ampicillin 100µg/ml. A single colony on 
the plate was touched using a sterile tip and then dropped in LB broth. The lids were 
loosely taped on the Falcon tubes and put in a shaker overnight at 37 °C. 
Plasmid was extracted using QIAprep Spin Miniprep Kit (Qiagen, 27106). Broth from the 
Falcon tube was aliquoted into 1.5ml Eppendorf tubes and then centrifuged for 1 min 
at 13000 rpm. The supernatant was discarded. Pellet was re-suspended in 250µl P1 
buffer (P1 kept at 4 °C) and mixed thoroughly by pipetting up and down. 250µl P2 lysis 
buffer was added into the resuspension and tubes were gently inverted 6 times. Then 
350µl N3 buffer was added and tubes were gently inverted 6-8 times. Then the mixture 
was spun for 10 minutes at 13000 rpm. Supernatant was transferred to the filter tube 
and spun for 1 min to allow plasmid binding to filter, and then the waste at the bottom 
of the collection tube was aspirated. Then the filter tube was washed with 750µl PE 
wash buffer, spun for 1 minute and the waste at the bottom of the collection tube was 
aspirated. Filter was put into a clean Eppendorf tube and 50 µl of EB elution buffer was 
added; the mixture was left to stand for 1 min and spun for 1 min. The liquid at the 
bottom of the tube was pure plasmid. Plasmid concentration was measured using the 
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NanoDrop™ 2000/2000c Spectrophotometers (Thermofisher, ND-2000, a full-spectrum, 
UV-Vis spectrophotometers used to quantify and assess purity of DNA, RNA, Protein 
and more). 
2.7 Chemical screen 
2.7.1 LOPAC primary screen 
HEK293 pRGIIIc (FGFR2 exon IIIc cloning in RG6 minigene) cells were used as reporter 
cells. 10,000 cells/well of HEK cells were seeded in a 96-well plate and incubated at 37 °C 
with 5% CO2. After 24 hours, cells were treated with compounds from LOPAC Library at 
10 µM. After 48 hours of treatment, the plate was read by a VICTOR plate reader. Data 
was analysed by One-way ANOVA using GraphPad Prism 7 (GraphPad, Prism 7 for Mac 
OS X, a commercial scientific 2D graphing and statistics software). 
2.7.2 Elimination of false positives in the control screen 
PC3 DSS (pRG8ab distal splice site control reporter) cells were used as GFP control and 
PC3 PSS (pRG8ab proximal splice site control reporter) cells were used as RFP control. 
The control plasmid DNA did not contain the intron of the original pRG8ab (VEGF exon 
8ab cloning in RG5 minigene) reporter, therefore, mimicked the mRNA transcripts that 
are produced when either a proximal or distal reporter 3’ splice site is chosen. (Figure 
2-4) The plasmids were termed PSS and DSS control reporters. Both control cell lines 
were treated as above, and the data was analysed as above as well. Then the analysed 
data was combined with the data from the primary screen to eliminate the false 





Figure 2-4 Design and expression of proximal splice site and distal splice site control reporters.  
DSS and PSS control reporters were constructed to mimic the two mature mRNA transcripts that 
can be produced from the splicing of pRG8ab pre-mRNA - proximal (PSS) and distal splice site 
(DSS) controls. Both reporters were transfected into PC3 cells individually and their expression 




2.8 In vitro cell assays 
2.8.1 Cell growth curve 
PC3 cells were seeded with 100,000 cells per well in eight 12-well plates, and then 
treated with chemicals 24 hours after seeding. The medium with chemicals was 
refreshed every 48 hours after first treatment. Cells were counted every 24 hours after 
seeding in the plate. All data was calculated and analysed with Prism and tested by two-
way ANOVA. All the treatments had 12 repeats. 
PC3 with control, ESRP2, and ESRP1/2 overexpressing cell lines (plasmids used see 
figure 2-1) were plated 100,000 cells per well (depending on cell type) in eight 12-well 
plates, and then treated with Doxycycline to induce ESRP2 expressing 24 hours after 
seeding. The medium with Doxycycline was refreshed every 48 hours after first 
treatment. Cells were counted every 24 hours after seeding in the plate. All data was 
calculated and analysed with Prism and tested by two-way ANOVA. All the treatments 
had 4 repeats. 
LNCaP cell lines were plated 100,000 cells per well in eight 12-well plates. The medium 
was refreshed every 48 hours and cells were counted every 24 hours after seeding in 
the plate. All data was calculated and analysed with Prism and tested by two-way 
ANOVA. All the treatments had 4 repeats. 
2.8.2 Cell migration assay – wound healing assay 
Cells were pre-treated with chemicals in T75 flasks for 48 hours and 500,000 cells plated 
per well in 6-well dishes. After an overnight starving, the cell monolayers were washed 
with pre-warmed PBS (5 minutes, twice), scraped across using a P-20 micropipette tip 
and a fresh medium with chemicals added to the wells. The initial gap area (0 h) and the 
residual gap area at 24h and 48h after wounding were calculated from 
photomicrographs and then analysed by Image J and Prism using two-way ANOVA. All 





2.8.3 Cell migration assay – Boyden chamber assay 
Cells were pre-treated with chemicals for 48 hours and starved overnight. After that 
cells were trypsinized, collected with serum free medium in 15ml Falcon tubes and spun 
down. Then the cells were re-suspended with serum-free medium, counted and seeded 
with 150,000 cells per 300 µl in inserts in a 24-well plate (Figure 2-4). A normal complete 
medium with 10% FBS Medium was placed in the well outside the inserts. Then the 
plates were incubated at 37C for 24 hours. The cells that migrated through the 
membrane at 24h after seeding were stained with DAPI and then counted from 
photomicrographs. The count number was analysed by Prism using two-way ANOVA. 
All the treatments had four repeats.  
  
Figure 2-5 Schematic diagram of experimental setup of Boyden Chamber assay. 
An insert is placed in the well; the insert has a semi-permeable membrane. Cells in a serum-free 
medium or low-serum medium are seeded in the insert and then travel through the membrane 
to the other side. (Adapted from Merck Millipore website) 
 
2.8.4 Proliferation assay – MTT assay 
MTT assay was done using Vybrant® MTT Cell Proliferation Assay Kit (Invitrogen 
V13154). Before the assay, 12 mM MTT stock solution was prepared by adding 1 mL of 
PBS to the 5 mg tube of MTT (Component A), and 10 mL of 0.01 M HCl was added to 
the tube containing 1 gm of SDS (Component B, which should be used promptly once 
prepared). The solutions A and B were gently mixed by inversion or sonication until 
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dissolved, respectively. All the experiment groups were pre-treated with either control 
(DMSO) or one of different doses of the three drugs (LLSOs) for 48 hours (for cell to 
reach the optimized measuring density 1*106) before seeding. After pre-treatment, PC3 
cells were seeded in a 96-well plate at 10000 cells per well. The next day, the medium 
was removed and 100 µl of fresh complete medium per well was added. 10 µl of 12 mM 
MTT stock solution per well was added and mixed well. Meanwhile, the same solution 
was added to wells with 100 µL of medium without cells as a negative control. Following 
a 4 hours incubation at 37 °C, 100 µL of the SDS-HCl solution per well was added and 
mixed carefully with pipettes. Finally, after another 4 hours incubation at 37°C, the 
absorbance at 570nm for each well was measured by Absorbance Microplate Readers 
from BMG LABTECH. Three repeats were applied for each cell line. 
2.8.5 Immunofluorescence (E-cadherin) 
Cells were split onto coverslips in a 12-well plate at 300,000 cells per well with 2ml pre-
warmed medium per well. Chemicals were added in wells 24 hours after seeding. During 
the experiment, cells were incubated in 37℃ incubators with 5% CO2. After another 48 
hours, cells were washed with PBS and fixed with 1.5ml 4% PFA per well for 10 minutes. 
After 5 mins washing twice with 1xPBS, cells were permeabilized with 1xPBS-TritonX 
(0.05%) (v/v) for 10 mins. Then cells on the coverslips were washed again with 1xPBS 
for 5 minutes twice and blocked with 1% BSA (w/v) + 5% normal goat serum in PBS (v/v) 
for 1 hour. After blocking, cells were incubated with a primary antibody in 1% BSA in 
PBS at 1:500 dilution overnight at 4 °C. After washing twice for 5 minutes with 1xPBS, 
cells were incubated with Alexa Fluor secondary antibody diluted in 1% BSA in PBS at 
1:1000 at room temperature for 1 hour. After two 5 mins washings with 1xPBS, cells on 
the coverslips were put onto slides with a drop of Vectashield mounting medium 
containing DAPI (VECTASHIELD® Antifade Mounting Medium with DAPI, Vector Labs, H-
1200) (cell-side down). The coverslips were sealed with nail polish and then imaged 





2.9 In vivo models 
2.9.1 Subcutaneous xenograft models 
PC3 with control, ESRP1, ESRP2 and ESRP1/2 overexpressing cells (see section 2.2) were 
cultured in media containing 2.5µg/ml Doxycycline or DMSO for 48 hours to induce 
ESRP2 expression. Cells were detached from culture flasks and diluted in pre-cold PBS 
to a density of 1x107/ml and placed on ice. 100 µl of cell suspension was subcutaneously 
injected into each right flank of CD1- nude mice (Charles River). Tumour sizes were 
measured by calliper two times a week. Mice were culled by cervical dislocation 
(Schedule 1) when the first tumour size reached the maximum allowed by our project 
licence (12mm x 12mm) and the tumours were extracted. Images of each tumour were 
taken and weighted. Tumours were flash frozen in liquid nitrogen. 1ml of Trizol was 
added to each tumour sample, which were homogenised for RNA extraction as 
described. 
For treatment studies, PC3 human prostate cancer cells were detached from culture 
flasks and diluted in pre-cold PBS to a density of 1x107/ml and placed on ice. 100 µl of 
cell suspension was subcutaneously injected into each right flank of CD1- nude mice, 18 
mice in total. Tumour sizes were measured by calliper two times per week. When the 
tumour size reached 3mm x 3mm, 10µM LLSO02 (one of the three hit compounds 
selected from LOPAC screen. Nemadipine-A, a L-type calcium channel protein inhibitor), 
50µM LLSO02 or DMSO were injected intraperitoneally two times a week, 6 mice per 
treatment group. Mice were culled by cervical dislocation (Schedule 1) when the 
tumour size reached a maximum (12mm x 12mm) and the tumours were extracted. 
Each tumour was imaged and weighed. Tumours were flash frozen in liquid nitrogen for 
further analysis.  
Tumour volumes were estimated using the formula ‘volume = [(length + width)/2] x 
length x width’. Quantitation of the tumour volumes was analysed by Two-way ANOVA 




2.10 Statistical analysis 
Comparisons of two datasets at a single timepoint were carried out using Students’ T-
test or Mann Whitney test. Comparisons of three or more datasets at a single timepoint 
were by one-way ANOVA with Dunnett’s post-test. A comparison of three or more 
groups at multi-timepoints was performed using two-way ANOVA. P<0.05 was 




Chapter 3  ESRPs functions in tumour progression 
Data presented in this chapter was published as part of publication “Androgen-
regulated transcription of ESRP2 drives alternative splicing patterns in prostate cancer.” 
eLife 2019;8:e47678 DOI: 10.7554/eLife.47678 
3.1 Introduction 
Epithelial splicing regulatory proteins (ESRP1 and ESRP2) switch splicing to epithelial 
phonotype during EMT (Warzecha, Shen, et al., 2009). EMT is a procedure that involves 
polar epithelial cells transforming into stromal cells and is essential in normal 
development of the body and the invasion and metastasis of tumour cells. ESRPs switch 
numerous genes splicing towards the epithelial phenotype. In EMT, ESRP is lost; those 
genes splice differently which results in a different phenotype - mesenchymal 
phenotype. Recently, lots of experimental data indicate that epithelial splicing 
regulatory proteins (ESRPs) have the effect of inhibiting tumour EMT, are negative 
regulators of malignant transformation of tumours and are regulated by TGF-β/Smad 
signalling pathway. ESRPs directly or indirectly regulate the proteins related to EMT 
such as FGFR2, Rac1b, E-cadherin and ZEBs at the post-transcriptional level by AS to 
inhibit EMT. Therefore, it is important to find what regulates ESRPs activity. 
3.2 Results 
3.2.1 The effects of ESRPs in prostate cancer cell growth and EMT markers in vitro 
Given that ESRPs have the effect of inhibiting tumour EMT, we hope to reveal the 
possible mechanism of ESRPs inhibiting EMT in tumour cells.  
First of all, we tried to figure out how ESRPs affect the prostate cancer cell line –PC3 
cells functions. I constructed PC3 ESRP1 overexpressing cells by transfecting ESRP1 
plasmids into PC3 cells and then selected stable clones by culturing cells in selective 
medium with 10µg/ml Blasticidin, PC3 ESRP2 overexpressing cells by transfecting ESRP2 
plasmids into PC3 cells and then selected stable clones by culturing cells in in selective 
medium with 150µg/ml Hygromycin, and PC3 ESRP1/2 overexpressing cells by 
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transfecting ESRP2 plasmids into stable PC3 ESRP1 overexpressing cells and then 
selected stable clones by culturing cells in in selective medium with 150µg/ml 
Hygromycin(described in Materials and Methods, 2.2). As ESRP2 plasmid is a TET-on 
inducible vector, ESRP2 was induced by 2-5µg/ml doxycycline for 48 hours. After ESRPs 
overexpression was confirmed by Western blot (Figure 3-1), a series of cell functional 
assays were carried out.  
The effect of ESRPs on cell growth was investigated by the cell growth curve (Figure 3-
2). Cells were seeded at 100,000 per well density in a 12-well plate, four repeat wells 
were used for control and each engineered cell line. Cells were counted every 24 hours 
and the media were changed every 48 hours. As a result, both cell lines – PC3 
overexpressing ESRP1 only and ESRP2 only, showed a significant cell growth decrease 
compared to the control cell line. Moreover, PC3 overexpressing both ESRP1 and ESRP2 
showed a greater reduction on cell growth, which may be the combined effect of ESRP1 
and ESRP2 overexpression. 
Furthermore, the effect of ESRPs on EMT markers was validated by 
immunofluorescence analysis. PC3 cells with ESRP1/ESPR2/ESRP1&2 overexpression 
were cultured on coverslips and cells were incubated for a further 48 hours. Triplicate 
wells were used for control and each engineered PC3 cell line. The coverslips were fixed 
and stained with a fluorescent antibody against E-cadherin, an epithelial cell marker. 
PC3 cells stained with mouse IgG instead of primary were used as negative control and 
LNCaP cells were used as a positive control. PC3 ESRP2 and PC3 ESRP1/2 cells were 
grown in a medium supplemented with 2.5µg/ml doxycycline for 48 hours prior to 
staining to induce ESRP2 expression. The immunofluorescences analysis of the EMT-
marker – E-cadherin confirmed that ESRPs not only increased E-cadherin expression 
level, but also changed the localization of it in PC3 cells (Figure 3-3). This result, in part, 
validates the previous publication's statement that ESRPs inhibit tumour EMT. 
Finally, whether or not ESRPs will decrease cell migration in PC3 cells was revealed by 
Boyden chamber assay (Figure 3-4). Boyden chamber assay was performed 48 hours 
after ESRP1, ESRP2, ESRP1&2 overexpressing PC3 cell lines and empty vector control 
PC3 cell line were seeded in the inserts. Four repeats were applied for each cell line. All 
the four experimental cells were grown overnight in a reduced medium with 2% FBS for 
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starving cells before seeding in the inserts. PC3 cells not starved were used as negative 




Figure 3-1 Validation of ESRPs transfection in PC3 cells and optimization of ESRP2 induction. 
Western blot analysis was carried out after transfection of ESRP1, ESRP2 and empty vector 
plasmid in PC3 cells. Total protein blot was used as an internal control. Top panel: Western blot 
of ESRP1 in PC3 control and ESRP1 overexpressing cells. LNCaP was used as a positive control. 
The blot is probed for ESRP1. Middle panel: Western blot of ESRP2 in PC3 control and ESRP2 
overexpressing cells. Bottom panel: Western blot of ESRP1 (left) and ESRP2(right) in PC3 control 
and ESRP1/2 overexpressing cells. PC3 ESRP2 cells were cultured in medium supplemented with 






Figure 3-2 ESRPs decrease PC3 cell growth. 
Left panel: Growth curve of PC3 ESRP1 overexpressing and control cells. Middle panel: Growth curve of PC3 ESRP2 overexpressing and control cells. Right 
panel: Growth curve of PC3 ESRP1/2 double overexpressing and control cells. All the three cell lines – PC3 overexpressing ESRP1 only, ESRP2 only and both 
ESRP1 and 2 showed significantly decreased cell growth. PC3 EV and ESRP1 cells were seeded with 100,000 cells per well in a 12-well plate using 8 plates. The 
medium was refreshed every 48 hours after seeding. Cells were counted every 24 hours after seeding in the plate. All data was calculated and analysed with 
Prism and tested by two-way ANOVA. All the treatments had 4 repeats. n=12, ***p＜0.001 by one-way ANOVA. 
 








































































Figure 3-3 ESRPs change E-cadherin localization in PC3 cells. 
Immunofluorescence analysis was carried out after transfection of ESRP1, ESRP2 and empty 
vector plasmid in PC3 cells. Upper-left panel: Immunofluorescence of E-cadherin in PC3 and 
LNCaP cells, PC3 cells stained with mouse IgG were used as negative control and LNCaP cells 
were used as a positive control. Upper-right panel: Immunofluorescence of E-cadherin in PC3 
ESRP1 overexpressing and control cells. Bottom-left panel: Immunofluorescence of E-cadherin 
in PC3 ESRP2 overexpressing and control cells. Bottom-right panel: Immunofluorescence of E-
cadherin in PC3 ESRP1/2 double overexpressing and control cells. PC3 ESRP2 and PC3 ESRP1/2 
cells were grown in a medium supplemented with 2.5µg/ml doxycycline for 48 hours prior to 







Figure 3-4 ESRPs do not affect migration rate in PC3 cells. 
Boyden chamber assay was performed following transfection of ESRP1, ESRP2 and empty vector plasmid in PC3 cells. PC3 cells were cultured overnight in 
reduced medium with 2% FBS for starving cells. Left panel: Normalized migration rate on Boyden chamber assay of PC3 ESRP1 overexpressing and control 
cells. Middle panel: Normalized migration rate on Boyden chamber assay of PC3 ESRP2 overexpressing and control cells. Right panel: Normalized migration 
rate on Boyden chamber assay of PC3 ESRP1/2 double overexpressing and control cells. PC3 ESRP2 and PC3 ESRP1/2 cells were grown in a medium 
supplemented with 2.5µg/ml doxycycline for 48 hours prior to experiment to induce ESRP2 expression. n=4, data was analyzed by one-way ANOVA. 
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3.2.2 The effects of ESRPs on tumour growth 
Many studies have shown that ESRPs can inhibit EMT progression in tumours, resulting 
in inhibition of many types of tumour growth, including colorectal tumours and breast 
cancers. However, there are few reports about the ESRPs' effect on the growth of 
prostate tumours. It was reported that ESRP1 was consistently down regulated, which 
is repressed by ZEB1, in prostate cancer specimens (Z. X. Lu et al., 2015). Our previous 
in vitro data showed that ESRPs are essential in the EMT process and promote EMT in 
the reverse direction. Moreover, we want to explore whether there is a significance to 
manipulate ESRPs functions in vivo. 
To explore whether ESRP1 is important in prostate cancer tumour growth, we firstly 
tried to knock down ESRP1 in LNCaP cells. LNCaP is a prostate cancer cell line, which is 
more epithelial in phenotype and grows slowly in xenografts. According to previous in 
vivo experiments, when ESRP1 only is knockdown, there is a significant increase in 
tumour growth (Figure 3-5, the results were obtained by previous student Hanna 
Zelinska from Oltean’s group). 
It will be very meaningful if we can illustrate what will happen when ESRPs are 
overexpressed in another more mesenchymal prostate cancer cell line – PC3 cells, 
which usually grow in xenografts in 2-5 weeks. One million PC3 ESRP1 overexpression 
or vehicle cells were injected subcutaneously in the right flank of male nude mice and 
tumour diameters were measured by callipers. 6 nude mice were used in each group. 




Figure 3-5 ESRP1-knockdown (KD) accelerates tumour growth in LNCaP xenografts in nude mice.  
Upper panel: Quantitation of the tumour volumes in control and ESRP1 knockdown mice. 
Bottom panel: Examples of tumour growth in mice and extracted tumours (tumours outlined in 
black). Tumour diameters were measured by calipers. n=6, data was analyzed by two-







Figure 3-6 ESRPs overexpression decrease tumour growth in PC3 xenografts. 
Left panel: Quantitation of the tumour volumes in control and ESRP1 overexpressing mice. Middle panel: Quantitation of the tumour volumes in control and 





Two million PC3 ESRP2 overexpressing, ESRP1/2 double overexpressing or control 
(empty vector) cells were injected subcutaneously in the right flank of male nude mice 
and tumour diameters were measured by calipers. PC3 ESRP2 and PC3 ESRP1/2 cells 
were cultured in a medium supplemented with 2.5µg/ml doxycycline for 48 hours prior 
to injecting into nude mice to induce ESRP2 expression. Six nude mice were used in each 
group. Both experimental mice groups showed significant decrease in tumour growth 
(Figure 3-7).  
All three in vivo experiments on ESRPs overexpressing PC3 xenografts combined with 
the ESRP1 knockdown in vivo experiment were consistent with in vitro experiments – 
suggesting that ESRPs have tumour suppressor functions. 
According to previous reports on ESRPs mechanisms, to clarify how ESRPs affect tumour 
growth, we analysed E-cadherin expression in the tumour xenografts – E-cadherin is an 
essential biomarker of EMT in tumour growth. Total protein was extracted from tumour 
tissues and used for western blot on E-cadherin level. The western blot analysis showed 
that all the three groups overexpressing ESRPs had increase on E-cadherin expression 







Figure 3-7 Examples of tumour growth in control and ESRP1, ESRP2 and ESRPs overexpressing 
mice groups. 
Upper panel: Examples of tumour growth in control and ESRP1 overexpressing mice groups. 
Bottom panel: Examples of tumour growth in control, ESRP2 overexpressing and ESRP1/2 




   
     
   
Figure 3-8 Overexpression of ESRPs promotes E-cadherin expression in tumour xenografts in vivo. 
Upper panel:  Left: E-cadherin expression fold change in ESRP1 overexpressing PC3 vs ctrl 
xenograft by western blot probing on E-cadherin. Right: E-cadherin expression fold change in 
ESRP2 overexpressing PC3 xenograft vs ctrl by western blot probing on E-cadherin. Middle panel: 
E-cadherin expression fold change in ESRP1/2 overexpressing PC3 xenograft vs ctrl by western 
blot probing on E-cadherin Bottom panel: example of western blot probing on E-cadherin of 
ESRP1&2 overexpressing PC3 vs ctrl xenograft. Western blot image was analysed by Image J, 
and total proteins were quantitated by Image Lab. N=3-9, Data was analysed by Paired T-Test, 
*p<0.05. 
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3.3 Discussion  
3.3.1 ESRPs have tumour suppressor functions 
In recent years there have been several publications reporting that ESRPs are low 
expressed in many different kinds of cancers, such as ovarian cancer, breast cancer, and 
colorectal cancer (Fagoonee et al., 2017; Hu, Li, Zhang, Zhuang, & Hu, 2017; Jeong et al., 
2017). Based on the ESRPs effect and mechanisms in EMT, most researchers introduced 
a tumour suppression function of ESRPs. Many studies verified that ESRPs were 
important in suppressing tumour growth. However, recently several publications have 
shown that ESRP1 promotes human colorectal cancer progression (L. Chen et al., 2017; 
Fagoonee et al., 2017; Jeong et al., 2017). This triggers the question of how a gene 
whose overexpression is positively correlated with tumour growth determines its role 
in inhibiting tumour growth or promoting tumour growth. Generally speaking, there are 
three possibilities. Firstly, when the tumour initializes, the body starts a self-defence 
function that up-regulates compensatory expression of the ESRPs to try and 
stop tumour growth. The second possible explanation is that ESRPs are overexpressed 
to promote tumour growth by promoting splicing of the genes that promote cell 
properties associated with tumour progression, but would this overcome the switch to 
an epithelial phenotype? Finally, it may be more likely that ESRPs increase in late 
tumour development because of promoting metastasis, which needs a reversal back to 
epithelial phenotypes. 
As shown in our in vivo data, ESRPs overexpressing in PC3 cells slow down the tumour 
growth, while ESRP1 knockdown only accelerates tumour growth in LNCaP xenografts 
in nude mice. The two reciprocal experiments at least prove that ESRP1 definitely has 
tumour suppressor functions in prostate cancer. To validate whether the ESRP2 also has 
tumour suppressor function, we tried to knockdown ESRP2 in LNCaP as well, but 
unfortunately, a massive cell death appears with transient knockdown ESRP2 in LNCaP 
cells, so we are not able to make a stable LNCaP ESRP2 KD cell line to carry out functional 
assays in vitro and xenografts in vivo. Thus, we cannot be sure whether ESRP2 are 
tumour suppressor or oncogene. In future, we may try to construct an inducible ESRP2 




manipulate ESRPs functions, which should be a good direction of tumour therapy 
targets. 
Furthermore, how ESRPs work to suppress tumour growth, or even promote tumour 
growth, will be meaningful to explore. Once we can figure out the signalling pathways 
that ESRPs involved to affect tumour initiation and progression, it will be very beneficial 
for new cancer treatment targets. 
3.3.2 ESRPs affect prostate cancer cell functions in various ways 
It has been reported that ESRP1 and ESRP2 inhibit tumour cell motility through 
distinctive roles (Ishii et al., 2014). However, most publications are about their similar 
functions (Hayakawa et al., 2017; Warzecha, Sato, et al., 2009; Warzecha, Shen, et al., 
2009). As can be realized from the above data, ESRPs have varying degrees of effect on 
many cellular functions of prostate cancer cell lines, such as decreasing cell growth and 
changing epithelial marker-E-cadherin localization. When ESRP1 and ESRP2 are both 
expressed, these effects are greatly increased. But we did not see any difference 
between ESRP1 and ESRP2 functions in PC3 cell lines. It is hard to say whether they just 
have very similar mechanisms in PC3 cell functions, or they get a similar functional effect 





Chapter 4  Screening for small molecules that can modulate 
FGFR2 alternative splicing  
4.1 Introduction 
As alternative splicing plays a vital role in gene regulation, there are many different 
methods to explore the control of AS and how the modulation of AS could be linked to 
diseases. To explore the splicing event of a single gene or a construct, there is one useful 
method, high throughput screening, which could be used for studying the effects of 
many siRNAs, cDNAs or chemicals on AS of a gene or construct. Through this procedure, 
it is possible to explore how AS is modulated and small molecules selected from the 
screen could potentially be used as a treatment option in clinics for splicing associated 
diseases.  
There are a lot of successful examples using splicing-sensitive reporters siRNA, cDNA 
and small molecule screens to explore individual alternative splicing events (Stoilov, Lin, 
Damoiseaux, Nikolic, & Black, 2008; Warzecha, Sato, et al., 2009). Screening for small 
molecules that can regulate FGFR2 splicing will help to reveal pathways involved in 
controlling splicing of FGFR2 and how the splicing pattern is changed in tumours. These 
may also be possible new anti-EMT treatment targets. Using the FGFR2 reporter we 
aimed to screen for small molecules that could silence FGFR2 exon IIIc and/or promote 
inclusion of exon IIIb. 
4.1.1 FGFR2 is a sensor of EMT and ESRPs activities 
ESRPs are cell-type-specific splicing factors controlling the switch of epithelial isoforms 
during the EMT. The endogenous FGFR2 gene, as one of the well-known genes 
regulated by tissue-specific AS, has two mutually exclusive and highly tissue-specific 
heterogeneous isoforms - FGFR2 III b and FGFR2 III c (Figure 1-14). During the EMT, the 
splicing of FGFR2 is switched to mesenchymal phenotype – increasing inclusion of exon 
IIIc and reducing inclusion of exon IIIb.  
As FGFR2 is a sensor for ESRP activity and EMT, FGFR2-based splicing reporter was used 




4.1.2 FGFR2 splicing-sensitive fluorescent reporter was designed based on 
endogenous FGFR2 splicing patterns 
FGFR2-based fluorescent splicing sensitive reporter was used to carry out the screen 
(Figure 1-16). The reporter was designed based on endogenous FGFR2 splicing patterns 
(Figure 1-14). It has an artificial exon followed by exon IIIc and neighbouring introns 
from the FGFR2. Exclusion of exon IIIc results in an RFP expression and GFP out-of-frame, 
while retention of exon IIIc gives an EGFP signal. Mesenchymal cells include exon IIIc 
and give a GFP signal while epithelial cells skip exon IIIc and give an RFP signal.  
4.2 Results 
4.2.1 A primary screen using the Library of Pharmacologically Active Compounds 
In HEK293 cells transfected with pRGIIIc constructs, pre-mRNA of the reporter is mainly 
spliced by including exon IIIc in the frame of EGFP producing EGFP protein. This mimics 
the alternative splicing of the endogenous FGFR2 gene - HEK293 cells have high level 
expression of mesenchymal FGFR2 isoforms – FGFR2 IIIc. A primary screen was carried 
out to select compounds that can switch FGFR2 reporter splicing. 
The screen was carried out using the VICTOR X multi-label plate reader. The plate reader 
has a range of parameters that can be adjusted to optimize fluorescent detection, 
including different filters, different excitation lamp energy, and different size of the 
measurement aperture etc. In this screen, to avoid bleed-through between the two 
fluorescent channels of dsRED and EGFR protein, bandwidth ranges of excitation and 
emission filters should be narrow. The parameters used in fluorescent detection are 








  dsRED EGFP 
Excitation filter (nm) 550 485 
Emission filter (nm) 632 535 
Measurement height (mm) 3 (above) 3 (above) 
Measurement time (secs) 3 3 
Emission aperture Small small 
Lamp energy 30000 30000 
 
Table 5 Fluorescent protein measurement parameters used during chemical screen. 
Each of the excitation or emission filters used were of the narrow bandwidth variety, only 
allowing passage of light within a +/- 10nm range of the stated wavelength. dsRED was 
measured using excitation filter with excitation range at 550 +/- 10nm and emission filter that 
detects at 632 +/- 10nm. EGFP was measured using excitation filter with excitation range at 485 






The LOPAC®,1280 chemical library used in the screen was manufactured by Sigma 
Aldrich. The “LOPAC” means “Library of Pharmacologically Active Compounds”. All the 
1280 compounds of the LOPAC are used in clinics and are U.S. Food and Drug 
Administration (FDA) approved. This library includes inhibitors, receptor ligands, 
pharma-developed tools (Bioactive Small Molecule Alphabetical Index, such as 
GSK1210151A, LY-294,002 and JNJ-40418677), and approved drugs, affecting the 
majority of signalling pathways and covering all major drug target classes, including 
GPCRs, ion channels and kinases (Joy et al., 2014). 
The primary screen was carried out to select chemicals that can switch FGFR2 reporter 
alternative splicing in HEK293 cells (Figure 4-1, step 1). 10,000 HEK293 pRGIIIc cells were 
seeded into a 96-well plate and treated with each LOPAC chemical at 10µM 
concentration, in triplicate. The wells at the edge of the 96-well plate were left 
untreated and not used as controls to avoid the edge-effect. All the chemicals were 
dissolved in DMSO, so the same volume DMSO treatments were set up as controls. Cells 
were kept in their normal culturing incubator for 48 hours before the reporter’s splicing 
condition was determined by measuring the dsRED and EGFP signal in each treated well 
using a fluorescent plate reader. The measurements for both dsRED and EGFP were 
compared to control and statistically analysed using one-way ANOVA. Each treatment 
was compared to DMSO control using Dunnett’s post-test. As the goal is to screen 
compounds that can decrease the mesenchymal FGFR2 isoform or increase the 
epithelial isoforms, compounds that produced an EGFP reduction or dsRED increase, or 





Figure 4-1 Workflow of screening for alternative splicing modulators of EMT using LOPAC library.  
We have used HEK293 pRGIIIc cells to select compounds from LOPAC (Library of 
Pharmacologically Active Compounds) library (1280 FDA approved compounds) that affect 
RFP/GFP ratio by the fluorescent plate reader. And then false positives (compounds that affect 
either fluorescence or RNA stability) were eliminated. Finally, we have validated lead compounds 







Figure 4-2 Examples for primary screen result.  
Left panel represents GFP read-outs from Vector and data analysed by Prism. Middle panel represents dsRED read-outs from Vector and data analysed by 
Prism, red circles marked the hits that increase dsRED without increasing GFP signal. Right panel represents the final result, in which red means RFP increase 
only. X-axis represents the location in the 96-well plate. Each well represents one repeat of one chemical treatment. Each treatment had three repeats. *p<0.05 
by One-way ANOVA using GraphPad Prism.  
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In the primary screen, there were 278 chemicals that resulted in a significant increase 
in dsRED or decrease in GFP or both (Figure 4-2). In principle, a switch in FGFR2 splicing 
from mainly inclusion of the exon IIIc to the exon IIIb should yield an increase in dsRED 
and reduction in EGFP. As the predominant alterations in fluorescent protein levels 
were raising dsRED, some bias in the screen may occur where a small reduction in EGFP 
is not sufficient to be detected using this method. Therefore, chemicals that only result 
in raising dsRED were also picked up for the next step - control screening. 
4.2.2 Using control reporter constructs to eliminate false positive hits 
There are some other factors that affect the fluorescent protein expressing level in the 
reporter cells besides alternative splicing; for example, chemical treatments on reporter 
cells may have unknown influence on the stability of fluorescent protein or the 
chemicals may have fluorescence themselves. All the factors other than AS will affect 
the readings by fluorescent plate reader and may result in a false positive in the primary 
screen. To eliminate the false positive, two control reporters - PSS or DSS control 
reporter were used for the control screening (Figure 4-3) The control plasmid DNA did 
not contain the intron of the original pRG8ab (VEGF exon 8ab cloning in RG5 minigene) 
reporter, therefore, mimicked the mRNA transcripts without splicing events. (Figure 2-
4) PC3 cells transfected with either the PSS or DSS control reporters were used for 
control screening.   
LOPAC chemicals that produced a significant increase in dsRED or decrease in EGFP or 
both were selected to treat PC3 PSS and DSS control cells at 10µM for 48 hours (Figure 
4-1, step 2). The control reporter mRNA cannot be spliced, therefore any changes in the 
fluorescence level detected by the plate reader were not because of an effect on the 
reporter by alternative splicing. The same as the primary screen, dsRED and EGFP 
readings were statistically compared to control. Chemicals that caused a significant 
difference (p<0.05) in fluorescence level were considered false positives and eliminated. 
For the elimination of false-positives, 124 compounds that significantly increased the 
dsRED signal, or decreased EGFP or caused both were selected from 278 ‘positive’ 
compounds with no direct effect on fluorescent level but which may affect alternative 
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Figure 4-3 Examples of eliminating false-positive.  
Red means RFP increase only, green means GFP decrease only, and yellow means both of them 
in the primary screen. Rack10 D07 showed RFP increase in primary screen but also showed the 
same result in elimination-screen, so it was eliminated. Rack13 B04 showed both changes in the 
primary screen while only increased RFP in the elimination screen; therefore, the effect 
suggested by GFP decrease may be a real one, related to splicing and not a false-positive. 
 
4.2.3 Validation and hit-list 
I used RT-PCR (RNA extracted from treated HEK293 cells) to check the FGFR2 splicing at 
the RNA level. The HEK293 cell line is a human embryoric kidney cell line which express 
very clear FGFR2 IIIc isoform. 
FGFR2 has two isoforms- FGFR2 IIIb in epithelial phenotype and FGFR2 IIIc in 
mesenchymal phenotype (Figure 1-14). 
Since the two exons of FGFR2 have quite a similar size, it is difficult to distinguish only 
by normal PCR; therefore, restrictive digestion of the PCR products is needed to 
differentiate inclusion of the two different exons. AvaI only cuts IIIb while HincII only 
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cuts IIIc. FGFR2 IIIb isoform in a size of 243bp is cut into two fragments of 57bp and 186 
bp by AvaI, however 240 bp isoform with IIIc is cut into 3 fragments in sizes of 63bp, 
119bp and 58bp (Figure 2-1). 
A mesenchymal pattern of FGFR2 restriction degest result was showed in Figure 4-4. 
HEK cells express clearly the mesenchymal phenotype FGFR2 IIIc isoform, so there are 
no FGFR2 IIIb cut by AvaI, and all FGFR2 IIIc cut by HincII have nothing left around size 
240bp. What is expected for a switch for FGFR2 IIIb is a band uncut by HincII left around 
size 240bp, or bands cut by AvaI occurring around size 119bp, 63bp and 58bp. Chemicals 
show the switch for IIIb are hits that may cause an increase of ESRP activity resulting in 
FGFR2 switching to the epithelial phenotype. 
Figure 4-4 Restriction digest result of HEK293 FGFR2.  
The lanes from the left represent separately h-actin control, uncut FGFR2, PCR products cut by 
AvaI and cut by HincII. HEK cells express clear mesenchymal phenotype FGFR2 IIIc isoform, so 
there are no FGFR2 IIIb cut by AvaI (no band around size 119bp, 63bp and 58bp), and all FGFR2 
IIIc cut by HincII (no band left around size 240bp). 
 
Three possible hit compounds that switch the FGFR2 endogenous gene from isoform 
FGFR2 IIIc to FGFR2 IIIb were found in this stage. HEK cells have clear mesenchymal 
phenotype FGFR2 IIIc, so for DMSO control there was no FGFR2 IIIb cut by AvaI, and no 
FGFR2 IIIc uncut left (Figure 4-5). For the 3 hits, bands at 240bp uncut by HincII were 





Figure 4-5 Three hit compounds change splicing of the FGFR2 endogenous gene.  
Lanes from left to right represent HEK 293 cells treated by DMSO, LLSO01, LLSO02 and LLSO03; 
all of these compounds were used to treat cells at 10 µM for 48 hours. Lanes marked AvaI or 
HincII means FGFR2 PCR products cut by AvaI or HincII. DMSO control showed nothing left on 
240bp for the HincII lane while all the three hits showed bands there, which means there are 
switches for FGFR2 IIIb under the effect of compound treatment. 
 
4.3 Discussion 
4.3.1 Achievements and limitations of current EMT-targeted therapies 
EMT is not only related to tumour invasion, metastasis, recurrence and treatment 
resistance, but also stimulates tumour cells to obtain stem cell characteristics. 
Therefore, researchers believe that EMT, CSCs, and drug resistance constitute a deadly 
“triple combination” or “evil” of cancer. This "axis" (Siebzehnrubl et al., 2013; A. Singh 
& Settleman, 2010) has become the root cause of difficult-to-treat tumours. Therefore, 
targeted inhibition of EMT may play a role of “one arrow, three aims”- preventing the 
invasion and metastasis of tumour cells, eliminating CSCs and overcoming drug 
resistance (Du & Shim, 2016; Mladinich, Ruan, & Chan, 2016). It has become a highly 
valued new strategy for cancer treatment. (Malek, Wang, Kekoa, & Tran, 2017; 
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Marcucci, Stassi, & De Maria, 2016). At present, targeted suppression of EMT mainly 
has the following strategies: 
1) Regulation of EMT-induced transcription factors 
There is sufficient evidence (Lamouille et al., 2014) that EMT-inducing transcription 
factors play a key role in triggering EMT. EMT-induced transcription factors mainly 
include: SNAI1 (SNAIL), SNAI2 (SLUG), ZEB1, ZEB2, TWIST1, and TWIST2. These EMT-
inducible transcription factors inhibit E-cadherin expression, leading to EMT. Therefore, 
inhibition of the expression and activity of these EMT-inducible transcription factors 
may prevent EMT from occurring (Tania et al., 2014). Studies (Hsu et al., 2013) have 
shown that Fucoidan can inhibit EMT of breast cancer cells by down-regulating the 
expression of TWIST1, SNAI1, and SNAI2. 
2) Adjust the EMT signal pathway 
The signalling pathways that activate EMT mainly include: transforming growth factor-
β (TGF-β), FGF, EGF, phosphatidyl PI3K/Akt, Hedgehog, Notch, Wnt, MO, HGF, Insulin-
like growth factor (IGF) and hypoxia/hypoxia-inducible factor signalling pathways 
(Gonzalez & Medici, 2014; Malek et al., 2017). 
3) Targeting non-coding RNAs associated with EMT 
Certain microRNAs (miRNAs) and long-chain noncoding RNAs mainly regulate EMT by 
regulating the expression of EMT-induced transcription factors and/or EMT signalling 
pathways (Diaz-Lopez, Moreno-Bueno, & Cano, 2014; Q. Xu et al., 2016; X. Zhang, Wei, 
Li, Liu, & Qu, 2017). Overexpression of long-chain non-coding RNA PTCSC3 inhibits EMT 
in glioma U87 cells by down-regulating Wnt signalling (Xia, Ji, & Zhan, 2017). Targeting 
EMT-associated miRNAs or long-chain non-coding RNAs has become one of the 
strategies for intervention in EMT. 
4) Targeting EMT markers 
EMT is characterized by the decrease of epithelial markers (e.g. E-cadherin, β-catenin, 
and cytokeratin, etc.) and the acquisition of mesenchymal markers (such as TWIST, and 
vimentin, etc.). Targeting these marker proteins may inhibit EMT and clear existing 
metastatic tumour cells. There are currently some measures targeting E-cadherin, N-
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cadherin, and vimentin. Polireddy et al. screened 41,472 compounds for EMT inhibitors 
and found that compound BSI can upregulate E-cadherin and significantly inhibit 
pancreatic cancer cell migration and invasion (Polireddy et al., 2016). 
At present, the research and development of drugs or compounds that target EMT 
inhibition is strong. There are a set of clinical trials and drug discovery experiments 
targeting EMT regulatory components. More than 20 types of EMT inhibitors are under 
study, such as salinomycin, Saracatinib, disulfiram, metformin, honokiol , and matrine 
(Autanski et al., 2014; Cheng & Hao, 2016; Han et al., 2015; R. Li et al., 2017; Reka et al., 
2011; Santamaria, Moreno-Bueno, Portillo, & Cano, 2017; Voon, Huang, Jackson, & 
Thiery, 2017; J. Yang et al., 2017). Resveratrol and compounds SB-525334 and SU9516 
are mostly in the preclinical stage (Grygielko et al., 2005; Lotz-Jenne et al., 2016; 
Santamaria et al., 2017).  
In summary, EMT is a dynamic, multi-step and multi-factor regulation process. It is 
difficult to suppress EMT when only one process of EMT is targeted. Comprehensive 
targeting interventions can better prevent or reverse EMT (Malek et al., 2017). With the 
discovery of more specific EMT inhibitors and the combined use of some new drugs, it 
is expected that the treatment of tumours by targeting EMT will be achieved. 
4.3.2 Screening for regulators of FGFR2 alternative splicing 
The aim is to find small molecules that could switch FGFR2 alternative splicing - switch 
the splicing event that gives mesenchymal FGFR2 isoforms to the epithelial isoforms in 
this screen. The LOPAC library was a biologically annotated chemical pool of FDA 
approved active chemicals. The screen is aimed at drug repurposing. Drug repurposing 
is to inspect recognized drugs for novel usages in different disorders. Another aim is to 
expand our vision on the principles of disease initiation and to speed up the translation 
from drugs to clinical medicines. Repurposed drugs need no toxicity or safety 
assessment compared to probable drugs found by usual high-throughput screening 
(Wilkinson & Pritchard, 2015). 
There are several examples of drugs used for a disease in clinics also found to be useful 
as anti-tumour medicines. For example, thalidomide was used to treat morning sickness, 
but it can cause serious neonatal defects. It is now considered an effective drug for the 
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treatment of leukaemia and leprosy. (Damato, Loughman, Flynn, & Folkman, 1994; 
Singhal et al., 1999) 
There are also numerous cases of clinical drugs found by high-throughput screens to be 
useful for a variety of disorders including tumours. Rapamycin (sirolimus), a drug used 
to inhibit the mTOR signalling target by kinase, can now be used in 
Lymphangioleiomyomatosis (LAM) (Harari et al., 2016). Mebenozole was known as 
triggering toxicity in colon cancer cell lines. This drug is ordinarily used for treating gut 
worm infection but is currently identified as a suppressor of kinases including B-Raf as 
well (Nygren, Fryknas, Anagel, & Larsson, 2013). Digoxin is another example. As an anti-
arrhythmic agent, Digoxin was found to decrease proliferation in prostate cancer cell 
lines - PC3 and LNCaP cells. A recent study by Platz et al. revealed that men who had 
used digoxin had a lower rate of  initiating prostate cancer (Platz et al., 2011). 
4.3.3 Statistical analysis of screen data 
In large-scale high-throughput screening, many statistical approaches could be used for 
identifying lead chemicals from the library. Usually in the primary screening for testing 
a large number of chemicals, each chemical is only checked a single time for target 
effects. This statistical analysis that could be used to analyse the outcome is restricted. 
The "percentage of control" method normalizes compound activity relative to a control 
by dividing the raw compound measurements by the average of the controls in each 
plate. The measured values can then be compared between many different plates. The 
"Z-score" approach is typically used to choose positive hits from a big data collection. 
The “Z-score” has no control measurement, but it was assumed that most of the 
chemicals in the collection were not effective during the assay and therefore could be 
used as controls. So, the average value in the panel is subtracted from the measuring 
value of the compounds and divided by the standard deviation across the plate. These 
two assays both accept random distribution errors which is unmeasurable without 
repeating. Another factor that affects the mean and standard deviation of the entire 
plate is an outlier.  
Since the compounds used in the screening of pRGIIIc splicing regulators are very small, 
it is possible to repeat the screen, accepting for computational fault and variation 
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analysis. The replication is determined by the accumulation and unequal spread of cells 
among plates of cell-based assays. Dehydration of the cell medium could also arise in 
edge wells of multiple-well plates, leading to different growth rate and bias. It is known 
that some false positives in the screen are produced by positional deviations. To 
minimize this, every chemical was applied in triplicate - three wells of a 96-well plate 
were treated. DMSO measurements of the same plate were used as the internal control 
when one-way AVOVA was used on the dsRED and EGFP values. Fluorescence 
measurements were normalized to DMSO control measurements from the same plate. 
Because the manual screening and measurements are not on the same day, it is better 
to add DMSO control to each plate rather than using the average measurements of the 
DMSO on all plates.  
As the method I used to validate the splicing change in RNA level (generic RT-PCR and 
separation and visualization of products on agarose gel) is not a very sensitive method 
to detect tiny amounts of RNA, it is possible that some of the positive compounds are 
missed at this step. However, for the ones that showed change in RT-PCR, even if the 
changes are small at the RNA level, it may result in a significant change on the protein 
expression level or in functional assays. 
4.3.4 Limitations and false positive elimination within fluorescent reporter assays 
Similar to all drug discovery procedures, screening has limitations and drawbacks. Cell-
based analysis is a beneficial tool in high-throughput screening processes, while the 
possibility of variation and noise can be enlarged by using live cells. This includes cell 
growth and reaction variation between different plates as well as uneven readings in 
the same plate. One of the common procedural problems is the "edge effect." It is well 
known that luminescent or fluorescent level measured from wells at the edge areas of 
a 96-well plate are typically much lower or higher than other areas in the plate. This 
may be due to the thermal gradient between the outer wells and the middle wells in 
the plate (Lundholt, Scudder, & Pagliaro, 2003; Malo, Hanley, Cerquozzi, Pelletier, & 
Nadon, 2006). This can cause uneven spreading of cells or different adhesion and 
morphological alterations. In LOPAC screening, cells seeded in edge wells were 
untreated and unused as controls to avoid "edge effects." 
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There were 278 ‘hit’ chemicals selected from the primary screen that produced a 
significant increase in dsRED, reduction in EGFP or both. Most of these 278 chemicals 
had produced a significant increase in dsRED. This indicates there might be a bias when 
using the plate reader, that alterations in dsRED are more easily detected.  
Small molecule screening has previously been used to illuminate chemicals that may 
alter the inclusion of an exon or the use of an alternative 5' or 3' splice site. It was 
reported that some screens have used splicing-sensitive reporters with luciferase or 
GFP output (Warzecha, Sato, et al., 2009). This kind of reporter may be useful but does 
have drawbacks. For instance, the effects of small molecules on the AS of reporter genes 
cannot always be distinguished from influences through transcription and translation. 
However, dual colour fluorescent splicing-sensitive reporters may potentially produce 
fewer false positives produced by transcription or translation as real switches in splicing 
should result in a rise in one fluorescent protein and a reduction in the other.  
A dual colour splicing reporter system was used to screen for chemicals that can 
modulate the alternative splicing of microtubule-associated protein tau (MAPT) (Stoilov 
et al., 2008). The researchers revealed that several chemicals that changed pan gene 
expression also affected the ratio between the two fluorescent proteins produced from 
the reporter. They established that the reason for this is the RFP and GFP have different 
half-lives. Transcription and splicing inhibitors could also produce false positives as a 
result of different stabilities of the two mRNA transcripts of a reporter’s AS. 
Furthermore, some chemicals themselves are fluorescent and fluoresces similar to the 
reporter fluorescent protein, which also results in a false positive. 
In the FGFR2 splicing-sensitive fluorescent reporter screen, the false positives were 
eliminated by using the two control reporters – PSS and DSS reporter (Figure 2-4). The 
control reporters do not splice as they do not have intron but exactly mimic the mature 
mRNA transcripts produced by alternative splicing. Any chemicals that change 
fluorescent protein expressing level in the primary screen through transcription or 
translation or via affecting RNA/protein stability, other than by splicing, will produce 
the same result on the control screen; while chemicals that change splicing truly will 
have no influence on the control reporters - no intron, no splicing. 
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In addition to transcriptional control and alternative splicing, there are other vital kinds 
of gene expression modulation that may affect reporter transcripts and eventually 
affect fluorescent protein expression. One such kind of mechanism is non-productive 
splicing, which is used to down regulate the expression of certain alternative spliced 
transcripts by post-transcriptional regulation with inducing NMD. NMD involves the 
identification of mRNA containing a premature stop codon (PTC) and prompts transcript 
degradation to produce a shortened protein product. Details about the NMD 
mechanism of detecting PTC and targeting mRNA degradation have yet to be revealed. 
Nonsense mutants and frameshifts can generate mRNAs containing PTC, from using 
alternative splice sites (Lareau, Green, Bhatnagar, & Brenner, 2004). It is indicated that 
45% of human genes known to undertake alternative splicing produce one or more PTC-
containing mRNAs, making them targets for NMD. This raises the concept that non-
productive splicing is not only an abnormality, but regulatory machinery for post-
transcriptional gene regulation (Lewis, Green, & Brenner, 2003). In addition to inducing 
the control of inclusion of FGFR2 exon IIIb or IIIc, some chemicals from compound 
libraries can prompt the use of another sequence as a splice site in a reporter construct. 
These transcripts may contain PTCs that induce NMD degradation. This can serve to 
reduce the expression of EGFP without splicing switch to the inclusion of IIIb. The 
control reporter used in the screen was not spliced at the proximal or distal splice sites 
of VEGF because the VEGF exon 7 intron sequence has been removed. Treatment of 
control reporter cells may still produce products for degradation, and these chemicals 
could not be removed by the control screen.  
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Chapter 5  EMT-modulating effect of compounds identified 
using FGFR2 splicing sensitive reporter 
5.1 Introduction 
Epithelial mesenchymal transition (EMT) indicates the transformation of epithelial cells 
into a biological process with interstitial phenotype cells by a specific procedure 
(Acloque, Adams, Fishwick, Bronner-Fraser, & Nieto, 2009; T. Chen et al., 2017; Kalluri, 
2009; Kalluri & Weinberg, 2009). Its main features are reduced expression of cell 
adhesion proteins (such as E-cadherin) and cytoskeletal transformation (Kalluri & 
Weinberg, 2009). During EMT, a loss of epithelial properties like their polarization, 
adhesion to the BM, and acquisition of mesenchymal phenotype properties like 
invasion, increase of proliferation, and degradation of EM is indicated (T. Chen et al., 
2017; J. M. Lee, Dedhar, Kalluri, & Thompson, 2006; Warzecha & Carstens, 2012). EMT 
is an extremely significant basic progression in early embryogenesis and organogenesis. 
It separates and migrates epithelial cells produced at specific sites from epithelial 
tissues to other sites and is the foundation of typical development, wound healing, and 
initiation of malignant epithelial tumours. EMT is key for epithelial cell-derived 
malignant tumour cells achieving migrating and invasion capability. To illuminate the 
mechanism of regulating the EMT process in tumour cells, to investigate its importance 
in occurrence, progression and metastasis of tumours, and to study the diagnostic 
techniques according to crucial factors in EMT and treatment methods pointing to EMT 
are the key scientific issues in the study of the EMT mechanism in tumour metastasis. 
Past studies have shown that various stimuli in the microenvironment can stimulate 
EMT in epithelial cells through a variety of different signalling pathways, both during 
normal development and during tumorigenesis. However, scientists have not been fully 
aware of the signalling pathways that prompt EMT and maintain the final status. 
The PC3 cell line is isolated from human PCa bone metastasis tumours and has a low 
degree of differentiation. It is an androgen-independent prostate cancer cell. It does 
not contain endogenous androgen receptors and has moderate metastatic potential 
(Dillard, Lin, & Khan, 2008; Lima et al., 2018; A. L. Yang et al., 2018). For the study of 
 
 109 
androgen-resistant prostate cancer, there is low expression of E-cadherin and high 
expression of Vimentin in PC3 cells. EMT is highly regulated at each stage. To investigate 
the effect of EMT on PC3, assays need to simulate each important stage of the process 
to be used to effectively evaluate potential therapeutics. In vitro assays designed to 
explore cell functions often focus on one phase of EMT i.e. cell growth, EMT markers, 
cell proliferation, migration etc (Auerbach, Lewis, Shinners, Kubai, & Akhtar, 2003; PS & 
JP, 2002 May). Cell proliferation can be assessed by MTT assay. The MTT assay is a 
colorimetric assay for measuring cell metabolic activity by measuring the absorbance of 
the coloured solution (mixture of cell-cultured medium and water soluble MTT)  
(Mosmann, 1983). Boyden chamber assays can be used to measure cell migration in 
response to a stimulus. In such assays, cells are cultured on a porous filter with their 
movement through the filter used as a quantification of their migratory phenotype 
(Auerbach et al., 2003; Koo et al., 2010). 
In vitro EMT and cell functional assays are an important step in validating drugs or 
determining which genes can alter EMT. But, due to the complexity of EMT, there is no 
way to fully monitor EMT in cancer in vitro; therefore, in vivo models must also be 
employed. An example is a mouse tumour xenografts model. There are various murine 
models for tumour research. The main aim of these models is to clarify the mechanisms 
of tumour initiation, invasion and metastasis, and also to check treatment outcomes. 
Human tumour xenograft is most widely used among these models. In the xenograft 
model, human tumour cells are injected subcutaneously, in the tail vein or any other 
type of organ into nude mice which are immunocompromised (C. L. Morton & Houghton, 
2007; J. J. Morton, Bird, Refaeli, & Jimeno, 2016; Richmond & Su, 2008). Depending on 
the number of cells injected, the tumour will progress around 1–8 weeks (or in some 
instances 1–4 months, or even longer), and the outcome of appropriate treatment 
administrations can be revealed in vivo. 
In the previous chapter I described a chemical screen, which used a reporter construct 
to identify molecules that may influence FGFR2 alternative splicing. Some of the 
chemicals were shown to increase expression of epithelial FGFR2 isoforms. Here, I 
investigate whether these compounds produce a MET effect (a reversal of EMT) and 




5.2.1 The effects of LLSOs compounds on prostate cancer cell functions 
A library of compounds was used in a screen to identify molecules that can alter FGFR2 
alternative splicing using a splicing-sensitive fluorescent reporter that mimics FGFR2 
terminal exon splicing. This splicing decision creates either epithelial or mesenchymal 
FGFR2 protein isoforms. Three compounds, with the given name LLSOs, were shown to 
reduce exon IIIc inclusion/ increase exon IIIb inclusion following a primary and 
secondary screen of a 1280 compound library. These hits had been shown to change 
the alternative splicing of a reporter based on FGFR2, increasing use of the exon IIIb 
involved in producing epithelial FGFR2. Some of the lead compounds affected the 
alternative splicing of endogenous FGFR2 mRNA transcripts in HEK293 cells. Following 
that, I wanted to establish if any of the compounds produced a reverse EMT response. 
I chose to investigate this by performing several EMT and cell functional assays in vitro 
and in vivo including cell growth curve, EMT marker expression, cell migration assay and 
proliferation assays as well as in vivo xenograft assays. 
First of all, we tried to figure out how LLSOs affect prostate cancer cell line –PC3 cells 
functions. 
The effect of LLSOs on cell growth was investigated by cell growth curve (Figure 5-1). 
PC3 cells were seeded with 100,000 cells per well in a 12 well plate and cultured in 
RPMI1640 - media containing either control (DMSO) or one of the three drugs (LLSOs) 
at 10µM in 12 repeats. Cells were counted every 24 hours and the mediums with DMSO 
and LLSOs were changed every 48 hours. As a result, the three treatments showed 
different effects on PC3 cell growth: LLSO01 is toxic to PC3 cells at 10µM, LLSO02 shows 
no significant effect on cell growth, while LLSO03 shows a significant decrease on cell 
growth.  
Whether or not LLSOs decrease cell migration in PC3 cells was revealed by Boyden 
Chamber assay (Figure 5-2). Boyden Chamber assay was performed 24 hours following 
seeding of different pre-treated PC3 cell lines in the inserts. Three repeats were applied 
for each treatment. All the four groups were pre-treated with either control (DMSO) or 
one of different doses of the three drugs (LLSOs) for 48 hours and then cultured 
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overnight in reduced medium with 2% FBS for starving cells before seeding in the inserts. 
PC3 cells not starved were used as negative control. All the three chemicals (LLSO01 at 




Figure 5-1 LLSOs affect PC3 cell growth in different ways.  
Growth curve of LLSOs and DMSO treated PC3 cells. For the three treatments – LLSO01(10µM) 
is toxic to PC3 cells, LLSO02 (10µM) shows no significant effect on cell growth, while LLSO03 
(10µM) shows a significant decrease on cell growth. Medium with drugs was refreshed every 48 
hours after seeding. Cells were counted every 24 hours after seeding in the plate. All the 
treatments had 12 repeats. n=12, ***p＜0.001 by two-way ANOVA. 
 
Finally, whether or not LLSOs decrease cell proliferation in PC3 cells was explored by 
the MTT assay (Figure 5-3). All the four groups were pre-treated with either control 
(DMSO) or one of different doses of the three drugs (LLSOs) for 48 hours for MTT assay. 
Three repeats were applied for each cell line. Only LLSO01 at 5µM indicates a significant 
decrease absorbance rate which means a reducing proliferation rate. Additionally, 
LLSO01 at 1µM and 2µM also show a decrease in absorbance rate that may illustrate a 
dose dependent response. 
















PC3 compounds treated growth curve
seeding density: 100K/well (12 well plate)





Figure 5-2 LLSOs decrease migration rate in PC3 cells. 
Boyden Chamber assay was performed following 48 hours pre-treatment of DMSO and LLSOs in PC3 cells. PC3 cells were cultured overnight in reduced medium 
with 2% FBS for starving cells. Left panel: Normalized migration rate on Boyden chamber assay of either control (DMSO) or one of a different dose of the three 
drugs (LLSOs) for pre-treated PC3 cells. PC3 cells not starved were used as negative control. Right panel: Normalized migrating rate on Boyden chamber assay 




























































Figure 5-3 LLSOs affect proliferation rate in PC3 cells. 
MTT assay was performed following 48 hours pre-treatment of DMSO and LLSOs in PC3 cells. Left panel: absorbance rate on MTT assay of PC3 treated with 
1µM, 2µM and 5µM LLSO01 and DMSO (as control) PC3 cells. Right panel: absorbance rate on MTT assay of PC3 treated with LLSO02 10µM, LLSO03 10µM 


















































































5.2.2 The effects of LLSOs on EMT properties in prostate cancer cells 
Furthermore, the effect of LLSOs on EMT markers was validated by western blot and 
immunofluorescence analysis.  
Proteins were extracted following 48 hours treatments of DMSO as control or one of 
the three hit compounds. Western blot of E-cadherin was performed with the LLSOs 
treated proteins. All the three chemicals showed increase on E-cadherin expressing 
level. (Figure 5-4) 
PC3 cells were seeded on coverslips in a 12-well plate and treated with DMSO as control 
or one of the three hits for a further 48 hours. Triplicate treatments were used for 
control and each hit treatment. The coverslips were fixed and stained with a fluorescent 
antibody against E-cadherin, an epithelial cell marker. PC3 cells stained with mouse IgG 
instead of primary antibody were used as negative control and LNCaP cells were used 
as a positive control. The immunofluorescence analysis of the EMT-marker – E-cadherin 
established that LLSOs not only increased E-cadherin expression level, but also altered 
the localization in PC3 cells, making it more junctional (Figure 5-4). This result, in part, 








Figure 5-4 LLSOs change not only expression but also localization of E-cadherin in PC3 cells. 
Top panel: western blot of E-cadherin expression was performed with proteins extracted 
following 48 hours treatments with DMSO and LLSOs of different doses (LLSO1: 1µM, 2µM, 5µM; 
LLSO02: 10µM, 20µM, 50µM; LLSO03: 10µM,20µM, 50µM) in PC3 cells. All the three chemicals 
showed increase in E-cadherin expressing level.  
Bottom panel: Immunofluorescence analysis was performed following 48 hours treatments with 
DMSO and LLSOs (LLSO1: 2µM; LLSO02: 10µM; LLSO03: 10µM) in PC3 cells. The staining was 
probed for E-cadherin. PC3 cells stained with mouse IgG were used as negative control and 
LNCaP cells were used as a positive control. All the three chemicals showed not only increase in 






















































































5.2.3 The effect of LLSOs compounds on tumour growth 
As my in vitro studies have shown that LLSOs promote MET, I wanted to see whether 
they are also effective in vivo. It will be very meaningful if we can illustrate what will 
happen when mice with tumours were treated with LLSOs. 
To explore whether LLSOs could inhibit PCa tumour growth, we choose to use PC3 to 
perform xenografts. PC3 is a prostate cancer cell line, which is more mesenchymal in 
phenotype and generally develops in xenografts in around 2-5 weeks. From the three 
hit compounds, we chose to use LLSO02 as it did not have an effect on cell growth but 
on cell migration rate and E-cadherin expression level and localization, in this case, if 
LLSO02 could depress tumour xenografts growth it should be through other factors like 
EMT other than cell growth. 
One million PC3 cells were injected subcutaneously in the right flank of male nude mice 
and tumour diameters were measured by callipers. Six nude mice were used in each 
group. Once tumour size reached 3mm by 3mm, mice were treated with either control 
(DMSO) or LLSO02 10µM by intraperitoneal injection twice weekly. LLSO02 significantly 





Figure 5-5 LLSO02 decreases tumour growth in PC3 xenografts in nude mice.  
Upper panel: Quantitation of the tumour volumes in control and LLSO02 10µM treated mice. 
Bottom panel: Examples of tumours (tumours outlined in black; left: mice with tumours; right: 
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5.3.1 The use and limitations of EMT properties assays and cell functional assays 
To investigate EMT properties, I used E-cadherin as a marker of epithelial phenotype to 
perform western blotting and immunofluorescences. E-cadherin is a 120 kDa 
transmembrane glycoprotein of the calcium-dependent adhesion molecules family 
which is encoded by the CDH1 gene in humans and is essential in a variety of biological 
progressions like cell growth, morphogenesis, polarity, migration and tissue integrity 
(Huntsman & Caldas, 1998). E-cadherin is a glycoprotein whose extracellular domain 
can interact with E-cadherin molecules of other neighbouring cells, thereby establishing 
a connection between epithelial cells. The loss of expression or loss of its function can 
lead to the destruction of cell junctions, which is associated with the infiltration and 
metastasis of tumour cells. In many tumours, E-cadherin expression is changed, and 
decreased expression often marks a poor prognosis. Thus, E-cadherin is a sensor of EMT 
and also of tumour progress. However, there are all kinds of markers that distinguish 
epithelial cells and mesenchymal cells, such as vimentin, N-cadherin, EpCAM, TWIST 
and cytokeratin and so on. To use only E-cadherin as a probe of monitoring EMT 
properties is not so convincing, so in the future a panel of marker proteins as indicators 
could be used.  
The cell growth curve is a common technique for measuring the absolute growth 
number of cells; it is also an important indicator for determining cell viability and is one 
of the basic parameters for evaluating cell characteristics. Our growth curve was 
obtained by plotting the number of surviving cells (10 000/mL) against the incubation 
time (hours). Otherwise, there are some other methods used to draw cell growth curves, 
such as MTT assay which is also used for analysing cell proliferation rate, CCK-8 assay 
and other colorimetric methods.(M. V. Berridge & Tan, 1993; Cory, Owen, Barltrop, & 
Cory, 1991; Mosmann, 1983) The operation flow of MTT and CCK-8 assay is more 
complicated, but they can both avoid deviations in the counting process. 
Motility is a vital characteristic of live cells. Cell migration plays a vital role in 
embryogenesis, immune system, and many disease progressions like tumour metastasis 




Hence, it is extremely important to find a suitable method to analyse cell migration, and 
also in research in many relevant fields (Guy et al., 2017; Justus, Leffler, Ruiz-Echevarria, 
& Yang, 2014; Kramer et al., 2013). The most commercially used cell migration assay is 
Boyden chamber assay.(Boyden, 1962) The Boyden chamber assay is relatively simple 
to perform; however, it has several limitations. The assay is difficult and time consuming, 
has poor reproducibility, requires a large number of cells to obtain a signal, and the 
movement of cells through the filter cannot be visualized.(Guy et al., 2017) 
5.3.2 In vitro assays identified compounds with potential EMT modulation activity 
E-cadherin is highly expressed by various cell lines including cancer cells. The expression 
or absence of E-cadherin function involves the development and metastasis of cancer. 
Decrease of E-cadherin reduces the strength of cell adhesion in tissue, resulting in 
increased motility. This can in turn allow cancer cells to attack surrounding tissues 
through the BM. The lead compounds identified were initially tested for EMT activity by 
treating PC3 for 48 hours with 10μM of each small molecule before extracting the total 
proteins and performing western blots to probe E-cadherin. Furthermore, 
immunofluorescences probing E-cadherin was also performed following treating PC3 
on coverslips in a 12-well plate for 48 hours with 2uM, 5uM, or 10μM of each small 
molecule. Three of the small molecules, NNC 55-0396 hydrate (LLSO01), Nemadipine-A 
(LLSO02), and Naltrexone hydrochloride (LLSO03) significantly increased the E-cadherin 
expressing level and enhanced cell-cell junction (Figure 5-4). This indicates these 
compounds can produce an effect on prostate cancer cells improving their adhesive 
ability; whereas in vivo, cell-cell junctions are usually preventing tumour cells from 
invading the surrounding tissue through the BM. 
5.3.3 What are the connections between LLSOs, EMT properties and tumour growth?  
NNC 55-0396 hydrate which is toxic to PC3 at 10uM, is a selective T-type calcium 
channel inhibitor, while Nemadipine-A is a cell permeable L-type calcium channel 
alpha1-subunit antagonist. It was revealed that TGF-β-induced EMT in human breast 
cancer cells is correlated with modifications in endoplasmic reticulum calcium 




function of calcium signalling pathway in the initiation of EMT in human breast cancer 
cells. Their study shows that TRPM7 regulates EMT partly in breast cancer cells, while 
there are some other calcium-permeable ion channels contributing to promote   
calcium-dependent EMT (Davis et al., 2014). Calcium channels play a vital role in 
numerous biological procedures, e.g. cell growth, differentiation, and cell death (M. J. 
Berridge, 2012; Loughlin, 2014; Shapovalov, Skryma, & Prevarskaya, 2013). Calcium 
channel blockers were reported to have effects on cancer invasion. Channel proteins 
were recognised as modulators and may play a role in tumour progression (Shapovalov 
et al., 2013). Maria Mancini and Alex Toker investigated the nuclear factor of activated 
T cells (NFAT), one of the vital steps in the calcium channel signalling pathway in cancer. 
It plays a role in multiple functions during carcinoma progression including cell growth, 
survival, invasion and angiogenesis (Mancini & Toker, 2009). All of these findings may 
explain to some extent why LLSO02 could affect EMT properties and therefore tumour 
growth. (Figure 5-5). It might be a novel cancer therapy to inhibit metastases through 
modulating the calcium signalling pathway in inducing EMT in tumours. 
Naltrexone hydrochloride (a competitive antagonist for μ, κ, δ, and σ-opioid receptors) 
is a substitute for naloxone which works better and longer through oral administration. 
Opioid receptors have aimed to release pain and related diseases over a long history 
and are still used commonly as anaesthetics in hospital (Al-Hasani & Bruchas, 2011). 
However, there are only a few publications that characterize the relationship between 
opioid receptor and EMT. Lennon FE et al. revealed that the Mu opioid receptor 
stimulates opioid and cell growth, immigration and EMT in human lung cancer provoked 
by GFs (Lennon et al., 2014). Simultaneous activation of MOR and SSTR2 influences the 
metastatic potential of PDAC cells, in which it was reported that a strong correlation 
may exist between aberrant ERK1/2 activation and a process that is important to 
initiating EMT (Jorand et al., 2016). There is a need to demonstrate whether opioid 





Chapter 6  Discussion and the future 
6.1 Alternative splicing dysregulation in disease and the potential for therapeutic 
intervention 
The human genome sequencing work has been completed in 2005, revealing that the 
number of genes contained in the human genome is far less than previously estimated 
and much lower than the number of proteins in the cell. How is the asymmetry between 
the number of genes and protein species in the human body achieved? Currently, 
known methods for increasing protein diversity include DNA recombination, RNA 
editing, and AS, but AS of mRNA is the main mechanism of diversity production of 
proteins.  
In recent years, the rapid development of high-throughput sequencing (NGS) 
technology, through the direct sequencing of mRNA fragments, has been able to cover 
most of the mRNA sequences. It has been possible to identify new subtypes resulting 
from splicing and accurately give quantitative information (E. T. Wang et al., 2008). The 
application of NGS technology has greatly promoted the understanding of alternative 
splicing. New data show that about 95% of human genes can be alternatively spliced, 
and according to the latest human genome annotation information (GENCODE Human 
Annotation, the data provided by Version 28, http://www.gencodegenes.org), the 
number of transcripts encoded on average by one gene has reached 4.14, which 
indicates the great contribution of alternative splicing to protein diversity. 
Basic research is ultimately required to serve clinical applications. Since the era of group 
science, the development of sequencing technology has enabled people to quickly and 
accurately compare the differences in alternative splicing patterns between normal 
physiological conditions and pathological conditions. The data indicate that many 
disease occurrences are associated with alternative splicing abnormalities, including 
growth hormone deficiency (GHD) (Braunschweig et al., 2014), Parkinson's disease 
(Alieva et al., 2014), and spinal muscular atrophy (SMA) (Naryshkin et al., 2014). As early 
as 2004, people recognized that there are inextricable links between alternative splicing 




& Weiss, 2015; Pajares et al., 2007; Venables, 2004). Since the alternative splicing that 
occurs in vivo is a complex process, it is a highly coordinated mechanism of various 
influencing factors, involving many regulatory elements and modifying factors. A 
mutation in any one of these key factors will alter the normal splicing pattern, resulting 
in a mutated transcript that encodes an abnormal protein. According to multiple 
genomic and proteomic data, crucial alterations of transcription factors, signalling 
molecules, membrane proteins, and secreted proteins in alternative splicing disorders, 
can often lead to disease. Fortunately, the alternative splicing that occurs in these key 
genes is not only to act as a predisposing factor for disease, but also more likely to act 
as a clinical diagnostic tool or therapeutic target providing new ideas for the ultimate 
cure of the disease (Feng, Qin, & Zhang, 2013). 
Since AS is controlled by cis-elements and trans-elements, disruption of this regulatory 
mechanism can result in abnormal mRNA expression, leading to disease. There are two 
subtypes of the disorders according to their derivation: changes in cis-elements (e.g. 
changing splicing signals) and mutants in trans elements (e.g. changing splicing gear 
itself)  (Sune-Pou et al., 2017).  
In addition to changes in the splicing factor that can cause abnormalities in splicing, 
similarly, changes in the sequence of splice sites can also lead to splicing anomalies. 
SNPs - single nucleotide polymorphisms - refer to mutations at a particular site in the 
sequence. If this mutation occurs at the alternative splice site, it will cause splicing 
anomalies so that introns cannot be spliced or exons that should not be spliced are 
spliced out. 
There are many examples of abnormal splicing resulting from mutations leading to 
diseases. Familial dysautonomia (FD; also known as "Riley-Day syndrome"), an 
Ashkenazi Jewish disorder, is a rare but well recognised set of multiple autonomic 
dysfunctions. (Slaugenhaupt et al., 2001) It mainly occurs in Jewish families and other 
racial children in Eastern Europe, and the genetic carriers of the patients' relatives are 
about 1/50. In 99.5% of patients with familial dysautonomia the 5' splice site of exon 20 
in the IKBKAP gene is mutated by a T to C substitution located at position 6 of the 20th 
intron. This point mutation interrupts the pairing with U1-snRNA, which results in the 




downstream nucleotides. Such mutations result in abnormal splicing of introns, leading 
to familial dysautonomia. 
Nek2 and its splice isoform, Nek2A, is a centrosome-associated kinase that is essential 
for the centrosome to properly replicate, isolate, mature, and establish a bipolar spindle. 
A team of researchers confirmed the differences in Nek2A protein and mRNA 
expression of Nek2 and its splice isoforms in different stages of breast cancer and said 
that this could provide new indicators for the clinical diagnosis of breast cancer, and 
Nek2 and its splice isoforms Nek2A may act as a potential new target for breast cancer 
management (S. L. Wang et al., 2012). The alternative splice Nek2C of the Nek2 gene is 
also considered to be closely associated with the progression of breast cancer. The 
inhibition of Nek2C expression has proved to be an operational means to potentially 
target breast cancer (Liu et al., 2012). 
Another example is the SMN2 gene. The SMN2 gene is important in relation to SMA 
disease (muscular dystrophy). SMN is a widely expressed protein that is essential in the 
functional diversity of eukaryotic cells. SMA is a genetic disease caused by a mutation 
or deletion of the SMN1 gene. Humans have two SMN genes (the gene product is 
necessary for the production of core snRNP complexes in cells), SMN1 and SMN2, 
respectively, and both can encode proteins. SMN2 is a homologue of SMN1 because 
selective cleavage shortens the transcript and produces few functional SMN proteins. 
However, in patients with SMA, the SMN1 gene is deleted, but SMN2 is retained. 
Studies through chemical screening and optimization showed that continuous 
treatment with SMN splicing regulators can selectively alter the cleavage of SMN2 pre-
mRNA to produce stable, full-length SMN proteins. Additionally, these small molecules 
were shown to be specific to SMN genes - by performing RNA sequence analysis; these 
modifiers altered the expression of very few genes. SMN splicing modifiers can also 
prolong the life span of SMA mice, restore their normal weight, and prevent SMA from 
movement disorders and neuromuscular defects (Naryshkin et al., 2014). 
In addition, the abnormal dynamic mechanism of the spliceosomes is also closely 
related to the occurrence of the disease (M. C. Wahl & Luhrmann, 2015). Spliceosomes 
are 60S multi-component complexes of RNA and protein molecules. This machine can 




mRNA. This is one of the important links in gene expression and regulation. From the 
point of view of the mechanism of action, the spliceosome, as a dynamic molecular 
machine, needs to be gradually assembled from the subunits to complete each splicing 
event. 
Understanding the mechanism of action of the spliceosome in cells is of great 
importance and can help us understand the mechanisms of the diseases associated with 
these spliceosomes. By understanding this process, researchers may eventually be able 
to develop disease treatment strategies that fix the wrong splicing process. 
For example, the spliceosome is important for hematopoietic malignancies, such as 
leukaemia. AML1 gene structural abnormalities are common in acute leukaemia, 
including balanced translocations and mutations such as point mutations, insertions or 
deletion mutations, resulting in the loss of transcriptional activity of AML1. AML1a is an 
alternative spliceosome of AML1 in which the transcript product only contains a DNA 
binding domain and lacks a transcriptional activation region, which results in loss of 
normal transcription factor function. However, this transcript product has a stronger 
target gene affinity than intact AML1 product, which enables it to competitively 
combine with the target gene and interfere with the function of the entire AML1.  
Designing treatments at the level of alternative splicing has unparalleled advantages. At 
present, at the level of gene expression, RNA interference (RNAi) and antisense 
oligonucleotides are two classical treatment methods. Through the specific binding of 
single-stranded RNA to target mRNA, the target mRNA can be degraded to down-
regulate gene expression. For example, in pancreatic cancer, abnormal pre-mRNA 
splicing can be detected. Serine-arginine protein kinase 1 (SRPK1) is overexpressed in 
pancreatic cancer cell lines, and SRPK1 is one of the major controlling proteins of pre- 
mRNA splicing. SRPK1 siRNA (small interfering RNA) was used to downregulate the 
presentation of SRPK1 and was found to cause cell growth and increase apoptosis, and 
even increase sensitivity of the chemotherapy drugs gemcitabine and cisplatin (Hayes, 
Carrigan, Beck, & Miller, 2006).  
In contrast, steric-blocking oligos that have just emerged in recent years are new 




& Altman, 2012; R. K. Singh & Cooper, 2012). Steric-blocking oligonucleotides can alter 
the pre-mRNA splicing pattern without degrading the target mRNA, hinder the splicing 
of the spliced complex to false exons in the spatial structure, and at the same time 
promote the generation of the correct subtype; ideally, it can even restore normal 
protein expression. (Gamazon & Stranger, 2014; Kole et al., 2012). There have been 
some successful cases using this strategy. For example, the combination of a specific 
ligand and a receptor for advanced glycation end-products can activate the relevant 
inflammatory signalling pathways, which cause degenerative lesions or induce hepatic 
tumourigenesis (Lertwittayapon, Tencomnao, & Santiyanont, 2012). The soluble RAGE 
subtype RAGEv1 present in the peripheral blood can neutralize these specific ligands 
and inhibit pro-inflammatory signalling pathways activation. By shifting the splicing of 
the RAGE, which makes it more likely to express soluble RAGEv1, a significant 
therapeutic effect can be achieved, and it is likely to become a new strategy for the 
treatment of liver tumours. Thus, compared to the previous two treatment approaches, 
the steric-block oligonucleotides can withstand more chemical modifications with good 
prospects in clinical application (Kole et al., 2012). 
6.2 EMT in tumours and the prospective for therapeutic intervention  
The EMT process is related to two important characteristics of tumours, which are 
tumour metastasis and tumour resistance to therapy, respectively. Both of these 
characteristics may be related to the stem cell-like characteristics of tumour cells 
resulting from EMT. Researchers have found that in mammary epithelial cells, after the 
expression of the TF TWIST1 or SNAI1 which induces EMT, the number of stem cell-like 
cells will increase significantly in cancer. This result is detected using cell surface antigen 
detection, gene expression profile detection, formation of mammosphere detection, 
and other detection methods, and the same results can be obtained with TGF-β (Al-Hajj, 
Wicha, Benito-Hernandez, Morrison, & Clarke, 2003; Mani et al., 2008; Tran, Corsa, 
Biswas, Aft, & Longmore, 2011). Transcription factors that can induce EMT, such as 
TWIST1, FOXC2, SNAI1, ZEB2 (aka SIP1), TWIST2, etc., vimentin and fibronectin 
expression levels in CD44+/CD24- stem cell-like tumour cells were much higher than 




These experimental results, together with previous studies, have shown that genes 
associated with tumour invasion, metastasis, and angiogenesis are up-regulated in 
CD44+/CD24- breast cancer tumour cells, and increase cell invasion and migration. At 
the same time, the study also found that the number of cells exhibiting the 
CD44+/CD24- antigen phenotype in breast cancer cells distributed into the circulatory 
system and bone marrow was also significantly increased (Mani et al., 2008). 
The large number of CD44+CD24-stem cell-like tumour cells and the large number of 
genes associated with the EMT process are associated with basal-like subtype of human 
breast cancer. It is revealed that proteins related to the EMT process, such as vimentin, 
α-smooth muscle actin, N-cadherin, SPARC protein, laminin, and fascin are abundantly 
expressed, while the expression of E-cadherin is reduced compared to others in breast 
cancer cells (Kulka et al., 2016; Scanlon, Van Tubergen, Inglehart, & D'Silva, 2013; S. S. 
Yang et al., 2013). Because these tumours are prone to metastasis, they have poor 
prognosis. The expression of FOXC2, a TF that can induce EMT, was evaluated in 117 
primary invasive breast cancer samples and it was found that the factor is closely related 
to basal cell-like breast cancer (Hollier et al., 2013). Combined with these experimental 
results, the CD44 +/CD24 - phenotype increased in basal-like breast tumours. 
EMT also plays a very important role in tumour resistance to treatment. In the tumour 
"residual" lesions following standard chemotherapy, the majority of the remaining 
tumour cells are stem cell-like tumour cells. For example, after neoadjuvant therapy 
and standard anthracycline/taxane-based chemotherapy for breast cancer patients, it 
can be found in the biopsy tissue that the number of CD44+/CD24- cells expressing 
genes related to the EMT process has increased significantly (Deng et al., 2017). 
However, this is not the case for ERBB2+ breast cancer patients treated with EGFR and 
ERBB2 dual inhibitor lapatinib (Montemurro, Valabrega, & Aglietta, 2007). For some 
tumours, such as lung cancer and colon cancer, the sensitivity of EGFR kinase inhibitors 
decreases after cells undergo EMT. This may be due to the fact that the cells activate 
PI3K and Akt, downstream factors of EGFR kinase, and are no longer needed in the role 
of the EGFR kinase signalling pathway (Buck et al., 2007; Huang & Fu, 2015; Jakobsen et 




The EMT and the stem cell characteristics of tumour cells after EMT are also related to 
the anti-apoptotic mechanisms of tumour cells (Acloque et al., 2009). After induction of 
EMT by TGF-β in the mammary epithelium of EpH-4 and NMUMG mice, these epithelial 
cells were resistant to UV-induced apoptosis (Robson, Khaled, Abell, & Watson, 2006). 
Similarly, in breast cancer cells, down-regulation of let-7 miRNA expression levels can 
enhance the metastatic capacity of tumour cells while also making tumour cells 
resistant to treatment. This is because the tumour cells gain stem cell characteristics 
and the gene expression profile of the cell also becomes a gene expression pattern 
associated with the EMT process (An, Sarmiento, Tan, & Zhu, 2017; Tang, Ahmad, & 
Sarkar, 2012). Co-culturing tumour epithelial cells with mesenchymal fibroblasts or 
placing tumour epithelial cells in an oxygen-deprived environment can also make them 
resistant to treatment (S. W. Lee, Kwak, Kang, Park, & Jeong, 2018; Shiga et al., 2015). 
This may also be due to the EMT of cells. 
More and more studies indicate that EMT and MET play a key role in the regulation of 
cellular plasticity (Jolly, Ware, Gilja, Somarelli, & Levine, 2017; Strauss, Hamerlik, Lieber, 
& Bartek, 2012; G. M. Wahl & Spike, 2017). At the same time, they also have an 
important responsibility for the treatment of tumours, metastases and recurrences, and 
the therapeutic tolerance of tumour cells. The role of EMT and MET programs and 
related regulatory factors on certain tumours, especially neuroectodermal neoplasias, 
mesenchymal neoplasias, and haematopoietic neoplasias also require further study. 
Since the results of EMT have very important clinical significance, the inhibition of the 
EMT has become a very promising treatment option. Nevertheless, due to the 
complexity of the signalling network that regulates the EMT process and the existence 
of a MET transformation mechanism that can reverse the EMT, the situation becomes 
even more complicated. In addition, we know very little regarding which tumour cells 
should be treated and at what stage of tumour development treatment should be given. 
Recent studies have shown that tumour cells have already begun systemic 
dissemination in early stage lesions (Kang & Pantel, 2013); in this case it is too late to 
give EMT suppression therapy after clinical diagnosis of tumours. However, if tumour 




metastasis), the use of EMT suppression therapy may inhibit subsequent tumour 
metastasis. 
We are not yet clear which pathways to inhibit when suppressing the EMT process to 
obtain the best therapeutic effect, while minimizing the toxic side effects to the body. 
The similarities between the EMT and the normal stem cell program make the toxic side 
effects of the EMT suppression therapy a major obstacle. At the same time, the 
reversible features of the EMT and MET also cast doubt on the efficacy of EMT 
suppression therapy. Another key issue is that, since tumour initiation often takes years 
or even decades (such as breast cancer), how can we determine whether EMT 
suppression is effective before tumour metastases occur? 
All the problems mentioned above indicate that although researchers have made a lot 
of efforts to discover some of the molecular mechanisms behind EMT and MET, and 
also prove the clinical significance for patients with cancer, there are still a lot of 
important and basic issues to be addressed. However, we believe that with the 
unremitting efforts of researchers, these problems will be resolved one by one in the 
future. 
6.3 Using splicing-sensitive fluorescent reporters as a screening tool 
As switching of FGFR2 alternative splicing could inactivate EMT and decrease tumour 
progression in vivo (M. Katoh, 2009; Ranieri et al., 2016; Silipo, Gautrey, & Tyson-Capper, 
2015; Zhao et al., 2013), additional study was needed to discover further small 
molecules that may affect FGFR2 splicing pattern and also EMT. If such chemicals are 
found, and they are able to be used in cancer treatment they can help us explore how 
FGFR2 splicing and therefore EMT is controlled. A splicing-sensitive fluorescent reporter 
was designed for this purpose to mimic the splicing event that gives either epithelial or 
mesenchymal FGFR2 isoforms. Primary validation of the FGFR2 construct and 
preliminary experiments suggested that the FGFR2 splicing-sensitive fluorescent 
reporter may be a suitable tool for screening chemicals that may affect FGFR2 splicing 
(Sebastian Oltean et al., 2008). There are a lot of examples of previous studies that have 




(Arslan et al., 2013; Datta et al., 2018; Newman et al., 2006; Orengo, Bundman, & 
Cooper, 2006; Stoilov et al., 2008). 
High-throughput or small screens typically include primary and control screens and 
validation in cell functional assays (Macarron et al., 2011; Malo et al., 2006; Michelini 
et al., 2010; Pereira & Williams, 2007). The primary screen was completed using the 
human embryonic kidney cell line HEK293. The EGFP and dsRED levels in cells treated 
with LOPAC library which contains 1,280 chemicals for repurposing were determined 
by a fluorescent plate reader. FGFR2 is a sensor of EMT and ESRPs activities while EMT 
is a key point during initiation of cancer progression and anti-tumour treatment. The 
screen is to select chemicals that could switch FGFR2 splicing and therefore EMT to 
decrease tumour growth and metastasis. Chemicals that raised reporter exon IIIb 
inclusion or decreased exon IIIc inclusion were used in the control screen that measured 
EGFP and dsRED without splicing event and then validated by RT-PCR on RNA level and 
Western blot on protein level. In the control screen, PC3 DSS (pRG8ab distal splice site 
control reporter) cells were used as GFP control and PC3 PSS (pRG8ab proximal splice 
site control reporter) cells were used as RFP control. The control plasmid DNA did not 
contain the intron of the original pRG8ab (VEGF exon 8ab cloning in RG5 minigene) 
reporter; therefore, they mimicked the mRNA transcripts that are produced when 
either proximal or distal reporter 3’ splice site is chosen. Three compounds were 
validated and entered further cell functional assays. 
Compared to drug screening by pharmaceutical companies, our screening scale is 
relatively small. Each screening technique has its benefits and disadvantages. Large 
libraries usually include many drug candidates that are not active, cannot penetrate cell 
membranes or may be toxic in vitro or in vivo, while the screen performed uses 
compounds that have known cellular targets in the library and are carried out using 
active cells instead of cell extracts or isolated proteins. 
Fluorescent plate readers were used in primary screening to determine dsRED and EGFP 
levels in cells treated with the compounds as a measure of keeping or skipping exon IIIc. 
In the preliminary screening analysis, more than 200 compounds significantly raised 
dsRED or reduced EGFP or both. After the false positives were removed and validated, 




selected many false positives and "hits" that failed verification. There are other 
fluorescence measuring methods that have higher screening accuracy, such as high-
content screening (e.g., using an IN cell analyzer) or high-throughput flow cytometry. 
6.4 Investigating the control of EMT activity by small molecules in vitro and in vivo 
The aim of a screen for molecules that can modify FGFR2 splicing was to ultimately use 
such molecules to inhibit EMT in vivo. Before animal studies are performed, there are 
many in vitro EMT activity assays that can be used (Koo et al., 2010). Each EMT activity 
assay has advantages and limitations. Western blot assays on EMT markers are simple 
to perform and reproduce but do not represent the protein properties as accurately as 
some other assays. Immunofluorescence assays are more accurate and could show the 
localization of proteins, but they are not easy to perform and hard to optimize. Boyden 
chamber migration assay is one of the most common migration assays and relatively 
simple to perform, allowing you to investigate migration with a chemotactic gradient 
using adherent or non-adherent cells.  Meanwhile, it has a disadvantage in that usually 
this assay can only measure the migrating rate at the endpoint (Guy et al., 2017). The 
MTT assay was the first broadly established technique to analyse cell proliferation but 
has limitations. The absorbance detecting technique has lower sensitivity compared to 
fluorescent and luminescent ones to identify cell density. Moreover, it does not mimic 
the complexity of metastasis in the tumour microenvironment. Animal models are 
required to investigate if reverse-EMT activity of a novel compound inhibits tumour 
growth. 
To explore the mechanism in tumour initiation, invasion and metastasis, one of the 
most commonly used models is the human tumour xenograft. Mouse subcutaneous 
xenografts model I used for investigating LLSO02 effects in tumours can evaluate the 
drug response of the tumour, provide convincing heterogeneity of tumours and allow 
for fast investigation of human tumour reaction to a treatment routine. However, this 
model only mimics a less representative tumour as mice are immunocompromised. 
Several of the lead compounds identified during the FGFR2 splicing sensitive fluorescent 
reporter screen exhibited reverse-EMT activity in vitro or in vivo. Some also increased 




protein level. Even though FGFR2 is known to be mainly regulated by ESRPs, it is not 
clearly established if the EMT activity changes observed are predominantly mediated 
by changes in the ESRPs expression. Whether modulation of ESRPs activities is the major 
mechanism that mediates the respective in vivo anti-tumour activity of Nemadipine-A 
requires further investigation. 
Anti-EMT as a cancer treatment has had relatively limited success. This has been 
attributed to several mechanisms, including resistance to therapy and reduced delivery 
of chemotherapeutics to the tumour (Brabletz et al., 2018; Du & Shim, 2016; A. F. Lee 
et al., 2017). Small molecules that induce the expression of EMT marker E-cadherin 
while promoting the endogenous anti-oncogenic factor, FGFR2 IIIb, is an attractive 
strategy for cancer therapy. 
6.5 Potential signalling pathway of LLSOs 
As the three chemicals belong to different classes of drug, their signalling pathway 
would be different according to their properties. 
NNC-55-0396 (LLSO01) is a selective T-type calcium channel blocker which is used for 
the treatment of hypertension and chronic angina pectoris in clinic. As NNC-55-0396 
(LLSO03) is toxic in most of the assays carried out to all the three cell lines (PC3, LNCaP 
and HEK293) we used, we chose first to explore the mechanism of the other two 
chemicals- Nemadipine-A (LLSO02) and Naltrexone hydrochloride (LLSO03). 
Nemadipine-A (LLSO02) is a cell permeable L-type calcium channel alpha1-subunit 
antagonist, prescribed as anti-hypertension drugs. It was investigated that the nuclear 
factor of activated T cells (NFAT) is one of the vital steps in calcium channel signalling 
pathway in cancer, which play a role in multiple functions during carcinoma progression 
including cell growth, survival, invasion and angiogenesis (Mancini & Toker, 2009). In 
addition, AKT and MAPK signalling pathways are also shown to be associated with 
reduced apoptosis in cancer (Jin et al., 2007). According to these findings, Nemadipine-
A may suppress L-type calcium channel expression, which results in an inhibition of 
Calmodulin signalling pathway. (Figure 6-1) Consequently, Calcineurin will be repressed 
and inactivate NFAT expression. NFAT could promote EMT through multiple 




Nuclear NFAT, including genes coding the autotaxin and cyclooxygenase (COX-2) 
proteins which subsequently result in an invasion of tumour cells by a cascade of 
signalling pathways. NFAT could also activate gene regulation and DNA fragmentation, 
which promotes apoptosis and proliferation. (Mancini & Toker, 2009). Additionally, 
CaM signalling could also trigger CaMK activation and consequently promote CREB1 
which lead to gene regulation and proliferation. Control of calcium-signalling pathways 
regulating EMT in cancer could potentially be a significant treatment approach for 
managing cancer progression. 
In addition, it was validated that Nemadipine-A triggers TRAIL-induced cell death by 
down-regulating surviving in TRAIL-resistant cells, which means nemadipine-A is a 
hypothetical treatment approach for lung cancer (Park et al., 2013).  
Naltrexone hydrochloride (LLSO03) is a competitive antagonist for μ, κ, δ, and σ-opioid 
receptors used as a supplementary treatment. Opioid receptors have aimed to treat 
pain and related disorders for thousands of years. Inhibitors of these receptors are still 
the most commonly used anaesthetics in the clinic (Al-Hasani & Bruchas, 2011).  
It was reported that mu opiates, for example fentanyl and morphine, displayed dose- 
dependent effects on proliferation and migration in human pulmonary and dermal cells. 
Morphine, at doses used in the clinic, showed around 70% of the capability of VEGF to 
promote vessel growth and therefore promote cell migrating and growth. MNTX was 
reported to inhibit the mu opioid receptor (MOR) and Src, while activate tyrosine 
phosphatase in breast cancer cells. (Singleton, Moss, Karp, Atkins, & Janku, 2015) MOR 
was also demonstrated to stimulate cell migrating, cell growth and EMT induced by 
opioids and GFs in human lung cancer (Lennon et al., 2014). Otherwise, it was illustrated 
that a raised level of the MOR in human NSCLC stimulates Akt and mTOR activation, 
tumour progress and metastasis (Lennnon et al., 2012). According to the previous 
report in breast cancer and lung cancer, Naltrexone hydrochloride, as an antagonist for 
opioid receptors and also derivative of naltrexone like MNTX, may inhibit the MOR and 
result in an increase in tyrosine phosphatase activity and inhibition of Src. (Figure 6-2) 
Collaborating with VEGF and VEGF receptors combination, and cascade signalling, two 
mTOR complex (I and II) was formed consequently, one of which is needed for 




Naltrexone hydrochloride may also combine with FKBP12 and then prevent mTOR 
complex II construction. By acting at different levels in VEGF-signalling, mTOR inhibitors 
are able to act synergistically. The effect on tumour growth may be achieved by MORs 
through a combined effect on EMT, vessel growth, etc. Thus, the mTOR inhibitors might 
act through the suppression of some key proteins and steps in a VEGF-induced 
angiogenic signalling. However, MOR and its signalling is a potential target in tumour 
management if interacting with EMT, vascular growth, mTOR, Src and some other 
signalling pathways. 
It was reported that stimulation of κ-opioid receptors (KOR) reduced gefitinib-resistant 
NSCLC cell growth by activating GSK3β. It suggested that the motivation of KOR may 
specify distinctive points for the inhibition and management of NSCLC (Kuzumaki et al., 
2012). Inactivation of GSK3β promotes c-Myc and β-catenin degrading, which are 
upregulated in cancer. Moreover, inactive GSK3β could also inactivate the tumour 
suppressor p53. Furthermore, inactivation of GSK3β, which is positively correlated with 
the phosphorylation of GSK3β, is crucial for lung cancer development (D. Tian et al., 
2006). To conclude, Naltrexone hydrochloride may work through inhibiting KOR to 
reduce the inactivation of cAMP, and then inhibit PKA or inactivate JNK signalling which 
both result in the suppression of GSK3β (Figure 6-2). GSK-3 is overexpressed in various 
categories of tumour, as well as prostate cancer. Most of GSK-3β is observed in high 
Gleason score tumours, where it could induce androgen-independent AR and/or 
promote other signalling, such as Akt.  
These potential signalling pathways still need more work and opioid receptor inhibitor 




Figure 6-1 Potential Nemadipine-A signalling pathway 
Nemadipine-A inhibits L-type Calcium channel which results in CaM inhibition and consequent inactivation of CaN signalling pathway. NFAT could promote 
EMT through multiple mechanisms including decreasing E-cadherin expression. Nuclear NFAT is involved in a complicated signalling to promote apoptosis, 




Figure 6-2 Potential Naltrexone hydrochloride signalling pathway 
The combination of VEGF and VEGFRs induce Src and subsequently motivate a cascade of 
signalling pathways, therefore construct mTOR complex II and I that is essential for angiogenesis, 
tumour growth and metastasis.  Naltrexone hydrochloride may inhibit the MOR and stimulate 
tyrosine phosphatase activity and inhibit Src. Naltrexone hydrochloride, as a mTOR inhibitor, 
may also bind to FKBP12 to prevent mTOR complex II construction. Naltrexone hydrochloride 
may also effort through cAMP/PKA/Glycogen synthase kinase (GSK-3). Adapted from (Kuzumaki 




Since the three chemicals were screened using FGFR2 based fluorescent sensitive 
reporter, which is a sensor of EMT and ESRPs, they may affect EMT properties through 
splicing regulators controlling FGFR2 splicing. Although FGFR2 is mainly regulated by 
ESRPs, there are many other splice factors that may affect FGFR2 splicing and involved 
in EMT (Shapiro et al., 2011; Ueda et al., 2014). EMT-regulated skipped exons were 
reported to be regulated by many different factors such as ESRP, PTB, HNRNPF/H, 
Muscleblind-like (MBNL), CUG-BP, Elav-like family (CELF) and RBFOX2, and some other 
unknown splice factors.(Shapiro et al., 2011). FGFR2 exon IIIb/IIIc switch may also be 
regulated by those splice factors (Figure 6-3). The LLSOs potential mechanism network 
based on splice factors and splicing signalling pathways were indicated in Figure 6-4. 
There still are some unknown key points of the signalling pathway and splice factor 
involved in FGFR2 splicing that need to be demonstrated. Therefore, how the splicing 
process connects to calcium channel and opioid receptor signalling is what needs to be 
explored next. Understanding LLSOs mechanisms in cancer might be a new direction for 




Figure 6-3 Splicing factors involved in control of EMT–specific splicing.  
Like other EMT- regulated exons, FGFR2 exon IIIb and IIIc may be regulated by many other different splice factors besides ESRPs, such as PTB, HNRNPF/H, 





Figure 6-4 Potential LLSOs mechanism network  
The LLSOs potential mechanism network based on splice factors and splicing signalling pathways. There are still some unknown key points involving the calcium 






In ESRP related xenograft experiments, ESRP1 knockdown in LNCaP, which is a more 
epithelial prostate cancer cell line, resulted in a significant increase in tumour growth 
in xenografts. ESRPs overexpression in PC3, which is a more mesenchymal prostate 
cancer cell line, resulted in a significant decrease in tumour growth. This suggests ESRPs 
may have tumour suppressor functions. It is worth seeing whether we could manipulate 
ESRPs functions. 
In in vitro experiments, ESRPs decreased cell growth, affected EMT - induced E-cadherin, 
and decreased proliferation rate in PC3 cells, but did not affect migration. This revealed 
part of the way in which ESRPs could reduce tumour growth. 
For the second aim – drug repurposing, I used FGFR2 splicing-sensitive fluorescent 
reporter to screen chemicals from LOPAC library, found some possible modulators of 
EMT in vitro- LLSOs, which affect cell growth in different ways, decrease cell migration, 
and reduce proliferation rate in PC3 cells. 
LLSO02 – Nemadipine-A at 10µM showed a significant decrease on tumour growth in 
the PC3 xenografts experiment. 
As a further plan, I would like to explore the mechanisms of LLSOs: which splice factor 
is involved in FGFR2 splicing and which signalling pathway is involved in EMT and 
tumour progression. Moreover, Nemadipine-A’s effect on tumour metastasis could also 
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